0001145443-12-000721.txt : 20120514 0001145443-12-000721.hdr.sgml : 20120514 20120514114518 ACCESSION NUMBER: 0001145443-12-000721 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120514 DATE AS OF CHANGE: 20120514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOHEART, INC. CENTRAL INDEX KEY: 0001388319 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 650945967 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33718 FILM NUMBER: 12837243 BUSINESS ADDRESS: STREET 1: 13794 NW 4TH STREET STREET 2: SUITE 212 CITY: SUNRISE STATE: FL ZIP: 33325 BUSINESS PHONE: 954-835-1500 MAIL ADDRESS: STREET 1: 13794 NW 4TH STREET STREET 2: SUITE 212 CITY: SUNRISE STATE: FL ZIP: 33325 10-Q 1 d29450.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________________________

FORM 10-Q




x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012




o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-33718

________________________

BIOHEART, INC.
(Exact name of registrant as specified in its charter)

________________________




Florida		65-0945967
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

13794 NW 4^th Street, Suite 212, Sunrise, Florida 33325
(Address of principal executive offices) (Zip Code)

(954) 835-1500
(Registrant’s telephone number, including area code)

______________

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value per share

(Title of Class)

______________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.045 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 2, 2012, there were 136,975,326 outstanding shares of the registrant’s common stock, par value $0.001 per share.

BIOHEART, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q FILING

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

TABLE OF CONTENTS



PART I		Financial Information	Page Number

	Item 1.	Financial Statements (unaudited)	3

		Condensed Consolidated Balance Sheets – March 31, 2012 (Unaudited) and December 31, 2011	4

		Unaudited Condensed Consolidated Statements of Operations – Three Months Ended March 31, 2012, March 31, 2011 and the period from August 12, 1999 (date of inception) to March 31, 2012	5

		Unaudited Condensed Consolidated Statements of Stockholders Deficit –Three Months Ended March 31, 2012	6

		Unaudited Condensed Consolidated Statements of Cash Flows – Three Months Ended March 31, 2012, March 31, 2011 and the period from August 12, 1999 (date of inception) to March 31, 2012	7

		Notes to Unaudited Condensed Consolidated Financial Statements	9

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34

	Item 4.	Controls and Procedures	34

PART II		Other Information	35

	Item 1.	Legal Proceedings	35

	Item 1A.	Risk Factors	35

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36

	Item 3.	Defaults Upon Senior Securities	37

	Item 4.	Mine Safety Disclosures	37

	Item 5.	Other Information	37

	Item 6.	Exhibits	37

SIGNATURES			42

EX-31.1			43

EX-32.1			44

PART I – FINANCIAL INFORMATION

Item 1. Interim Financial Statements and Notes to Interim Financial Statements

General

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company's annual report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that can be expected for the year ending December 31, 2012.


BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
	2012		2011
	(unaudited)
ASSETS
Current assets:
Cash	$	69,945	$	36,828
Accounts receivable, net		-		3,495
Inventory		63,286		63,702
Prepaid and other		88,427		49,828
Total current assets		221,658		153,853

Property and equipment, net		11,151		15,476

Other assets		99,164		99,164

Total assets	$	331,973	$	268,493

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	2,631,964	$	2,377,807
Accrued expenses		4,170,146		3,882,115
Advances, related party		456,000		456,000
Deposits		465,286		465,286
Subordinated debt, related party		1,500,000		1,500,000
Notes payable, related party		365,000		365,000
Notes payable, net of debt discount		2,946,837		3,232,762
Total current liabilities		12,535,233		12,278,970

Stockholders’ deficit:
Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding as of March 31, 2012 and December 31, 2011		-		-
Common stock, par value $0.001; 195,000,000 shares authorized, 132,919,498 and 95,625,236 shares issued and outstanding as of March 31, 2012 and December 31, 2011, respectively		132,920		95,625
Additional paid in capital		99,631,969		98,915,155
Deficit accumulated during development stage		(111,968,149)		(111,021,257)
Total stockholders’ deficit		(12,203,260)		(12,010,477)

Total liabilities and stockholders’ deficit	$	331,973	$	268,493


See the accompanying notes to these unaudited condensed consolidated financial statements


BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

						From August 12,
						1999 (date of
	Three months ended March 31,					Inception) to
	2012		2011			March 31, 2012
			(restated)
Revenue	$	40,485		$	-	$	1,249,016
Cost of sales		417			-		551,251
Gross profit		40,068			-		697,765

Operating expenses:
Research and development		96,729			170,111		64,387,840
Marketing, general and administrative		468,099			490,508		35,127,583
Impairment of investment		-			-		58,695
Depreciation and amortization		4,325			8,705		887,650
Total operating expenses		569,153			669,324		100,461,768

Net loss from operations		(529,085)			(669,324)		(99,764,003)

Other income (expenses):
Development revenues		-			-		117,500
Loss on change of fair value of derivative liability		-					(25,026)
Interest income		-			-		762,277
Other income		11,353			3,389		264,184
Interest expense		(429,160)			(409,720)		(13,323,081)
Total other income (expenses)		(417,807)			(406,331)		(12,204,146)

Net loss before income taxes		(946,892)			(1,075,655)		(111,968,149)

Income taxes (benefit)		-			-		-

NET LOSS	$	(946,892)		$	(1,075,655)	$	(111,968,149)

Net loss per common share, basic and diluted	$	(0.01)		$	(0.03)

Weighted average number of common shares outstanding, basic and diluted		114,974,051			40,517,481

See the accompanying notes to these unaudited condensed consolidated financial statements


BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
THREE MONTHS ENDED MARCH 31, 2012
(unaudited)
																				Deficit
																				Accumulated
									Additional								Common			During
	Preferred stock				Common stock				Paid in		Deferred			Subscription			Stock			Development
	Shares	Amount			Shares		Amount		Capital		Compensation			Receivable			Subscription			Stage			Total
Balance, December 31, 2011	-		$	-		95,625,236	$	95,625	$	98,915,155		$	-		$	-		$	-		$	(111,021,257)	$	(12,010,477)
Issuance of common stock	-			-		9,321,430		9,321		158,179			-			-			-			-		167,500
Common stock issued for services	-			-		250,000		250		9,750			-			-			-			-		10,000
Common stock issued upon conversion of notes payable	-			-		27,722,832		27,724		359,309														387,033
Stock based compensation	-			-		-		-		19,051			-			-			-			-		19,051
Beneficial conversion feature connection with issuance of convertible note	-			-		-		-		170,525			-			-			-			-		170,525
Net loss	-			-		-		-		-			-			-			-			(946,892)		(946,892)
Balance, March 31, 2012	-		$	-		132,919,498	$	132,920	$	99,631,969		$	-		$	-		$	-		$	(111,968,149)	$	(12,203,260)

See the accompanying notes to these unaudited condensed consolidated financial statements


BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

					From August 12,
					1999 (date of
	Three months ended March 31,				Inception) to
	2012		2011		March 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:			(Restated)
Net loss	$	(946,892)	$	(1,075,655)	$	(111,968,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		4,325		8,705		887,650
Bad debt expense		-		1,266		166,266
Discount on convertible debt		248,776		136,288		1,391,763
Gain on change in fair value of derivative liability		-		-		25,026
Non cash payment of interest		21,169		-		199,070
Amortization of warrants issued in exchange for licenses and intellectual property		-		-		5,413,156
Amortization of warrants issued in connection with notes payable		50,761		92,158		5,393,074
Amortization of loan costs		927		3,054		1,228,717
Warrants issued in exchange for services		-		-		285,659
Equity instruments issued in connection with R&D agreement		-		-		360,032
Equity instruments issued in connection with settlement agreement		-		-		3,381,629
Common stock issued in connection with accounts payable		-		-		756,816
Common stock issued in exchange for services		10,000		-		1,457,922
Common stock issued in connection with amounts due to guarantors of Bank of America loan		-		-		69,159
Common stock issued in exchange for distribution rights and intellectual property		-		-		99,997
Warrants issued in connection with accounts payable				-		7,758
Stock based compensation		19,051		105,347		9,893,379
(Increase) decrease in:
Receivables		3,495		-		(1,265)
Inventory		416		-		(63,287)
Prepaid and other current assets		(38,599)		(50,761)		(98,396)
Other assets		-		-		(28,854)
Increase (decrease) in:
Accounts payable		254,157		363,511		3,189,572
Accrued expenses		288,031		109,531		5,534,834
Deferred revenue		-		-		465,287
Net cash used in operating activities		(84,383)		(306,556)		(71,953,185)


BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

							From August 12,
							1999 (date of
	Three months ended March 31,						Inception) to
	2012			2011			March 31, 2012
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment			-			-		(898,800)
Net cash used by investing activities			-			-		(898,800)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net			117,500			518,300		63,414,475
Proceeds from (payments for) initial public offering of common stock, net			-			-		1,447,829
Proceeds from subordinated related party note			-			-		3,000,000
Payment of note payable			-			-		(3,000,000)
Proceeds from notes payable, related party			-			-		505,000
Proceeds from related party advances			-			140,000		456,000
Proceeds from exercise of stock options			-			-		293,749
Proceeds from notes payable			-			25,000		11,557,750
Repayments of notes payable			-			(210,042)		(3,533,605)
Payment of loan costs			-			-		(1,219,268)
Net cash provided in financing activities			117,500			473,258		72,921,930

Net increase in cash and cash equivalents			33,117			166,702		69,945

Cash and cash equivalents, beginning of period			36,828			3,298		-
Cash and cash equivalents, end of period		$	69,945		$	170,000	$	69,945

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid		$	128,696		$	67,635	$	1,909,160
Income taxes paid		$	-		$	-	$	-

Non cash financing activities:
Common stock issued in settlement of notes payable		$	387,033		$	139,729	$	3,919,778

See the accompanying notes to these unaudited condensed consolidated financial statements

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

The accompanying unaudited condensed consolidated financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated December 31, 2011 financial statements and footnotes thereto included in the Company’s SEC Form 10-K.

Basis and business presentation

Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2012, the Company has accumulated a deficit through its development stage of $111,968,149.

The unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. The most significant estimates are those used in the analysis of potential derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.

The Company accounts for Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.

Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.

Cash

The Company considers cash to consist of cash on hand.

Accounts Receivable

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

Allowance for Doubtful Accounts

Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of March 31, 2012 and December 31, 2011, allowance for doubtful accounts was $8,751.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

Long-Lived Assets

The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

Income Taxes

The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of differences in carrying value of certain debt liability and stock compensation accounting versus tax basis.

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Net Loss per Common Share, basic and diluted

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 124,077,413 and 40,950,819 for the three months ended March 31, 2012 and 2011, respectively.

Stock based compensation

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non employees be recognized in the income statement based on their fair values. (See note 10)

As of March 31, 2012, there were outstanding stock options to purchase 4,636,318 shares of common stock, 2,944,178 shares of which were vested.

Concentrations of Credit Risk

The Company’s financial instrument that is exposed to a concentration of credit risk is cash and accounts receivable. Effective December 31, 2010 and extending through December 31, 2012, all non-interest-bearing transaction accounts are fully insured by the Federal Deposit Insurance Corporation (FDIC), regardless of the balance of the account. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

There were no accounts receivables as of March 31, 2012, as of December 31, 2011, three customers represented 98% of the Company’s accounts receivable.

For the three month period ended March 31, 2012, the Company's revenues earned from the sale of products and services were $40,485, from two customers. For the three month period ended March 31, 2011, the Company did not generate revenues.

Reliance on Key Personnel and Consultants

The Company has 7 full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $96,729 and $170,111 for the three months ended March 31, 2012 and 2011, respectively and $64,387,840 from August 12, 1999 (date of inception) to March 31, 2012.

Fair Value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Reclassification

Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

NOTE 2 – RESTATEMENT

The accompanying unaudited condensed consolidated Statement of Operations for the three months ended March 31, 2011 have been restated to correct the errors in the accounting of the Company's issuances of notes payable during the three months ended March 31, 2011. These changes correct the treatment recording of issued notes payable in exchange for payment of debt obligations.

Unaudited Condensed Consolidated Statement of Operations
For the Three Months Ended March 31, 2011


	As previously reported		Adjustment	Reference	As restated

Revenue	$ -		$ -		$ -
Cost of sales	-		-		-
Gross profit	-				-

Operating expenses:
Research and development	170,111		-		170,111
Marketing, general and administrative	490,508		-		490,508
Depreciation and amortization	8,705		-		8,705
Total operating expenses	669,324		-		669,324

Net loss from operations	(669,324	)	-		(669,324)

Other income (expenses):
Other income	3,389		-		3,389
Loss on settlement of debt	(110,872	)	110,872	(1)	-
Interest expense	(409,720	)	-		(409,720)
Total other income (expenses)	(517,203	)	110,872		(406,331)

Net loss before income taxes	(1,186,527	)	110,872		(1,075,655)

Income taxes (benefit)	-		-		-

NET LOSS	$ (1,186,527	)	$ 110,872		$ (1,075,655)

(1) reverse recording of loss on assignment of debt

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

NOTE 3 – GOING CONCERN MATTERS

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, during three months ended March 31, 2012, the Company incurred net losses attributable to common shareholders of $946,892 and used $84,383 in cash for operating activities. As of March 31, 2012 we had a working capital deficit of approximately $12.3 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 4 – INVENTORY

Inventory consists of raw materials. Costs of raw materials are determined using the FIFO method. Inventory is stated at the lower of costs or market (estimated net realizable value).

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2012 and December 31, 2011 is summarized as follows:

	March 31, 2012			December 31, 2011
Laboratory and medical equipment	$	352,358		$	352,358
Furniture, fixtures and equipment		130,916			130,916
Computer equipment		53,481			53,481
Leasehold improvements		362,046			362,046
		898,801			898,801
Less accumulated depreciation and amortization		(887,650	)		(883,325	)
	$	11,151		$	15,476

Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.

Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

NOTE 6 – ACCRUED EXPENSES

Accrued expenses consisted of the following as of March 31, 2012 and December 31, 2011:

	March 31, 2012		December 31, 2011
License and royalty fees	$	1,610,420	$	1,540,204
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,183,086		1,164,306
Interest payable on notes payable		806,671		732,556
Vendor accruals and other		115,132		115,312
Employee commissions, compensation, etc		313,562		329,737
Other		141,275		-
	$	4,170,146	$	3,882,115

NOTE 7 – NOTES PAYABLE

Notes payable were comprised of the following as of March 31, 2012 and December 31, 2011:


	March 31, 2012			December 31, 2011
Seaside Bank note payable. Terms described below	$	980,000		$	980,000
BlueCrest Capital Finance note payable. Monthly payments of principal and interest as described below, net of unamortized debt discount of $44,530 and $96,218 respectively		499,737			711,609
Short-term note payable		1,384,972			1,384,972
Short-term note payable, net of unamortized debt discount of $7,555 and $11,391, respectively. Terms described below		27,445			23,609
Short-term note payable, net of unamortized debt discount of $4,721. Terms described below		-			7,854
Short-term note payable, net of unamortized debt discount of $60,663. Terms described below		-			79,066
Short-term note payable, net of unamortized debt discount of $8,552. Terms described below		-			45,652
Short term note payable, net of unamortized debt discount of $85,046. Terms described below		54,683			-
		2,946,837			3,232,762
Less current portion		(2,946,837	)		(3,232,762	)
Notes payable – long term	$	—		$	-

Seaside Bank

On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was be used to refinance the Company’s loan with a previous Bank of America loan. The obligation was guaranteed by shareholders of the Company.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

In connection with the Loan Agreement with Seaside Bank and Trust Company, the Company made and delivered a promissory note in the principal amount of the loan that matures in two years.. In connection with the loan transaction with Seaside Bank and Trust Company, the Company entered into an Amended and Restated Loan and Security Agreement with BlueCrest Venture Finance Master Fund Limited.

BlueCrest Capital Finance Note Payable

On June 1, 2007, the Company closed on a $5.0 million senior loan from BlueCrest Capital Finance, L.P. with a term of 36 months which bears interest at an annual rate of 12.85% (the “BlueCrest Loan”). The first three months required payment of interest only with equal principal and interest payments over the remaining 33 months. As consideration for the loan, the Company issued to BlueCrest Capital Finance, L.P. a warrant to purchase 65,030 shares of common stock at an exercise price of $7.69 per share. The warrant, which became exercisable one year following the date the warrant was issued, has a ten year term. This warrant had a fair value of $455,483, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan. The Company also paid the lender a fee of $100,000 to cover diligence and other costs and expenses incurred in connection with the loan. On August 31, 2007, BlueCrest Capital Finance, L.P. assigned its rights, liabilities, duties and obligations under the BlueCrest Loan and warrant to BlueCrest Venture Finance Master Fund Limited (“BlueCrest”).

The loan may be prepaid in whole but not in part. As collateral to secure its repayment obligations under the loan, the Company granted BlueCrest a first priority security interest in all of the Company’s assets, excluding intellectual property but including the proceeds from any sale of any of the Company’s intellectual property. The loan has certain restrictive terms and covenants including among others, restrictions on the Company’s ability to incur additional senior or pari-passu indebtedness or make interest or principal payments on other subordinate loans.

In the event of an uncured event of default under the loan, all amounts owed to BlueCrest are immediately due and payable and BlueCrest has the right to enforce its security interest in the assets securing the loan. During the continuance of an event of default, all outstanding amounts under the loan will bear interest (payable on demand) at an annual rate of the 14.85%. In addition, any unpaid amounts are subject, until paid, to a service charge in an amount equal to two percent (2%) of the unpaid amount. Events of default include, among others, the Company’s failure to timely make payments of principal when due, the Company’s uncured failure to timely pay any other amounts owing to BlueCrest under the loan, the Company’s material breach of the representations and warranties contained in the loan agreement and the Company’s default in the payment of any debt to any of its other lenders in excess of $100,000 or any other default or breach under any agreement relating to such debt, which gives the holders of such debt the right to accelerate the debt.

On January 2, 2009, the Company failed to make the monthly payment of principal and interest of approximately $181,000 due on such date. On January 28, 2009, the Company received from BlueCrest notice of this event of default (the “Default Notice”) under the BlueCrest Loan. By reason of the stated event, BlueCrest demanded payment of a 2% late fee of approximately $3,600, together with the principal and interest payment of approximately $181,000. On February 2, 2009, the Company received from BlueCrest notice of acceleration of the outstanding principal amount of the BlueCrest Loan and demanded repayment in full of all outstanding principal and accrued interest on the loan, including late fees, in the aggregate amount of $2,947,045. (The acceleration notice, together with the Default Notice, are referred to as the “Notices”).

The Company and BlueCrest entered into an amendment to the BlueCrest Loan as of April 2, 2009 (the “ BlueCrest Loan Amendment”), that, among other things, includes BlueCrest’s agreement to forbear from exercising any of its rights or remedies regarding the defaults described in Notices (the “Forbearance”) as long as there are no new defaults under the BlueCrest Loan, as amended.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

The BlueCrest Loan Amendment, (a) increases the amount of permitted unsecured indebtedness of the Company, (b) amended the amortization schedule for the Loan to provide for interest-only payments until July 1, 2009, at which time monthly principal and interest payments of $262,692 will commence, and (c) prohibits the Company from granting any lien against its intellectual property and grants to BlueCrest a lien against the Company’s intellectual property that will become effective in the event of a default. In addition, the Company issued BlueCrest a warrant to purchase 1,315,542 shares of the Company’s common stock at $0.53 per share. The fair value of the issued warrants of $539,676 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan. In connection with the BlueCrest Loan Amendment the Company paid BlueCrest accrued interest in the aggregate amount of $126,077. The Company also paid BlueCrest a fee of $15,000. Effective July 1, 2009, the Company and BlueCrest agreed to enter into an amendment to the BlueCrest Loan to amend the amortization schedule for the Loan to provide for interest-only payments until January 1, 2010, at which time monthly principal and interest payments of $139,728 were to commence. In connection with that Amendment the Company issued BlueCrest a warrant to purchase $600,000 of the Company’s common shares and paid a fee of $29,435. The fair value of the issued warrants of $575,529 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan.

Effective December 31, 2009, the Company and BlueCrest entered into an amendment to the BlueCrest Loan to amend the amortization schedule for the Loan to provide for interest-only payments until July 1, 2010, at which time monthly principal and interest payments of $139,728.82 were to commence. In connection with that Amendment, the Company issued BlueCrest a warrant to purchase $600,000 of the Company’s common shares and paid a fee of $20,000. The Company also provided BlueCrest with a lien on its Intellectual Property. The fair value of the issued warrants of $507,606 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan.

The outstanding principal amount of the Loan as of December 31, 2010 was $2,276,543.03. On January 7, 2011, BlueCrest agreed with the Company and Magna Group, LLC (“Magna”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The Company exchanged the BlueCrest note for a convertible note with Magna in consideration for a payment by Magna to BlueCrest of $139,729.82. Additionally, Magna purchased a $25,000 convertible note from the Company (the “Convertible Note”). On July 18, 2011, the Company issued 625,000 shares of its common stock in settlement of the convertible note and related accrued interest.

The loans evidenced by the New Magna Convertible Note are in the nature of convertible debt evidenced by two unsecured convertible promissory notes, each bearing interest at the rate of 8% per annum, payable at maturity and each convertible into common stock of the Company at a price that is 50% less than the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.



•	In January 2011, the Company issued an aggregate of 538,542 shares of our common stock in connection with the conversion of $87,729 of the convertible note.

•	In February 2011, the Company issued an aggregate of 421,392 shares of our common stock in connection with the conversion of the remaining balance of $52,000 of the convertible note.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

On May 16, 2011, BlueCrest agreed with the Company and Magna Group, LLC (“Magna”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Magna in consideration for a payment by them to BlueCrest of $139,729.82, and thereafter exchanged for a new Convertible Note. Additionally, Magna purchased a $34,750 convertible note from the Company (the “Convertible Note”).

The loans evidenced by the New Note and Convertible Note are in the nature of convertible debt evidenced by two unsecured convertible promissory notes, each bearing interest at the rate of 8% per annum, payable at maturity and each convertible into common stock of the Company at a price that is 45% less than the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.



•	In June 2011, the Company issued an aggregate of 338,834 shares of our common stock in connection with the conversion of $29,729 of the convertible note.

•	In July 2011, the Company issued an aggregate of 2,304,615 shares of our common stock in connection with the conversion of $110,000 of the convertible note.

On June 15, 2011, BlueCrest agreed with the Company and Lotus Funding Group, LLC (“Lotus”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Lotus in consideration for a payment by them to BlueCrest of $139,729.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.



•	In June 2011, the Company issued an aggregate of 836,775 shares of our common stock in connection with the conversion of $40,000 of the convertible note.

•	In July 2011, the Company issued an aggregate of 2,594,458 shares of our common stock in connection with the conversion of $99,729 of the convertible note.

On July 8, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $140,380.21, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $140,380.21, and thereafter exchanged for a new Convertible Note.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

•	In July 2011, the Company issued an aggregate of 3,829,001 shares of our common stock in connection with the conversion of the $140,380.21 convertible note.

On August 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

•	In August 2011, the Company issued an aggregate of 3,358,866 shares of our common stock in connection with the conversion of the $139,728.82 convertible note.

On September 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.

•	In September 2011, the Company issued an aggregate of 5,769,150 shares of our common stock in connection with the conversion of the $139,728.82 convertible note.

On October 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

•	In October 2011, we issued an aggregate of 4,997,487 shares of our common stock in connection with the conversion of the $115,144 convertible note.
•	In November 2011, we issued an aggregate of 500,000 shares of our common stock in connection with the conversion of $12,010 convertible note.
•	In January 2012, we issued an aggregate of 937,242 shares of our common stock in connection with the conversion of $12,575 convertible note.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

On November 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

•	In January 2012, we issued an aggregate of 3,404,363 shares of our common stock in connection with the conversion of the $44,999 convertible note.
•	In February 2012, we issued an aggregate of 6,756,803 shares of our common stock in connection with the conversion of $94,730 convertible note.

On December 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

•	In February 2012, we issued an aggregate of 2,695,853 shares of our common stock in connection with the conversion of the $39,001 convertible note.
•	In March 2012, we issued an aggregate of 7,142,857 shares of our common stock in connection with the conversion of $100,728 convertible note.

On January 3, 2012, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

On February 6, 2012, BlueCrest agreed with the Company and Greg Knutson to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $95,000.00, the amount of the monthly payment due on the BlueCrest loan (the “New Note”) after combined with payment of $50,000 by a common stock subscription. The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $95,000.00, and thereafter exchanged for a new Convertible Note.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right, but in no event lower than $0.01 per share.

On March 30, 2012, Bioheart, Inc. (the “Company”) and Northstar Biotechnology Group, LLC (“Northstar”), the holder by assignment of the Amended and Restated Promissory Note (Term A), dated February 6, 2012, issued by the Company to Blue Crest Venture Finance Master Fund Limited, in the principle amount of$544,267.19 (the “Note”), agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company understands that Northstar is owned in part by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart, and received an assignment of the Note from BlueCrest Master Fund Limited on February 29, 2012. The Company and Northstar are in discussions regarding

certain additional amendments to the terms of the Note.

For the three months ended March 31, 2012 the Company paid $263,560 in principal and $11,641 in interest. As of March 31, 2012 the balance due under the Loan remains at $544,267.

Short-term Notes Payable

On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term. Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Noteholder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.

The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan.

At December 31, 2011 and December 31, 2010, the Company has two other outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the BlueCrest Loan is paid off.

On January 3, 2012, the Company issued a $139,729 Unsecured Convertible Note that matures in January 3, 2013 in exchange for Bluecrest Capital Finance note payable. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of 65% of the average of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, but in no event lower than $0.01 per share.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in Convertible Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the Convertible Note.

The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $112,063 is charged operations ratably over the note term as interest expense. For the three months ended March 31, 2012, the Company amortized $27,018 to current period operations as interest expense.

On February 6, 2012, the Company issued a $95,000 Unsecured Convertible Note that matures in February 6, 2013 in exchange for Bluecrest Capital Finance note payable. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of 65% of the average of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, but in no event lower than $0.01 per share.

The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $58,462 is charged operations ratably over the note term as interest expense. On February 21, 2012, the Company issued 6,785,714 shares of common stock in settlement of the Unsecured Convertible Note.

For the three months ended March 31, 2012, the Company amortized $58,462 to current period operations as interest expense.

On September 28, 2011, the Company issued a $35,000 Unsecured Convertible Note that matures in September 2012. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of the lower of $0.13 per share or 65% of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, minimum conversion rate of $0.01 per share.

In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the New Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the New Note.

The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $15,342 is charged to operations ratably over the note term as interest expense.

For the three months ended March 31, 2012, the Company amortized $3,836 to current period operations as interest expense.

For the three months ended March 31, 2012, the Company amortized and wrote off an aggregate of $291,744 to current period operations as interest expense.

Notes payable, related party

As of March 31, 2012 and December 31, 2011, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at 8% per annum and are due upon payoff of the BlueCrest note payable described above.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

At March 31, 2012 and December 31, 2011, the Company has outstanding three related party notes payable with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The company is not obligated to make payment until BlueCrest loan is paid off.

NOTE 8 – STOCKHOLDERS’ EQUITY

Common stock

During the three months ended March 31, 2012, the Company issued an aggregate of 9,321,430 shares of common stock and warrants for the purchase of our common stock, for aggregate gross proceeds of $167,500.

During the three months ended March 31, 2012, the Company issued an aggregate of 250,000 shares of common stock for services rendered valued at $10,000.

During the three months ended March 31, 2012, the Company issued an aggregate of 27,722,832 shares of common stock in settlement of $387,033 of outstanding convertible notes and accrued interest (see Note 7).

NOTE 9 – STOCK OPTIONS AND WARRANTS

Stock Options

In December 1999, our Board of Directors and shareholders adopted our 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.

As of March 31, 2012, the Company does not have a stock option plan.

A summary of options at March 31, 2012 and activity during the year then ended is presented below:


	Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Term (in years)
Options outstanding at January 1, 2011	2,158,447	$ 2.79	6.8
Granted	4,620,092	$ 0.057
Exercised	(1,982,995)	$ 0.001
Forfeited/Expired	(159,226)	$ 1.80
Options outstanding at December 31, 2011	4,636,318	$ 1.20	8.1
Granted	-
Exercised
Forfeited/Expired	-
Options outstanding at March 31, 2012	4,636,318	$ 1.20	7.9
Options exercisable at March 31, 2012	2,944,178	$ 1.75	7.4
Available for grant at March 31, 2012	0

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

The following information applies to options outstanding and exercisable at March 31, 2012:


	Options Outstanding						Options Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares		Weighted- Average Exercise Price
$0.00 – $0.70		3,494,360		9.1	$	0.19		1,846,161	$	0.18
$0.71 – $1.28		324,780		6.1	$	0.77		315,712	$	0.76
$5.25 – $5.67		770,810		3.2	$	5.58		759,185	$	5.58
$7.69		39,572		4.4	$	7.69		39,572	$	7.69
$8.47		6,796		5.0	$	8.47		6,796	$	8.47
		4,636,318		7.5	$	1.20		2,967,426	$	1.75

The fair value of all options vesting during the year ended December 31, 2011 and 2010 of $409,314 and $248,457, respectively, was charged to current period operations.

Warrants

A summary of warrants at March 31, 2012 and activity during the year then ended is presented below:


	Shares			Weighted- Average Exercise Price			Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2011		13,920,729			$	1.98		5.8
Issued		20,817,034			$	0.07
Exercised		—			$	0.00
Forfeited		(2,127,688	)		$	0.69
Outstanding at December 31, 2011		32,610,075			$	0.86		3.8
Issued		9,321,430			$	0.018		2.9
Exercised		—			$
Forfeited		-			$
Outstanding at March 31, 2012		41,931,505			$	0.67		3.6
Exercisable at March 31, 2012		20,660,810			$	0.76		3.5

The following information applies to warrants outstanding and exercisable at March 31, 2012:

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

	Warrants Outstanding				Warrants Exercisable
	Shares	Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price	Shares	Weighted- Average Exercise Price
0.01 – $0.50	32,548,150	2.6	$	0.09	12,821,905	0.13
0.52 – $0.68	3,800,078	5.3	$	0.59	3,800,078	$ 0.59
0.70 – $1.62	2,626,285	3.1	$	0.79	2,626,285	$ 0.79
1.81 – $2.61	33,710	0.5	$	1.90	33,710	$ 1.90
3.60 – $4.93	105,000	1.4	$	4.87	105,000	$ 4.87
5.67 – $7.69	2,818,282	10.2	$	7.50	1,273,832	$ 7.26
	41,931,505	3.6	$	0.86	20,660,810	$ 0.76

During the three months ended March 31, 2012, in connection with the sale of common stock, the Company issued an aggregate of 9,321,430 warrants to purchase the Company's common stock at an exercise prices from $0.014 to $0.03 per shares exercisble in six months and expiring three years from issuance.

NOTE 10 – RELATED PARTY TRANSACTIONS

Lease Guarantee

The Company’s former Chairman of the Board, Chief Executive Officer and Chief Technology Officer has personally guaranteed the Company’s obligations under its lease for its facilities in Sunrise, Florida and has provided a personal guarantee for the Company credit card, which is for his own use only.

Sister-in-Law of former Chairman of the Board

The former sister-in-law of the Company’s former Chairman was an officer of the Company until March, 2012. The amount paid to this individual as salary and bonus for the three months ended March 31, 2012, in 2011, 2010, 2009, 2008, 2007 and for the period from August 12, 1999 (date of inception) to March 31, 2012 was $42,934 $108,892, $106,000, $77,165, $86,209, $87,664 and $580,314, respectively.

Northstar Biotechnology Group, LLC Promissory Note

On March 30, 2012, Bioheart, Inc. (the “Company”) and Northstar Biotechnology Group, LLC (“Northstar”), the holder by assignment of the Amended and Restated Promissory Note (Term A), dated February 6, 2012, issued by the Company to Blue Crest Venture Finance Master Fund Limited, in the principle amount of $544,267.19 (the “Note”), agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company understands that Northstar is owned in part by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart, and received an assignment of the Note from BlueCrest Master Fund Limited on February 29, 2012. The Company and Northstar are in discussions regarding certain additional amendments to the terms of the Note.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

NOTE 11 – COMMITMENTS AND CONTINGENCIES

Royalty Payments

The Company is obligated to pay royalties on commercial sales of certain products that may be developed and sold under various licenses and agreements that have been obtained by the Company.

The Company has entered into various licensing agreements, which include the potential for royalty payments, as follows:

William Beaumont Hospital

In June 2000, the Company entered into an exclusive license agreement to use certain patents for the life of the patents in future projects. The patents expire in 2015. In addition to a payment of $55,000 the Company made to acquire the license, the Company is required to pay an annual license fee of $10,000 and royalties ranging from 2% to 4% of net sales of products that are covered by the patents. In order to maintain the exclusive license rights, the agreement also calls for a minimum annual royalty threshold. The minimum royalty threshold was $200,000 for 2011 and $200,000 for 2010. This minimum royalty threshold will remain $210,000 for 2012 and thereafter. As of March 31, 2012, the Company has not made any payments other than the initial payment to acquire the license. At March 31, 2012 and December 31, 2011, the Company’s liability under this agreement was $1,601,420 and $1,540,204, respectively, which is reflected as a component of accrued expenses on the consolidated balance sheets (see Note 6). During the three months ended March 31, 2012 and 2011, the Company incurred expenses of $52,500, $52,500, and $1,610,420 from August 12, 1999 (date of inception) to March 31, 2012. The Company has accrued interest for the past due commitment at 2% over the prime rate per the terms of the agreement. The Company has included $257,920 in accrued expenses as of March 31, 2012.

Approximate annual future minimum obligations under this agreement as of March 31, 2012 are as follows:

Year Ending December 31,


2012	$	157,500
2013		210,000
2014		210,000
2015		210,000
Total	$	787,500

Contingency for Registration of the Company’s common stock

The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2012 or December 31, 2011.

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2012

Litigation

The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2012, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, consolidated results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

NOTE 12 – SUBSEQUENT EVENTS

In April, 2012, we issued an aggregate of 3,055,828 shares of our common stock valued at $36,400, in settlement of a Convertible Promissory Note of $35,000, and balance of $1,400 charged to interest expense.

Pursuant to the terms and conditions of the Standby Equity Distribution Agreement with Greystone Capital Partners dated November 2, 2011, The Company drew down the sum of $25,000 and issued 1,000,000 shares of our common stock, registered on a Form S-1, declared effective February 10, 2012, to Greystone Capital Partners. The shares were valued at a price of $.025 per share (such price determined based on the terms and conditions of the Standby Equity Distribution Agreement).

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” are to the Company and all subsidiaries, unless the context requires otherwise.. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and the accompanying related notes included in this quarterly report and our audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission.

Cautionary Statement Regarding Forward-Looking Statements

This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Additional information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011.

Our Ability To Continue as a Going Concern

Our independent registered public accounting firm has issued its report dated April 12, 2012, in connection with the audit of our consolidated financial statements as of December 31, 2011, that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern. Our unaudited condensed consolidated financial statements as of March 31, 2012 have been prepared under the assumption that we will continue as a going concern. Specifically, note 3 of our unaudited financial statement for the quarter ended March 31, 2012 addresses the issue of our ability to continue as a going concern. If we are not able to continue as a going concern, it is likely that holders of our common stock will lose all of their investment. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Overview

We are committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to regenerate damaged tissue, if possible, improve a patient’s quality of life, reduce hospitalizations and reduce overall health care costs.

We were incorporated in the state of Florida in August 1999. Our principal executive offices are located at 13794 NW 4th Street, Suite 212, Sunrise, Florida 33325 and our telephone number is (954) 835-1500. Information about us is available on our corporate web site at www.bioheartinc.com. Information contained on the web site does not constitute part of, and is not incorporated by reference in, this report.

Biotechnology Product Candidates

Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. MyoCell is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. Our most recent clinical trials of MyoCell include the SEISMIC Trial, a completed 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe and the MYOHEART Trial, a completed 20-patient, multicenter, Phase I dose-escalation trial conducted in the United States. We were approved by the U.S. Food and Drug Administration (the “FDA”) to proceed with a 330-patient, multicenter Phase II/III trial of MyoCell in North America and Europe (the “MARVEL Trial”). We completed the MyoCell implantation procedure on the first patient in the MARVEL Trial on October 24, 2007. Thus far, 20 patients, including 6 control patients, have been treated. Initial results for the 20 patients were released at the Heart Failure Society of American meeting in September, 2009, showing a significant (35%) improvement in the 6 minute walk for those patients who were treated, and no improvement for those who received a placebo. We are planning, on the basis of these results, to request the FDA to consider the MARVEL Trial a pivotal trial (pivotal from Phase II to Phase III) and to reduce the number of patients in the trial to 150. No assurances can be provided that this request will be approved. The SEISMIC, MYOHEART and MARVEL Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart. Upon regulatory approval of MyoCell, we intend to generate revenue in the United States from the sale of MyoCell cell-culturing services for treatment of patients by qualified physicians. Abroad, we are identifying centers where it is already acceptable to use the Myocell treatment so that greater numbers of patients with this problem can have access to treatment.

We received approval from the FDA in July of 2009 to conduct a Phase I safety study on 15 patients of a combined therapy (Myocell with SDF-1), which we believe is the first approval of a study combining gene and cell therapies. We initially commenced work on this study, called the REGEN trial, during the first quarter of 2010. We suspended activity on the trial in 2010 while seeking additional funding necessary to conduct the trial. Work on the trial was reinitiated in 2011. Based on the results of the trial, we intend to either incorporate the combined treatment into the Marvel Trial, or continue with the Marvel Trial based on the use of Myocell alone.

In our pipeline, we have multiple product candidates for the treatment of heart damage, including autologous, adipose cell treatment for acute heart damage, chronic ischemia and critical limb ischemia. We hope to demonstrate that our various product candidates are safe and effective complements to existing therapies for chronic and acute heart damage as well as peripheral arterial disease.

MyoCell

MyoCell is a clinical therapy intended to improve cardiac function for those with congestive heart failure and is designed to be utilized months or even years after a patient has suffered severe heart damage due to a heart attack or other cause. We believe that MyoCell has the potential to become a leading treatment for severe, chronic damage to the heart due to its perceived ability to satisfy, at least in part, what we believe to be an unmet demand for more effective and/or more affordable therapies for chronic heart damage. MyoCell uses myoblasts, cells that are precursors to muscle cells, from the patient’s own body. The myoblasts are removed from a patient’s thigh muscle, isolated, grown through our proprietary cell culturing process, and injected directly in the scar tissue of a patient’s heart. A qualified physician performs this minimally invasive procedure using an endoventricular catheter. We entered into an agreement with a Johnson & Johnson company to use its NOGA® Cardiac Navigation System along with its MyoStar™ injection catheter for the delivery of MyoCell in the MARVEL Trial.

When injected into scar tissue within the heart wall, myoblasts have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells. In a number of clinical and animal studies, the engrafted skeletal muscle cells have been shown to express various proteins that are important components of contractile function. By using myoblasts obtained from a patient’s own body, we believe MyoCell is able to avoid certain challenges currently faced by other types of cell-based clinical therapies including tissue rejection and instances of the cells differentiating into cells other than muscle. Although a number of therapies have proven to improve the cardiac function of a damaged heart, no currently available treatment, to our knowledge, has demonstrated an ability to generate new muscle tissue within the scarred regions of a heart.

We believe the market for treating patients in NYHA Class II or NYHA Class III heart failure is significant. According to the AHA Statistics and the European Society of Cardiology Task Force for the Treatment of Chronic Heart Failure, in the United States and Europe there are approximately 5.2 million and 9.6 million, respectively, patients with heart failure. The AHA Statistics further indicate that, after heart failure is diagnosed, the one-year mortality rate is high, with one in five dying and that 80% of men and 70% of women under age 65 who have heart failure will die within eight years. We believe that approximately 60% of heart failure patients are in either NYHA Class II or NYHA Class III heart failure based upon a 1999 study entitled “Congestive Heart Failure Due to Diastolic or Systolic Dysfunction – Frequency and Patient Characteristics in an Ambulatory Setting” by Diller, PM, et. al.

MyoCath

The MyoCath was developed by Bioheart co-founder Robert Lashinski specifically for delivering new cells to damaged tissue. It is a deflecting tip needle injection catheter that has a larger needle which is 25 gauge for better flow rates and less leakage than systems that are 27 gauge. This larger needle allows for thicker compositions to be injected which helps with cell retention in the heart. Also, the MyoCath needle has more fluoroscopic brightness than the normally used nitinol needle, enabling superior visualization during the procedure. Seeing the needle well during injections enables the physician who is operating the catheter to pinpoint targeted areas more precisely, thus improving safety. The MyoCath competes well with other biological delivery systems on price and efficiency and allows the physician to utilize standard fluoroscopy and echo equipment found in every cath lab. The MyoCath is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemic and congestive heart failure. Inventory of MyoCath is limited as it is not currently in production. Our management are considering several contract manufacturers to produce additional inventory.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our critical accounting policies are described in Note 1 to our consolidated financial statements appearing elsewhere in this report, we believe the following policies are important to understanding and evaluating our reported financial results:

Stock-Based Compensation

Revenue Recognition

We recognize revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

We account for Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.

Research and Development Activities

We account for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred

Results of Operations

We are a development stage company and our MyoCell product candidate has not received regulatory approval or generated any material revenues and is not expected to until the last quarter or 2012 or 2013, if ever. We have generated substantial net losses and negative cash flow from operations since inception and anticipate incurring significant net losses and negative cash flows from operations for the foreseeable future as we continue clinical trials, undertake new clinical trials, apply for regulatory approvals, make capital expenditures, add information systems and personnel, make payments pursuant to our license agreements upon our achievement of certain milestones, continue development of additional product candidates using our technology, establish sales and marketing capabilities and incur the additional cost of operating as a public company.

Comparison of the Three Months Ended March 31, 2012 and 2011

Revenues

We recognized revenues of $40,485 in the three month period ended March 31, 2012 compared to revenues of nil in the three month period ended March 31, 2011. The revenue in the three month period ended March 31, 2012 was generated from the sale of MyoCath catheters.

Cost of Sales

Cost of sales was $417 in the three month period ended March 31, 2012 compared to nil in the three month period ended March 31, 2011.

Research and Development

Research and development expenses were $96,729 in the three month period ended in March 31, 2012, 2011, a decrease of $73,382 from research and development expenses of $170,111 in the three month period ended in March 31, 2011. The decrease was primarily attributable to a reduction in the amount of funds allocated to our clinical trials.

The timing and amount of our planned research and development expenditures is dependent on our ability to obtain additional financing. See “- Existing Capital Resources and Future Capital Requirements” and Item 1A. “Risk Factors - We will need to secure additional financing …” as filed with our Form 10-K with the Securities and Exchange Commission on April 12, 2012.

Marketing, General and Administrative

Marketing, general and administrative expenses were approximately $468,000 in the three month period ended March 31, 2012, a decrease of $23,000 from marketing, general and administrative expenses of approximately $491,000 in the three month period ended in March 31, 2011. The decrease in marketing, general and administrative expenses is attributable, in part, to reduction in the value of stock based compensation issued to officers, directors and key employees.

Interest Expense

Interest expense was $429,160 in the three month period ended March 31, 2012 compared to interest expense of $409,720 in the three month period ended in March 31, 2011, an increase of $19,440. During the three months ended March 31, 2012, we incurred a non cash interest expense of $320,706 from the write off and amortization of debt discounts associated with our issued convertible notes as compared to $136,288 for the same period last year.

Inflation

Our opinion is that inflation has not had, and is not expected to have, a material effect on our operations.

Climate Change

Our opinion is that neither climate change, nor governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations.

Concentrations of Credit Risk

There were no accounts receivable as of March 31, 2012, as of December 31, 2011, three customers represented 98% of our accounts receivable.

Liquidity and Capital Resources

In the three month period ended March 31, 2012, we continued to finance our considerable operational cash needs with cash generated from financing activities.

Operating Activities

Net cash used in operating activities was $84,383 in the three month period ended March 31, 2012 as compared to $306,556 of cash used in the three month period ended in March 31, 2011.

Our use of cash for operations in the three months ended March 31, 2012 reflected a net loss generated during the period of approximately $0.9 million, adjusted for non-cash items such as stock-based compensation of $19,051, amortization of the fair value of warrants granted in connection with the Note payable of $51,688, amortization of debt discounts incurred in connection with the BlueCrest Loan and Bank of America and other Loans of $248,776, non cash interest paid of $21,169 and depreciation of $4,325. Partially offsetting these uses of cash was a net increase in operating assets of $34,688 and an increase in accrued expenses of $288,031 and accounts payable of $254,157.

Our use of cash for operations in the three months ended March 31, 2011 reflected a net loss generated during the period of $1 million, adjusted for non-cash items such as stock-based compensation of $105,347 amortization of the fair value of warrants granted in connection with the BlueCrest Loan and Bank of America loan of $95,212, amortization of loan costs incurred in connection with the BlueCrest Loan and Bank of America Loan of $136,288 and depreciation of $8,705 and an increase in prepaid and other current assets of $50,761. Partially offsetting these uses of cash were increases in accrued expenses of $109,531 and accounts payable of $363,511.

Financing Activities

Net cash provided by financing activities was an aggregate of $167,500 in the three month period ended March 31, 2012 as compared to $473,258 in the three month period ended in March 31, 2011.In the three month period ended March 31, 2012 we sold, in two private placements, shares of common stock and warrants for aggregate net cash proceeds of $117,500 and $50,000 respectively.

Existing Capital Resources and Future Capital Requirements

Our MyoCell product candidate has not received regulatory approval or generated any material revenues. We do not expect to generate any material revenues or cash from sales of our MyoCell product candidate until commercialization of MyoCell, if ever. We have generated substantial net losses and negative cash flow from operations since inception and anticipate incurring significant net losses and negative cash flows from operations for the foreseeable future. Historically, we have relied on proceeds from the sale of our common stock and our incurrence of debt to provide the funds necessary to conduct our research and development activities and to meet our other cash needs.

At March 31, 2012 we had cash and cash equivalents totaling $69,945 however, our working capital deficit as of such date was approximately $12.29 million. Our independent registered public accounting firm has issued its report dated April 12, 2012 in connection with the audit of our consolidated financial statements as of December 31, 2011 that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

. We do not hold any derivative instruments and do not engage in any hedging activities.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and Controller, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our CEO and Controller, an evaluation was performed on the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our CEO and Controller, concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to the Company’s limited resources and limited number of employees. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and outsourced accounting professionals. As we grow, we expect to increase our number of employees, which, we believe, will enable us to implement adequate segregation of duties within the internal control framework.

Changes In Internal Control Over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting during the most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Our company is not involved in any material litigation and we are unaware of any threatened material litigation. However, the biotechnology and medical device industries have been characterized by extensive litigation regarding patents and other intellectual property rights. In addition, from time to time, we may become involved in litigation relating to claims arising from the ordinary course of our business.

Item 1A. Risk Factors

The risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2011, filed on April 12, 2012, have not changed except that we disclose the following new risk factors related to our securities and disclosures as follows:

The market price of our common stock may limit its eligibility for clearing house deposit.

We are advised that if the market price for shares of our common stock is less than $0.10 per share, Depository Trust Company and other securities clearing firms may decline to accept our shares for deposit and refuse to clear trades, in our securities. This would materially and adversely affect the marketability and liquidity of our shares and, accordingly may materially and adversely affect the value of an investment in our common stock.

We are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the Jumpstart our Business Startups Act of 2012 or JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including not being required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. An “emerging growth company” can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

We will incur increased costs and demands upon management as a result of complying with the laws and regulations that affect public companies, which could materially adversely affect our results of operations, financial condition, business and prospects.

As a public company and particularly after we cease to be an “emerging growth company,” we will incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting and corporate governance requirements. These requirements include compliance with Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC.

The increased costs associated with operating as a public company will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business. Additionally, if these requirements divert our management’s attention from other business concerns, they could have a material adverse effect on our results of operations, financial condition, business and prospects.

However, for as long as we remain an “emerging growth company” as defined in the JOBS Act, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.”

If the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30, we would cease to be an “emerging growth company” as of the following June 30, or if we issue more than $1 billion in non-convertible debt in a three-year period, we would cease to be an “emerging growth company” immediately.

There have been no other material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Subscription Agreements – Common Stock and Warrants

In January 2012, the Company sold an aggregate of 5,750,000 shares of the Company’s common stock and warrants to purchase 5,750,000 shares of the Company’s common stock for aggregate gross cash proceeds of $117,500. The warrants are (i) exercisable solely for cash at an exercise prices of $0.02 to $0.03 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

In February 2012, the Company sold an aggregate of 3,571,430 shares of the Company’s common stock and warrants to purchase 3,571,430 shares of the Company’s common stock for aggregate gross cash proceeds of $50,000. The warrants are (i) exercisable solely for cash at an exercise price of $0.014 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

The offer and sale of such shares of our common stock and warrants were effected in reliance on the exemptions for sales of securities not involving a public offering, as set forth in Rule 506 promulgated under the Securities Act of 1933 (the “Securities Act”) and in Section 4(2) of the Securities Act, based on the following: (a) the investors confirmed to us that they were “accredited investors,” as defined in Rule 501 of Regulation D promulgated under the Securities Act and had such background, education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to the offering; (c) the investors were provided with certain disclosure materials and all other information requested with respect to our company; (d) the investors acknowledged that all securities being purchased were “restricted securities” for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; and (e) a legend was placed on the certificates representing each such security stating that it was restricted and could only be transferred if subsequent registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.

Loan agreement amendment

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% less than the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

For the three months ended March 31, 2012 the Company paid $263,560 in principal and $11,641 in interest. As of March 31, 2012 the balance due under the Loan is $544,267.

Item 3. Defaults Upon Senior Securities

There were no defaults upon senior securities during the period ended March 31, 2012.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

There is no information with respect to which information is not otherwise called for by this form.

Item 6.

Exhibits


Exhibit No.		Exhibit Description

3.1(6)		Amended and Restated Articles of Incorporation of the registrant, as amended
3.2(9)		Articles of Amendment to the Articles of Incorporation of the registrant
3.3(8)		Amended and Restated Bylaws
4.1(5)		Loan and Security Agreement, dated as of May 31, 2007 by and between BlueCrest Capital Finance, L.P. and the registrant
4.2(12)		Notice of Event of Default, from BlueCrest Venture Finance Master Fund Limited to the Company, dated January 28, 2009
4.3(12)		Notice of Acceleration, from BlueCrest Venture Finance Master Fund Limited to the Company, dated February 2, 2009
4.4(13)		Amendment to Loan and Security Agreement, between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
4.5(13)		Grant of Security Interest (Patents), between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
4.6(13)		Security Agreement (Intellectual Property), between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
4.7(13)		Subordination Agreement, by Hunton & Williams, LLP in favor of BlueCrest Venture Finance Master Fund Limited, entered into and effective April 2, 2009
4.8(13)		Amended and Restated Promissory Note, dated April 2, 2009, by the Company to BlueCrest Venture Finance Master Fund Limited


4.9(13)		Warrant to purchase 1,315,542 shares of the registrant’s common stock, dated April 2, 2009, issued to BlueCrest Venture Finance Master Fund Limited
4.10(14)		Warrant to purchase 451,043 shares of the registrant’s common stock, dated April 2, 2009, issued to Rogers Telecommunications Limited
4.11(14)		Warrant to purchase 173,638 shares of the registrant’s common stock, dated April 2, 2009, issued to Hunton & Williams, LLP
4.12(4)		Warrant to purchase shares of the registrant's common stock issued to Howard J. Leonhardt and Brenda Leonhardt
4.12(19)		10% Convertible Promissory Note Due July 23, 2010, in the amount of $20,000, payable to Dana Smith
4.13(19)		10% Convertible Promissory Note Due July 23, 2010, in the amount of $100,000, payable to Bruce Meyers
4.14(19)		Registration Rights Agreement, dated July 23, 2009
4.15(4)		Warrant to purchase shares of the registrant's common stock issued to the R&A Spencer Family Limited Partnership
4.15(19)		Subordination Agreement, dated July 23, 2009
4.16(19)		Note Purchase Agreement, dated July 23, 2009
4.17(19)		Closing Confirmation of Conversion Election, dated July 23, 2009
4.20(6)		Warrant to purchase shares of the registrant's common stock issued to Samuel S. Ahn, M.D.
4.23(7)		Warrant to purchase shares of the registrant's common stock issued to Howard and Brenda Leonhardt
4.27(11)		Form of Warrant Agreement for October 2008 Private Placement
4.30(19)		10% Convertible Promissory Note Due July 23, 2010, in the amount of $100,000, payable to Bruce Meyers
10.1**(1)		1999 Officers and Employees Stock Option Plan
10.2**(1)		1999 Directors and Consultants Stock Option Plan
10.3(1)		Form of Option Agreement under 1999 Officers and Employees Stock Option Plan
10.4(3)		Form of Option Agreement under 1999 Directors and Consultants Stock Option Plan
10.5**(4)		Employment Letter Agreement between the registrant and Scott Bromley, dated August 24, 2006.
10.6(1)		Lease Agreement between the registrant and Sawgrass Business Plaza, LLC, as amended, dated November 14, 2006.
10.7(1)		Asset Purchase Agreement between the registrant and Advanced Cardiovascular Systems, Inc., dated June 24, 2003.
10.8(4)		Conditionally Exclusive License Agreement between the registrant, Dr. Peter Law and Cell Transplants International, LLC, dated February 7, 2000, as amended.
10.9(4)		Loan Guarantee, Payment and Security Agreement, dated as of June 1, 2007, by and between the registrant, Howard J. Leonhardt and Brenda Leonhardt
10.10(4)		Loan Guarantee, Payment and Security Agreement, dated as of June 1, 2007, by and between the registrant and William P. Murphy Jr., M.D.
10.11(4)		Loan Agreement, dated as of June 1, 2007, by and between the registrant and Bank of America, N.A.
10.13(4)		Warrant to purchase shares of the registrant's common stock issued to Howard J. Leonhardt and Brenda Leonhardt
10.14(4)		Warrant to purchase shares of the registrant's common stock issued to William P. Murphy, Jr., M.D.
10.16(4)		Material Supply Agreement, dated May 10, 2007, by and between the registrant and Biosense Webster
10.17(5)		Warrant to purchase shares of the registrant's common stock issued to BlueCrest Capital Finance, L.P.
10.18(6)		Loan Guarantee, Payment and Security Agreement, dated as of September 12, 2007, by and between the registrant and Samuel S. Ahn, M.D.


10.19(6)		Loan Guarantee, Payment and Security Agreement, dated as of September 12, 2007, by and between the registrant and Dan Marino
10.21(6)		Loan Guarantee, Payment and Security Agreement, dated as of September 19, 2007, by and between the registrant and Jason Taylor
10.22(7)		Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and Howard and Brenda Leonhardt
10.24(7)		Second Amendment to Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and Howard and Brenda Leonhardt
10.25(7)		Second Amendment to Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and William P. Murphy, Jr., M.D.
10.26**(10)		Bioheart, Inc. Omnibus Equity Compensation Plan
10.28(11)		Form of Registration Rights Agreement for October 2008 Private Placement
10.29(19)		10% Convertible Promissory Note Due July 23, 2010, in the amount of $20,000, payable to Dana Smith
10.31(19)		Registration Rights Agreement, dated July 23, 2009
10.32(19)		Subordination Agreement, dated July 23, 2009
10.33(19)		Note Purchase Agreement, dated July 23, 2009
10.34(19)		Closing Confirmation of Conversion Election, dated July 23, 2009
10.35**(20)		Amended and Restated 1999 Directors and Consultants Stock Option Plan
10.36(21)		Preliminary Commitment Letter with Seaside National Bank and Trust, dated September 30, 2010.
10.37(22)		Loan Agreement with Seaside National Bank and Trust, dated October 25, 2010.
10.38(22)		Promissory Note with Seaside National Bank and Trust, dated October 25, 2010.
10.39(22)		Amended and Restated Loan and Security Agreement with BlueCrest Venture Finance Master Fund Limited, dated October 25, 2010.
10.40(23)		Form of Subscription Agreement, executed November 30, 2010.
10.41(23)		Form of Common Stock Purchase Warrant, issued November 30, 2010.
10.42(23)		Form of Registration Rights Agreement, dated November 30, 2010.
10.43(24)		Unsecured Convertible Promissory Note for $25,000, with Magna Group, LLC, dated January 3, 2011.
10.44(24)		Promissory Note for $139,728.82 with Magna Group, LLC, dated January 3, 2011.
10.45(24)		Securities Purchase Agreement with Magna Group, LLC, dated January 3, 2011.
10.46(24)		Subordination Agreement, dated January 3, 2011.
10.47(24)		Notice of Conversion Election, dated January 3, 2011.
10.48(25)		Unsecured Convertible Promissory Note for $34,750, with Magna Group, LLC, dated May 16, 2011.
10.49(25)		Promissory Note for $139,728.82 with Magna Group, LLC, dated May 16, 2011.
10.50(25)		Securities Purchase Agreement with Magna Group, LLC, dated May 16, 2011.
10.51(25)		Subordination Agreement, dated May 16, 2011.
10.52(26)		Promissory Note for $139,728.82 with Lotus Funding Group, LLC, dated June 15, 2011.
10.53(26)		Partial Assignment and Modification Agreement, dated June 15, 2011.
10.54(26)		Subordination Agreement, dated June 15, 2011.
10.55(27)		Promissory Note for $140,380.21 with Greystone Capital Partners, dated July 8, 2011.
10.56(27)		Partial Assignment and Modification Agreement, dated July 8, 2011.
10.57(27)		Subordination Agreement, dated July 8, 2011.
10.58(28)		Promissory Note for $139,728.82 with Greystone Capital Partners, dated August 1, 2011.
10.59(28)		Partial Assignment and Modification Agreement, dated August 1, 2011.
10.60(28)		Subordination Agreement, dated August 1, 2011.
10.61(29)		Promissory Note for $139,728.82 with Greystone Capital Partners, dated September 1, 2011.


10.62(29)		Partial Assignment and Modification Agreement, dated September 1, 2011.
10.63(29)		Subordination Agreement, dated September 1, 2011.
10.64(30)		Promissory Note for $139,728.82 with Greystone Capital Partners, dated October 1, 2011.
10.65(30)		Partial Assignment and Modification Agreement, dated October 1, 2011.
10.66(30)		Subordination Agreement, dated October 1, 2011.
10.67(29)		Right of First Refusal with Greystone Capital Partners dated September 28, 2011
10.68(29)		Promissory Note for $35,000 with Thalia Woods Management, Inc. dated September 28, 2011.
10.69(29)		Subordination Agreement, dated September 28, 2011
10.70(31)		Promissory Note for $139,728.82 with Greystone Capital Partners, dated November 1, 2011.
10.71(31)		Partial Assignment and Modification Agreement, dated November 1, 2011.
10.72(31)		Subordination Agreement, dated November 1, 2011.
10.73(32)		Promissory Note for $139,728.82 with Greystone Capital Partners, dated December 1, 2011
10.74(32)		Form of Partial Assignment and Modification Agreement.
10.75(32)		Form of Subordination Agreement.
10.76(31)		Standby Equity Distribution Agreement dated as of November 2, 2011.
10.74(33)		Promissory Note for $139,728.82 with Greystone Capital Partners, dated January 3, 2012
10.75(34)		Promissory Note for $139,728.82 with Mr. Charles Hart and Mr. Greg Knutson dated February 6, 2012.
10.76(36)		Unsecured Convertible Promissory Note for $63,000, with Asher Enterprises, Inc., dated April 2, 2012

14.1(2)		Code of Ethics for Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer and persons performing similar functions
14.2(2)		Code of Business Conduct and Ethics

31.1*		Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Filed herewith

** Indicates management contract or compensatory plan.


(1)		Incorporated by reference to the Company’s Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2007.
(2)		Incorporated by reference to Amendment No. 1 to the Company’s Form S-1 filed with the SEC on June 5, 2007.
(3)		Incorporated by reference to Amendment No. 2 to the Company’s Form S-1 filed with the SEC on July 12, 2007.
(4)		Incorporated by reference to Amendment No. 3 to the Company’s Form S-1 filed with the SEC on August 9, 2007.
(5)		Incorporated by reference to Amendment No. 4 to the Company’s Form S-1 filed with the SEC on September 6, 2007.


(6)		Incorporated by reference to Amendment No. 5 to the Company’s Form S-1 filed with the SEC on October 1, 2007.
(7)		Incorporated by reference to Post-effective Amendment No. 1 to the Company’s Form S-1 filed with the SEC on October 11, 2007.
(8)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 3, 2008.
(9)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2008.
(10)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2008.
(11)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2008.
13)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 8, 2009.
(14)		Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2009.
(15)		Incorporated by reference to the Company’s Annual Report on Form 10-K/A filed with the SEC on April 30, 2009.
(16)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2009.
(17)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 20, 2009.
(18)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 9, 2009.
(19)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 3, 2009.
(20)		Incorporated by reference to Exhibit 4.6 to the Company’s Post Effective Amendment to Registration Statement on Form S-8/A, filed with the SEC on June 2, 2010.
(21)		Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 6, 2010.
(22)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 29, 2010.
(23)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on December 6, 2010.
(24)		Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on January 12, 2011.
(25)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on May 25, 2011
(26)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on June 21,2011
(27)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15. 2011
(28)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2011
(29)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on January 13, 2012
(30)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on January 30, 2012
(31)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on March 23, 2012
(32)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on March 30, 2012
(33)		Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on April 2, 2012
(34)		Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on April 12, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




		Bioheart, Inc.

Date: May 15, 2012	By:	/s/Mike Tomas
		Mike Tomas
		Chief Executive Officer & President and Principal Accounting Officer

EX-31.1 2 d29450_ex31-1.htm EX-31.1 UNITED STATES

EXHIBIT 31.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mike Tomas, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2012, of Bioheart, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2012

/s/ Mike Tomas

Mike Tomas

Chief Executive Officer and President and Principal Financial and Accounting Officer

EX-32.1 3 d29450_ex32-1.htm EX-32.1 UNITED STATES

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bioheart, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mike Tomas, Chief Executive Officer and President And Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

/s/Mike Tomas

Mike Tomas

Chief Executive Officer and President

And Principal Financial and Accounting Officer

May 14, 2012

EX-101.INS 4 bhrt-20120331.xml XBRL INSTANCE FILE 0001388319 2010-12-31 0001388319 2011-01-01 2011-03-31 0001388319 2011-03-31 0001388319 2011-12-31 0001388319 us-gaap:CommonStockMember 2011-12-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001388319 bhrt:DeficitAccumulatedDuringDevelopmentStageMember 2011-12-31 0001388319 us-gaap:PreferredStockMember 2011-12-31 0001388319 us-gaap:DeferredCompensationShareBasedPaymentsMember 2011-12-31 0001388319 bhrt:CommonStockSubscriptionMember 2011-12-31 0001388319 bhrt:SubscriptionReceivableMember 2011-12-31 0001388319 2012-01-01 2012-03-31 0001388319 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-03-31 0001388319 bhrt:DeficitAccumulatedDuringDevelopmentStageMember 2012-01-01 2012-03-31 0001388319 1999-08-12 2012-03-31 0001388319 2012-03-31 0001388319 us-gaap:CommonStockMember 2012-03-31 0001388319 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001388319 bhrt:DeficitAccumulatedDuringDevelopmentStageMember 2012-03-31 0001388319 us-gaap:PreferredStockMember 2012-03-31 0001388319 us-gaap:DeferredCompensationShareBasedPaymentsMember 2012-03-31 0001388319 bhrt:CommonStockSubscriptionMember 2012-03-31 0001388319 bhrt:SubscriptionReceivableMember 2012-03-31 0001388319 2012-05-02 xbrli:shares iso4217:USD iso4217:USDxbrli:shares BIOHEART, INC. 0001388319 bhrt Yes No --12-31 Smaller Reporting Company 136975326 10-Q 2012-03-31 false 2012 Q1

3298

170000

36828

69945

3495

63702

63286

49828

88427

153853

221658

15476

11151

99164

268493

331973

2377807

2631964

3882115

4170146

456000

465286

1500000 1500000

365000

3232762 2946837

12278970

12535233

95625

132920

98915155

99631969

111021257

111968149

-12010477

95625

98915155

-111021257

-12203260

132920

99631969

-111968149

268493

331973

0.001

5000000

0.001

195000000

95625236

132919498

95625236

132919498

40485

1249016

417

551251

40068

697765

170111

96729

64387840

490508

468099

35127583

58695

8705

4325

887650

669324

569153

100461768

-669324

-529085

-99764003

117500

-25026

762277

3389

11353

264184

409720

429160

13323081

-406331

-417807

-12204146

-1075655

-946892

-111968149

-1075655

-946892

-111968149

-0.03

-0.01

40517481

114974051

95625236

132919498

167500

9321

158179

9321430

10000 250 9750 250000

387033

27724

359309

27722832

19051

170525

8705

4325

887650

1266

166266

136288

248776

1391763

21169

199070

5413156 92158 50761 5393074

3054

927

1228717

285659

360032 3381629 756816 10000 1457922 69159 99997 7758

105347

19051

9893379

-3495

1265

-416

63287

50761

38599

98396

28854

363511

254157

3189572

109531

288031

5534834

465287

-306556

-84383

-71953185

898800

-898800

518300

117500

63414475

1447829

3000000

3000000 505000 140000 456000

293749

25000

11557750

210042

3533605

1219268

473258

117500

72921930

166702

33117

69945

67635

128696

1909160

139729 387033 3919778

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES  A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows: General  The accompanying unaudited condensed consolidated financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated December 31, 2011 financial statements and footnotes thereto included in the Company’s SEC Form 10-K. Basis and business presentation  Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2012, the Company has accumulated a deficit through its development stage of $111,968,149. The unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Estimates  The preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. The most significant estimates are those used in the analysis of potential derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates. Revenue Recognition  The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company accounts for Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets. Cash  The Company considers cash to consist of cash on hand. Accounts Receivable  Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts  Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of March 31, 2012 and December 31, 2011, allowance for doubtful accounts was $8,751. Property and Equipment  Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years. Long-Lived Assets  The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. Income Taxes  The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of differences in carrying value of certain debt liability and stock compensation accounting versus tax basis. Comprehensive Income The Company does not have any items of comprehensive income in any of the periods presented. Net Loss per Common Share, basic and diluted  The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 124,077,413 and 40,950,819 for the three months ended March 31, 2012 and 2011, respectively. Stock based compensation  The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non employees be recognized in the income statement based on their fair values. (See note 10) As of March 31, 2012, there were outstanding stock options to purchase 4,636,318 shares of common stock, 2,944,178 shares of which were vested. Concentrations of Credit Risk  The Company’s financial instrument that is exposed to a concentration of credit risk is cash and accounts receivable. Effective December 31, 2010 and extending through December 31, 2012, all non-interest-bearing transaction accounts are fully insured by the Federal Deposit Insurance Corporation (FDIC), regardless of the balance of the account. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. There were no accounts receivables as of March 31, 2012, as of December 31, 2011, three customers represented 98% of the Company’s accounts receivable. For the three month period ended March 31, 2012, the Company's revenues earned from the sale of products and services were $40,485, from two customers. For the three month period ended March 31, 2011, the Company did not generate revenues. Reliance on Key Personnel and Consultants  The Company has 7 full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place. Research and Development  The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $96,729 and $170,111 for the three months ended March 31, 2012 and 2011, respectively and $64,387,840 from August 12, 1999 (date of inception) to March 31, 2012. Fair Value  Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows. Reclassification  Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Recent Accounting Pronouncements  There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

<p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; font-size: 10pt; margin: 0px;">NOTE 2 – RESTATEMENT<p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; font-size: 10pt; margin-top: 8pt; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">The accompanying unaudited condensed consolidated Statement of Operations for the three months ended March 31, 2011 have been restated to correct the errors in the accounting of the Company's issuances of notes payable during the three months ended March 31, 2011. These changes correct the treatment recording of issued notes payable in exchange for payment of debt obligations.<p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; font-size: 10pt; margin-top: 8pt; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; text-align: center;">Unaudited Condensed Consolidated Statement of Operations For the Three Months Ended March 31, 2011<p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; font-size: 10pt; margin-top: 8pt; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; text-align: center;"> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; font-family: 'times new roman', times, serif; orphans: 2; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;" cellspacing="0"><tr style="font-size: 0px;"><td nowrap="nowrap"></td><td nowrap="nowrap"></td><td width="5%" nowrap="nowrap"></td><td nowrap="nowrap"></td><td width="5%" nowrap="nowrap"></td><td nowrap="nowrap"></td><td width="5%" nowrap="nowrap"></td><td nowrap="nowrap"></td><td width="5%" nowrap="nowrap"></td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">As previously reported</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">Adjustment</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">Reference</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">As restated</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="background-color: #cceeff;" valign="bottom" nowrap="nowrap">Revenue</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">$            -</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">$         -</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">$             -</td></tr><tr><td valign="bottom" nowrap="nowrap">Cost of sales</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">-</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">-</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">-</td></tr><tr><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" nowrap="nowrap"> Gross profit</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">-</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td valign="bottom" nowrap="nowrap">Operating expenses:</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="background-color: #cceeff;" valign="bottom" nowrap="nowrap">Research and development</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">170,111</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">170,111</td></tr><tr><td valign="bottom" nowrap="nowrap">Marketing, general and administrative</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">490,508</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">-</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">490,508</td></tr><tr><td style="background-color: #cceeff;" valign="bottom" nowrap="nowrap">Depreciation and amortization</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">8,705</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">8,705</td></tr><tr><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" nowrap="nowrap"> Total operating expenses</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">669,324</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">669,324</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" nowrap="nowrap">Net loss from operations</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">(669,324</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap">) </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">(669,324)</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="background-color: #ccecff;" valign="bottom" nowrap="nowrap">Other income (expenses):</td><td style="background-color: #ccecff;" nowrap="nowrap"> </td><td style="background-color: #ccecff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #ccecff;" nowrap="nowrap"> </td><td style="background-color: #ccecff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #ccecff;" nowrap="nowrap"> </td><td style="background-color: #ccecff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #ccecff;" nowrap="nowrap"> </td><td style="background-color: #ccecff;" valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td valign="bottom" nowrap="nowrap">Other income</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">3,389</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">-</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">3,389</td></tr><tr><td style="background-color: #cceeff;" valign="bottom" nowrap="nowrap">Loss on settlement of debt</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">(110,872</td><td style="background-color: #cceeff;" nowrap="nowrap">)</td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">110,872</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">(1)</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">-</td></tr><tr><td valign="bottom" nowrap="nowrap">Interest expense</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">(409,720</td><td nowrap="nowrap">) </td><td valign="bottom" width="5%" nowrap="nowrap">-</td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap">(409,720)</td></tr><tr><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" nowrap="nowrap"> Total other income (expenses)</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">(517,203</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap">) </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">110,872</td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="background-color: #cceeff; border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">(406,331)</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" nowrap="nowrap">Net loss before income taxes</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">(1,186,527</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap">) </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">110,872</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">(1,075,655)</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="background-color: #cceeff;" valign="bottom" nowrap="nowrap">Income taxes (benefit)</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">-</td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="background-color: #cceeff;" nowrap="nowrap"> </td><td style="background-color: #cceeff;" valign="bottom" width="5%" nowrap="nowrap">-</td></tr><tr><td valign="bottom" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td><td nowrap="nowrap"> </td><td valign="bottom" width="5%" nowrap="nowrap"> </td></tr><tr><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" valign="bottom" nowrap="nowrap">NET LOSS</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">$   (1,186,527</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" nowrap="nowrap">) </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">$  110,872</td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" valign="bottom" width="5%" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" nowrap="nowrap"> </td><td style="border-top-width: 2px; border-top-style: solid; border-top-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; border-bottom-color: #000000;" valign="bottom" width="5%" nowrap="nowrap">$      (1,075,655)</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; font-size: 10pt; margin-top: 8pt; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; text-align: justify;">(1) reverse recording of loss on assignment of debt

NOTE 3 – GOING CONCERN MATTERS The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, during three months ended March 31, 2012, the Company incurred net losses attributable to common shareholders of $946,892 and used $84,383 in cash for operating activities. As of March 31, 2012 we had a working capital deficit of approximately $12.3 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 7 – NOTES PAYABLE  Notes payable were comprised of the following as of March 31, 2012 and December 31, 2011: <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td style="width: 73%; font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td><td style="width: 1%; font: 1pt times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;"> </td><td style="font-weight: bold;"> </td><td style="text-align: center; font-weight: bold;" colspan="3"> March 31, 2012</td><td style="font-weight: bold;"> </td><td style="text-align: center; font-weight: bold;" colspan="3">December 31, 2011</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="border-top: black 1.5pt solid;">Seaside Bank note payable. Terms described below</td><td style="border-top: black 1.5pt solid;"> </td><td style="border-top: black 1.5pt solid;">$</td><td style="text-align: right; border-top: black 1.5pt solid;">980,000</td><td style="border-top: black 1.5pt solid;"> </td><td style="border-top: black 1.5pt solid;"> </td><td style="border-top: black 1.5pt solid;">$</td><td style="text-align: right; border-top: black 1.5pt solid;">980,000</td><td style="border-top: black 1.5pt solid;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td>BlueCrest Capital Finance note payable. Monthly payments of principal and interest as described below, net of unamortized  debt discount of $44,530 and $96,218 respectively</td><td> </td><td> </td><td style="text-align: right;">499,737</td><td> </td><td> </td><td> </td><td style="text-align: right;">711,609</td><td> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td>Short-term note payable</td><td> </td><td> </td><td style="text-align: right;">1,384,972</td><td> </td><td> </td><td> </td><td style="text-align: right;">1,384,972</td><td> </td></tr><tr style="vertical-align: bottom;"><td>Short-term note payable, net of unamortized debt discount of $7,555 and $11,391, respectively. Terms described below</td><td> </td><td> </td><td style="text-align: right;">27,445</td><td> </td><td> </td><td> </td><td style="text-align: right;">23,609</td><td> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td>Short-term note payable, net of unamortized debt discount of $4,721. Terms described below</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">-</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">7,854</td><td style="padding: 0.75pt;"> </td></tr><tr style="vertical-align: bottom;"><td>Short-term note payable, net of unamortized debt discount of $60,663. Terms described below</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">-</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">79,066</td><td style="padding: 0.75pt;"> </td></tr><tr style="background-color: #ccecff; vertical-align: bottom;"><td>Short-term note payable, net of unamortized debt discount of $8,552. Terms described below</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">-</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">45,652</td><td style="padding: 0.75pt;"> </td></tr><tr style="vertical-align: bottom;"><td>Short term note payable, net of unamortized debt discount of $85,046.  Terms described below</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">54,683</td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="padding: 0.75pt;"> </td><td style="text-align: right;">-</td><td style="padding: 0.75pt;"> </td></tr><tr style="background-color: #ccecff; vertical-align: bottom;"><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="text-align: right; border-top: windowtext 1.5pt solid;">2,946,837</td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="text-align: right; border-top: windowtext 1.5pt solid;">3,232,762</td><td style="border-top: windowtext 1.5pt solid;"> </td></tr><tr style="vertical-align: bottom;"><td>Less current portion</td><td> </td><td> </td><td style="text-align: right;">(2,946,837</td><td>)</td><td> </td><td> </td><td style="text-align: right;">(3,232,762</td><td>)</td></tr><tr style="background-color: #ccecff; vertical-align: bottom;"><td style="border-top: windowtext 1.5pt solid;">Notes payable – long term</td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;">$</td><td style="text-align: right; border-top: windowtext 1.5pt solid;">— </td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;"> </td><td style="border-top: windowtext 1.5pt solid;">$</td><td style="text-align: right; border-top: windowtext 1.5pt solid;">-</td><td style="border-top: windowtext 1.5pt solid;"> </td></tr></table>   Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was be used to refinance the Company’s loan with a previous Bank of America loan. The obligation was guaranteed by shareholders of the Company. In connection with the Loan Agreement with Seaside Bank and Trust Company, the Company made and delivered a promissory note in the principal amount of the loan that matures in two years.. In connection with the loan transaction with Seaside Bank and Trust Company, the Company entered into an Amended and Restated Loan and Security Agreement with BlueCrest Venture Finance Master Fund Limited.   BlueCrest Capital Finance Note Payable On June 1, 2007, the Company closed on a $5.0 million senior loan from BlueCrest Capital Finance, L.P. with a term of 36 months which bears interest at an annual rate of 12.85% (the “BlueCrest Loan”). The first three months required payment of interest only with equal principal and interest payments over the remaining 33 months. As consideration for the loan, the Company issued to BlueCrest Capital Finance, L.P. a warrant to purchase 65,030 shares of common stock at an exercise price of $7.69 per share. The warrant, which became exercisable one year following the date the warrant was issued, has a ten year term. This warrant had a fair value of $455,483, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan. The Company also paid the lender a fee of $100,000 to cover diligence and other costs and expenses incurred in connection with the loan. On August 31, 2007, BlueCrest Capital Finance, L.P. assigned its rights, liabilities, duties and obligations under the BlueCrest Loan and warrant to BlueCrest Venture Finance Master Fund Limited (“BlueCrest”). The loan may be prepaid in whole but not in part. As collateral to secure its repayment obligations under the loan, the Company granted BlueCrest a first priority security interest in all of the Company’s assets, excluding intellectual property but including the proceeds from any sale of any of the Company’s intellectual property. The loan has certain restrictive terms and covenants including among others, restrictions on the Company’s ability to incur additional senior or pari-passu indebtedness or make interest or principal payments on other subordinate loans. In the event of an uncured event of default under the loan, all amounts owed to BlueCrest are immediately due and payable and BlueCrest has the right to enforce its security interest in the assets securing the loan. During the continuance of an event of default, all outstanding amounts under the loan will bear interest (payable on demand) at an annual rate of the 14.85%. In addition, any unpaid amounts are subject, until paid, to a service charge in an amount equal to two percent (2%) of the unpaid amount. Events of default include, among others, the Company’s failure to timely make payments of principal when due, the Company’s uncured failure to timely pay any other amounts owing to BlueCrest under the loan, the Company’s material breach of the representations and warranties contained in the loan agreement and the Company’s default in the payment of any debt to any of its other lenders in excess of $100,000 or any other default or breach under any agreement relating to such debt, which gives the holders of such debt the right to accelerate the debt. On January 2, 2009, the Company failed to make the monthly payment of principal and interest of approximately $181,000 due on such date. On January 28, 2009, the Company received from BlueCrest notice of this event of default (the “Default Notice”) under the BlueCrest Loan. By reason of the stated event, BlueCrest demanded payment of a 2% late fee of approximately $3,600, together with the principal and interest payment of approximately $181,000. On February 2, 2009, the Company received from BlueCrest notice of acceleration of the outstanding principal amount of the BlueCrest Loan and demanded repayment in full of all outstanding principal and accrued interest on the loan, including late fees, in the aggregate amount of $2,947,045. (The acceleration notice, together with the Default Notice, are referred to as the “Notices”). The Company and BlueCrest entered into an amendment to the BlueCrest Loan as of April 2, 2009 (the “ BlueCrest Loan Amendment”), that, among other things, includes BlueCrest’s agreement to forbear from exercising any of its rights or remedies regarding the defaults described in Notices (the “Forbearance”) as long as there are no new defaults under the BlueCrest Loan, as amended. The BlueCrest Loan Amendment, (a) increases the amount of permitted unsecured indebtedness of the Company, (b) amended the amortization schedule for the Loan to provide for interest-only payments until July 1, 2009, at which time monthly principal and interest payments of $262,692 will commence, and (c) prohibits the Company from granting any lien against its intellectual property and grants to BlueCrest a lien against the Company’s intellectual property that will become effective in the event of a default. In addition, the Company issued BlueCrest a warrant to purchase 1,315,542 shares of the Company’s common stock at $0.53 per share. The fair value of the issued warrants of $539,676 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan. In connection with the BlueCrest Loan Amendment the Company paid BlueCrest accrued interest in the aggregate amount of $126,077. The Company also paid BlueCrest a fee of $15,000. Effective July 1, 2009, the Company and BlueCrest agreed to enter into an amendment to the BlueCrest Loan to amend the amortization schedule for the Loan to provide for interest-only payments until January 1, 2010, at which time monthly principal and interest payments of $139,728 were to commence. In connection with that Amendment the Company issued BlueCrest a warrant to purchase $600,000 of the Company’s common shares and paid a fee of $29,435. The fair value of the issued warrants of $575,529 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan. Effective December 31, 2009, the Company and BlueCrest entered into an amendment to the BlueCrest Loan to amend the amortization schedule for the Loan to provide for interest-only payments until July 1, 2010, at which time monthly principal and interest payments of $139,728.82 were to commence. In connection with that Amendment, the Company issued BlueCrest a warrant to purchase $600,000 of the Company’s common shares and paid a fee of $20,000. The Company also provided BlueCrest with a lien on its Intellectual Property. The fair value of the issued warrants of $507,606 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan. The outstanding principal amount of the Loan as of December 31, 2010 was $2,276,543.03. On January 7, 2011, BlueCrest agreed with the Company and Magna Group, LLC (“Magna”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The Company exchanged the BlueCrest note for a convertible note with Magna in consideration for a payment by Magna to BlueCrest of $139,729.82. Additionally, Magna purchased a $25,000 convertible note from the Company (the “Convertible Note”). On July 18, 2011, the Company issued 625,000 shares of its common stock in settlement of the convertible note and related accrued interest. The loans evidenced by the New Magna Convertible Note are in the nature of convertible debt evidenced by two unsecured convertible promissory notes, each bearing interest at the rate of 8% per annum, payable at maturity and each convertible into common stock of the Company at a price that is 50% less than the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px; font-family: times new roman, times, serif; padding: 0.75pt;"> </td><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: top;"><td> </td><td> </td></tr><tr style="vertical-align: top;"><td>•</td><td>In January 2011, the Company issued an aggregate of 538,542 shares of our common stock in connection with the conversion of $87,729 of the convertible note.</td></tr><tr style="vertical-align: top;"><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: top;"><td>•</td><td>In February 2011, the Company issued an aggregate of 421,392 shares of our common stock in connection with the conversion of the remaining balance of $52,000 of the convertible note.</td></tr></table>  On May 16, 2011, BlueCrest agreed with the Company and Magna Group, LLC (“Magna”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Magna in consideration for a payment by them to BlueCrest of $139,729.82, and thereafter exchanged for a new Convertible Note. Additionally, Magna purchased a $34,750 convertible note from the Company (the “Convertible Note”). The loans evidenced by the New Note and Convertible Note are in the nature of convertible debt evidenced by two unsecured convertible promissory notes, each bearing interest at the rate of 8% per annum, payable at maturity and each convertible into common stock of the Company at a price that is 45% less than the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px; font-family: times new roman, times, serif; padding: 0.75pt;"> </td><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: top;"><td> </td><td> </td></tr><tr style="vertical-align: top;"><td>•</td><td>In June 2011, the Company issued an aggregate of 338,834 shares of our common stock in connection with the conversion of $29,729 of the convertible note.</td></tr><tr style="vertical-align: top;"><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: top;"><td>•</td><td>In July 2011, the Company issued an aggregate of 2,304,615 shares of our common stock in connection with the conversion of $110,000 of the convertible note.</td></tr></table> On June 15, 2011, BlueCrest agreed with the Company and Lotus Funding Group, LLC (“Lotus”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Lotus in consideration for a payment by them to BlueCrest of $139,729.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px; font-family: times new roman, times, serif; padding: 0.75pt;"> </td><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: top;"><td> </td><td> </td></tr><tr style="vertical-align: top;"><td>•</td><td>In June 2011, the Company issued an aggregate of 836,775 shares of our common stock in connection with the conversion of $40,000 of the convertible note.</td></tr><tr style="vertical-align: top;"><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td><td style="font-family: times new roman, times, serif; padding: 0.75pt;"> </td></tr><tr style="vertical-align: top;"><td>•</td><td>In July 2011, the Company issued an aggregate of 2,594,458 shares of our common stock in connection with the conversion of $99,729 of the convertible note.</td></tr></table> On July 8, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $140,380.21, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $140,380.21, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.<table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px;">•</td><td>In July 2011, the Company issued an aggregate of 3,829,001 shares of our common stock in connection with the conversion of the $140,380.21 convertible note.</td></tr></table> On August 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px;">•</td><td>In August 2011, the Company issued an aggregate of 3,358,866 shares of our common stock in connection with the conversion of the $139,728.82 convertible note.</td></tr></table> On September 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px;">•</td><td>In September 2011, the Company issued an aggregate of 5,769,150 shares of our common stock in connection with the conversion of the $139,728.82 convertible note.</td></tr></table> On October 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px;">•</td><td>In October 2011, we issued an aggregate of 4,997,487 shares of our common stock in connection with the conversion of the $115,144 convertible note.</td></tr><tr style="vertical-align: top;"><td>•</td><td>In November 2011, we issued an aggregate of 500,000 shares of our common stock in connection with the conversion of $12,010 convertible note.</td></tr><tr style="vertical-align: top;"><td>•</td><td>In January 2012, we issued an aggregate of 937,242 shares of our common stock in connection with the conversion of $12,575 convertible note.</td></tr></table> On November 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px;">•</td><td>In January 2012, we issued an aggregate of 3,404,363 shares of our common stock in connection with the conversion of the $44,999 convertible note.</td></tr><tr style="vertical-align: top;"><td>•</td><td>In February 2012, we issued an aggregate of 6,756,803 shares of our common stock in connection with the conversion of $94,730 convertible note.</td></tr></table> On December 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right. <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 20px;">•</td><td>In February 2012, we issued an aggregate of 2,695,853 shares of our common stock in connection with the conversion of the $39,001 convertible note.</td></tr><tr style="vertical-align: top;"><td>•</td><td>In March 2012, we issued an aggregate of 7,142,857 shares of our common stock in connection with the conversion of $100,728 convertible note.</td></tr></table> On January 3, 2012, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right. On February 6, 2012, BlueCrest agreed with the Company and Greg Knutson to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $95,000.00, the amount of the monthly payment due on the BlueCrest loan (the “New Note”) after combined with payment of $50,000 by a common stock subscription. The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $95,000.00, and thereafter exchanged for a new Convertible Note. The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right, but in no event lower than $0.01 per share. On March 30, 2012, Bioheart, Inc. (the “Company”) and Northstar Biotechnology Group, LLC (“Northstar”), the holder by assignment of the Amended and Restated Promissory Note (Term A), dated February 6, 2012, issued by the Company to Blue Crest Venture Finance Master Fund Limited, in the principle amount of$544,267.19 (the “Note”), agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company understands that Northstar is owned in part by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart, and received an assignment of the Note from BlueCrest Master Fund Limited on February 29, 2012. The Company and Northstar are in discussions regardingcertain additional amendments to the terms of the Note. For the three months ended March 31, 2012 the Company paid $263,560 in principal and $11,641 in interest. As of March 31, 2012 the balance due under the Loan remains at $544,267.  Short-term Notes Payable On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term. Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Noteholder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share. The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan. At December 31, 2011 and December 31, 2010, the Company has two other outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the BlueCrest Loan is paid off. On January 3, 2012, the Company issued a $139,729 Unsecured Convertible Note that matures in January 3, 2013 in exchange for Bluecrest Capital Finance note payable. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of 65% of the average of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, but in no event lower than $0.01 per share. In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in Convertible Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the Convertible Note. The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $112,063 is charged operations ratably over the note term as interest expense. For the three months ended March 31, 2012, the Company amortized $27,018 to current period operations as interest expense. On February 6, 2012, the Company issued a $95,000 Unsecured Convertible Note that matures in February 6, 2013 in exchange for Bluecrest Capital Finance note payable. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of 65% of the average of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, but in no event lower than $0.01 per share. In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in Convertible Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the Convertible Note. The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $58,462 is charged operations ratably over the note term as interest expense. On February 21, 2012, the Company issued 6,785,714 shares of common stock in settlement of the Unsecured Convertible Note. For the three months ended March 31, 2012, the Company amortized $58,462 to current period operations as interest expense. On September 28, 2011, the Company issued a $35,000 Unsecured Convertible Note that matures in September 2012. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of the lower of $0.13 per share or 65% of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, minimum conversion rate of $0.01 per share. In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the New Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the New Note. The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $15,342 is charged to operations ratably over the note term as interest expense. For the three months ended March 31, 2012, the Company amortized $3,836 to current period operations as interest expense. For the three months ended March 31, 2012, the Company amortized and wrote off an aggregate of $291,744 to current period operations as interest expense. Notes payable, related party As of March 31, 2012 and December 31, 2011, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at 8% per annum and are due upon payoff of the BlueCrest note payable described above. At March 31, 2012 and December 31, 2011, the Company has outstanding three related party notes payable with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The company is not obligated to make payment until BlueCrest loan is paid off.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">NOTE 9 – STOCK OPTIONS AND WARRANTS<p style="font: 8pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Stock Options<p style="font: 8pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">In December 1999, our Board of Directors and shareholders adopted our 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.<p style="font: 8pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">As of March 31, 2012, the Company does not have a stock option plan.<p style="font: 8pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">A summary of options at March 31, 2012 and activity during the year then ended is presented below:<p style="font: 8pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; font-family: 'times new roman', times, serif; orphans: 2; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;" cellspacing="0"><tr style="font-size: 0px;"><td width="360"></td><td width="64"></td><td width="96"></td><td width="96"></td></tr><tr><td valign="bottom" width="360"> </td><td valign="bottom" width="64">Shares</td><td valign="bottom" width="96">Weighted- Average Exercise Price</td><td valign="bottom" width="96">Weighted- Average Remaining Contractual Term (in years)</td></tr><tr><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="360">Options outstanding at January 1, 2011</td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="64">2,158,447 </td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="96">$      2.79</td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="96">6.8</td></tr><tr><td valign="bottom" width="360">Granted</td><td valign="bottom" width="64">4,620,092 </td><td valign="bottom" width="96">$    0.057</td><td valign="bottom" width="96"> </td></tr><tr><td style="background-color: #cceeff;" valign="bottom" width="360">Exercised</td><td style="background-color: #cceeff;" valign="bottom" width="64">(1,982,995)</td><td style="background-color: #cceeff;" valign="bottom" width="96">$    0.001</td><td style="background-color: #cceeff;" valign="bottom" width="96"> </td></tr><tr><td valign="bottom" width="360">Forfeited/Expired</td><td valign="bottom" width="64">(159,226)</td><td valign="bottom" width="96">$      1.80</td><td valign="bottom" width="96"> </td></tr><tr><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="360">Options outstanding at December 31, 2011</td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="64">4,636,318 </td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="96">$      1.20</td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="96">8.1</td></tr><tr><td valign="bottom" width="360">Granted</td><td valign="bottom" width="64">- </td><td valign="bottom" width="96"> </td><td valign="bottom" width="96"> </td></tr><tr><td style="background-color: #cceeff;" valign="bottom" width="360">Exercised</td><td style="background-color: #cceeff;" valign="bottom" width="64"> </td><td style="background-color: #cceeff;" valign="bottom" width="96"> </td><td style="background-color: #cceeff;" valign="bottom" width="96"> </td></tr><tr><td valign="bottom" width="360">Forfeited/Expired</td><td valign="bottom" width="64">- </td><td valign="bottom" width="96"> </td><td valign="bottom" width="96"> </td></tr><tr><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="360">Options outstanding at March 31, 2012</td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="64">4,636,318 </td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="96">$      1.20</td><td style="border-top-color: #000000; border-top-width: 2px; border-top-style: solid; background-color: #cceeff;" valign="bottom" width="96">7.9</td></tr><tr><td valign="bottom" width="360">Options exercisable at March 31, 2012</td><td valign="bottom" width="64">2,944,178 </td><td valign="bottom" width="96">$      1.75</td><td valign="bottom" width="96">7.4</td></tr><tr><td style="border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;" valign="bottom" width="360">Available for grant at March 31, 2012</td><td style="border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;" valign="bottom" width="64">0 </td><td style="border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;" valign="bottom" width="96"> </td><td style="border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;" valign="bottom" width="96"> </td></tr></table><div> </div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The following information applies to options outstanding and exercisable at March 31, 2012:<p style="font: 12pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 1333px; font-family: 'times new roman', times, serif; orphans: 2; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 358px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 25px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 12px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 145px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 25px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 25px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 158px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 25px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 25px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 132px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 24px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 11px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 144px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 24px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 24px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 131px;"> </td><td style="font: 1pt/normal 'times new roman', times, serif; padding: 0.75pt; width: 11px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;"> </td><td style="text-align: center;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="8">Options Outstanding</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="5">Options Exercisable</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;"> </td><td style="text-align: center;"> </td><td style="text-align: center;" colspan="2">Shares</td><td style="text-align: center;"> </td><td style="text-align: center;" colspan="2">Weighted- Average Remaining Contractual Term</td><td style="text-align: center;"> </td><td style="text-align: center;" colspan="2">Weighted- Average Exercise Price</td><td style="text-align: center;"> </td><td style="text-align: center;" colspan="2">Shares</td><td style="text-align: center;"> </td><td style="text-align: center;" colspan="2">Weighted- Average Exercise Price</td><td style="text-align: center;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">$0.00 – $0.70</td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">3,494,360</td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">9.1</td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">$</td><td style="text-align: right; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">0.19</td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">1,846,161</td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">$</td><td style="text-align: right; border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;">0.18</td><td style="border-top-color: black; border-top-width: 1.5pt; border-top-style: solid;"> </td></tr><tr style="vertical-align: bottom;"><td>$0.71 – $1.28</td><td> </td><td> </td><td style="text-align: right;">324,780</td><td> </td><td> </td><td style="text-align: right;">6.1</td><td> </td><td>$</td><td style="text-align: right;">0.77</td><td> </td><td> </td><td style="text-align: right;">315,712</td><td> </td><td>$</td><td style="text-align: right;">0.76</td><td> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>$5.25 – $5.67</td><td> </td><td> </td><td style="text-align: right;">770,810</td><td> </td><td> </td><td style="text-align: right;">3.2</td><td> </td><td>$</td><td style="text-align: right;">5.58</td><td> </td><td> </td><td style="text-align: right;">759,185</td><td> </td><td>$</td><td style="text-align: right;">5.58</td><td> </td></tr><tr style="vertical-align: bottom;"><td>$7.69</td><td> </td><td> </td><td style="text-align: right;">39,572</td><td> </td><td> </td><td style="text-align: right;">4.4</td><td> </td><td>$</td><td style="text-align: right;">7.69</td><td> </td><td> </td><td style="text-align: right;">39,572</td><td> </td><td>$</td><td style="text-align: right;">7.69</td><td> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>$8.47</td><td> </td><td> </td><td style="text-align: right;">6,796</td><td> </td><td> </td><td style="text-align: right;">5.0</td><td> </td><td>$</td><td style="text-align: right;">8.47</td><td> </td><td> </td><td style="text-align: right;">6,796</td><td> </td><td>$</td><td style="text-align: right;">8.47</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="text-align: right; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">4,636,318</td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="text-align: right; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">7.5</td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">$</td><td style="text-align: right; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">1.20</td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="text-align: right; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">2,967,426</td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">$</td><td style="text-align: right; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;">1.75</td><td style="border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid;"> </td></tr></table><p style="font: 12pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The fair value of all options vesting during the year ended December 31, 2011 and 2010 of $409,314 and $248,457, respectively, was charged to current period operations.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Warrants<p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">A summary of warrants at March 31, 2012 and activity during the year then ended is presented below:<p style="font: 12pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 1333px; font-family: 'times new roman', times, serif; orphans: 2; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="3"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="3"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="3"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; padding-bottom: 2pt; font-family: 'times new roman', times, serif;"> </td><td style="text-align: center; padding-bottom: 2pt; font-family: 'times new roman', times, serif; font-weight: bold;"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold;" colspan="3">Shares</td><td style="text-align: center; padding-bottom: 2pt; font-family: 'times new roman', times, serif; font-weight: bold;"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold;" colspan="3">Weighted- Average Exercise Price</td><td style="text-align: center; padding-bottom: 2pt; font-family: 'times new roman', times, serif; font-weight: bold;"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold;" colspan="2">Weighted- Average Remaining Contractual Term (in years)</td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 599px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">Outstanding at January 1, 2011</td><td style="width: 53px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 12px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 133px; text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">13,920,729</td><td style="width: 16px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 53px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 16px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 13px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">$</td><td style="width: 133px; text-align: right; font-family: 'times new">1.98</td><td style="width: 12px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 53px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">5.8</td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif;">  Issued</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">20,817,034</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.07</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif;">  Exercised</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">—  </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.00</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;">  Forfeited</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">(2,127,688</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.69</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">Outstanding at December 31, 2011</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">32,610,075</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">0.86</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">3.8</td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif;">  Issued</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">9,321,430</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.018</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">2.9</td><td style="font-family: 'times new roman', times,"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif;">  Exercised</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">—  </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$ </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;">  Forfeited</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">Outstanding at March 31, 2012</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">41,931,505</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">0.67</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">3.6</td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;">Exercisable at March 31, 2012</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">20,660,810</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.76</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">3.5</td><td style="font-family: 'times new roman', times, serif;"> </td></tr></table><p style="font: 12pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The following information applies to warrants outstanding and exercisable at March 31, 2012:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <p align="center" style="font: 15px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 5.73px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 1333px; font-family: 'times new roman', times, serif; orphans: 2; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="9" nowrap="nowrap">Warrants Outstanding</td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"> </td><td style="text-align: center; font-family: 'times new roman', times, serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="5" nowrap="nowrap">Warrants Exercisable</td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap">Weighted- Average  Remaining Contractual Term</td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap">Weighted- Average  Exercise Price</td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap"> </td><td style="text-align: center; padding-bottom: 1pt; font-family: 'times new roman', times, serif; font-weight: bold;" nowrap="nowrap">Weighted-  Average Exercise Price</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 466px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">0.01 – $0.50</td><td style="width: 26px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 119px; text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">32,548,150</td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 26px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 146px; text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">2.6</td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 26px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 13px; font-family: 'times new">$</td><td style="width: 119px; text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">0.09</td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 26px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 119px; text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">12,821,905</td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="width: 8px; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">0.13</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif;">0.52 – $0.68</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">3,800,078</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">5.3</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.59</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">3,800,078</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">$          0.59</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif;">0.70 – $1.62</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">2,626,285</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">3.1</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.79</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">2,626,285</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">$          0.79</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif;">1.81 – $2.61</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">33,710</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">0.5</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">1.90</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">33,710</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">$          1.90</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif;">3.60 – $4.93</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">105,000</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">1.4</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">4.87</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">105,000</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">$          4.87</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;">5.67 – $7.69</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; padding-bottom: 1pt; font-family: 'times new roman', times, serif;">2,818,282</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif;">10.2</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif;">7.50</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; padding-bottom: 1pt; font-family: 'times new roman', times, serif;">1,273,832</td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="padding-bottom: 1pt; font-family: 'times new roman', times, serif;"> </td><td style="text-align: right; padding-bottom: 1pt; font-family: 'times new roman', times, serif;">$          7.26</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">41,931,505</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">3.6</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">0.86</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">20,660,810</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="text-align: right; font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;">$          0.76</td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td><td style="font-family: 'times new roman', times, serif; border-top-color: windowtext; border-top-width: 1.5pt; border-top-style: solid;"> </td></tr></table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 2.3pt 0px 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">During the three months ended March 31, 2012, in connection with the sale of common stock, the Company issued an aggregate of 9,321,430 warrants to purchase the Company's common stock at an exercise prices from $0.014 to $0.03 per shares exercisble in six months and expiring three years from issuance.<div> </div>

EX-101.CAL 5 bhrt-20120331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 bhrt-20120331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 bhrt-20120331_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, At Carrying Value Cash Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Accounts Receivable, Net, Current Accounts receivable, net Accounts receivable, net Inventory, Net Inventory Inventory Prepaid Expense and Other Assets, Current Prepaid and other Prepaid Expense and Other Assets, Current, Total Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Assets Total assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Accrued Liabilities, Current Accrued expenses Accrued Liabilities, Current, Total Due To Related Parties, Current Advances, related party Due to Related Parties, Current, Total Deposit Liability, Current Deposits Subordinated Debt, Related Party Subordinated debt, related party The portion of the carrying value of subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle, if longer. Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets to related party. Notes Payable, Related Parties, Current Notes payable, related party Notes Payable Net Of Debt Discount Notes payable, net of debt discount Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable Net Of Debt Discount due within one year or the operating cycle if longer. Liabilities, Current Total current liabilities Total current liabilities Stockholders Equity Attributable To Parent [Abstract] Stockholders' deficit: Preferred Stock, Value, Outstanding Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding as of March 31, 2012 and December 31, 2011 Common Stock, Value, Outstanding Common stock, par value $0.001; 195,000,000 shares authorized, 132,919,498 and 95,625,236 shares issued and outstanding as of March 31, 2012 and December 31, 2011, respectively Additional Paid In Capital Additional paid in capital Additional paid in capital Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated during development stage Deficit accumulated during development stage Stockholders Equity Attributable To Parent Total stockholders' deficit Total stockholders' deficit Balance Balance Liabilities and Equity Total liabilities and stockholders' deficit Total liabilities and stockholders' deficit Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Income Statement [Abstract] Income Statement [Abstract] Revenue, Net Revenue Revenue Cost Of Goods and Services Sold Cost of sales Cost of sales Gross Profit Gross profit Gross profit Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development Research and development Selling, General and Administrative Expense Marketing, general and administrative Marketing, general and administrative Other Asset Impairment Charges Impairment of investment Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation and amortization Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) Net loss from operations Net loss from operations Nonoperating Income (Expense) [Abstract] Other income (expenses): Development Profits, Nonoperating Development revenues Gain (Loss) On Derivative Instruments, Net, Pretax Loss on change of fair value of derivative liability Loss on change of fair value of derivative liability Gain on change in fair value of derivative liability Investment Income, Interest Interest income Other Nonoperating Income Other income Interest Expense Interest expense Interest expense Interest expense Nonoperating Income (Expense) Total other income (expenses) Total other income (expenses) Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Net loss before income taxes Net loss before income taxes Net loss before income taxes Income Tax Expense (Benefit) Income taxes (benefit) Income taxes (benefit) Income taxes (benefit) Net Income (Loss) Attributable To Parent Net loss Net loss NET LOSS Earnings Per Share, Basic and Diluted Net loss per common share, basic and diluted (in dollars per share) Net loss per common share, basic and diluted (in dollars per share) Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding, basic and diluted (in shares) Statement Of Stockholders Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Statement, Equity Components [Axis] Preferred Stock [Member] Preferred stock Common Stock [Member] Common stock Additional Paid-In Capital [Member] Additional Paid in Capital Deferred Compensation, Share-Based Payments [Member] Deferred Compensation Subscription Receivable [Member] Subscription Receivable Receivable from sale of subscriptions. Common Stock Subscription [Member] Common Stock Subscription Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Deficit Accumulated During Development Stage [Member] Deficit Accumulated During Development Stage Cumulative net losses reported during the development stage. Statement [Line Items] Statement [Line Items] Increase (Decrease) In Stockholders Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, Outstanding Balance (shares) Balance (in shares) Balance (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock Stock Issued During Period, Shares, New Issues Issuance of common stock (in shares) Stock Issued During Period, Value Exchange For Services Common stock issued for services Equity impact of the common stock issued in exchange for services. Stock Issued During Period, Shares, Exchange For Services Common stock issued for services (in shares) Number of Common stock in exchange for services Shares. Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments Common stock issued upon conversion of notes payable Stock Issued During Period, Shares, Conversion Of Convertible Securities Common stock issued upon conversion of notes payable (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Requisite Service Period Recognition Stock based compensation Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature Beneficial conversion feature connection with issuance of convertible note Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Provision For Doubtful Accounts Bad debt expense Amortization Of Debt Discount (Premium) Discount on convertible debt Discount on convertible debt Paid-In-Kind Interest Non cash payment of interest Amortization Of Warrants Issued In Exchange For Licenses and Intellectual Property Amortization of warrants issued in exchange for licenses and intellectual property The aggregate expense recognized in the current period that Amortization Of Warrants Issued In Exchange For Licenses And Intellectual Property. Amortization Of Warrants Issued In Connection With Notes Payable Amortization of warrants issued in connection with notes payable Amortization of warrants issued in connection with notes payable The aggregate expense recognized in the current period that Amortization Of Warrants Issued In Connection With Notes Payable. Amortization Of Financing Costs Amortization of loan costs Issuance Of Stock and Warrants For Services Or Claims Warrants issued in exchange for services Equity Instruments Issued In Connection With Rd Agreement Equity instruments issued in connection with R&D agreement The aggregate expense recognized in the current period that Equity Instruments Issued In Connection With R&D Agreement. Equity Instruments Issued In Connection With Settlement Agreement Equity instruments issued in connection with settlement agreement The aggregate expense recognized in the current period that Equity Instruments Issued In Connection With Settlement Agreement. Common Stock Issued In Connection With Accounts Payable and Accrued Interest Common stock issued in connection with accounts payable The aggregate expense recognized in the current period that Common Stock Issued In Connection With Accounts Payable and accrued interest. Common Stock Issued In Exchange For Services Common stock issued in exchange for services The aggregate expense recognized in the current period that Common Stock Issued In Exchange For Services. Common Stock Issued In Connection With Amounts Due To Guarantors Of Bank Of America Loan Common stock issued in connection with amounts due to guarantors of Bank of America loan The aggregate expense recognized in the current period thatCommon Stock Issued In Connection With Amounts Due To Guarantors Of Bank of America loan. Common Stock Issued In Exchange For Distribution Rights and Intellectual Property Common stock issued in exchange for distribution rights and intellectual property The aggregate expense recognized in the current period that Common Stock Issued In Exchange For Distribution Rights And Intellectual Property. Warrants Issued In Connection With Accounts Payable Warrants issued in connection with accounts payable The aggregate expense recognized in the current period thatWarrants Issued In Connection With Accounts Payable. Share-Based Compensation Stock based compensation Stock based compensation Increase (Decrease) In Operating Assets [Abstract] (Increase) decrease in: Increase (Decrease) In Receivables Receivables Receivables Receivables Increase (Decrease) In Inventories Inventory Inventory Inventory Increase (Decrease) In Prepaid Expense and Other Assets Prepaid and other current assets Prepaid and other current assets Prepaid and other current assets Increase (Decrease) In Other Operating Assets Other assets Other assets Other assets Increase (Decrease) In Operating Liabilities [Abstract] Increase (decrease) in: Increase (Decrease) In Accounts Payable Accounts payable Accounts payable Increase (Decrease) In Accrued Liabilities Accrued expenses Accrued expenses Increase (Decrease) In Deferred Revenue Deferred revenue Net Cash Provided By (Used In) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments To Acquire Property, Plant, and Equipment Acquisitions of property and equipment Acquisitions of property and equipment Acquisitions of property and equipment Net Cash Provided By (Used In) Investing Activities, Continuing Operations Net cash used by investing activities Net cash used by investing activities Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock, net Proceeds From (Repurchase Of) Equity Proceeds from (payments for) initial public offering of common stock, net Proceeds from (payments for) initial public offering of common stock, net Proceeds From Related Party Debt Proceeds from subordinated related party note Payment Of Note Payable Payment of note payable The cash outflow for a borrowing supported by a written promise to pay an obligation. Payment of note payable Proceeds From Notes Payable Related Party Proceeds from notes payable, related party The cash inflow associated with the Notes Payable to Related Party. Proceeds From Related Party Advances Proceeds from related party advances The cash inflow associated with the Related Party Advances. Proceeds From Stock Options Exercised Proceeds from exercise of stock options Proceeds From Notes Payable Proceeds from notes payable Proceeds from Notes Payable, Total Repayments Of Notes Payable Repayments of notes payable Repayments of notes payable Payments Of Loan Costs Payment of loan costs Payment of loan costs Net Cash Provided By (Used In) Financing Activities, Continuing Operations Net cash provided in financing activities Net cash provided in financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Interest Paid Interest paid Income Taxes Paid Income taxes paid Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non cash financing activities: Common Stock Issued In Settlement Of Notes Payable Common stock issued in settlement of notes payable The cash inflow associated with the Common Stock Issued In Settlement Of Notes Payable. Accounting Policies [Abstract] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] SIGNIFICANT ACCOUNTING POLICIES Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Restatement [Text Block] RESTATEMENT Going Concern Matters [Abstract] Going Concern Matters [Abstract] Liquidity Disclosure [Policy Text Block] GOING CONCERN MATTERS Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] INVENTORY Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES Notes Payable [Abstract] Notes Payable [Abstract] Notes Payable Disclosure [Text Block] NOTES PAYABLE The entire disclosure for notes payable. Stockholders Equity Note [Abstract] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Stock Option and Warrants Disclosure [Abstract] Stock Option and Warrants Disclosure [Abstract] Stock Option and Warrants [Text Block] STOCK OPTIONS AND WARRANTS The entire disclosure for Stock Option And Warrants. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENTS Equity Component [Domain] EX-101.PRE 8 bhrt-20120331_pre.xml XBRL PRESENTATION FILE EX-101.SCH 9 bhrt-20120331.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - RESTATEMENT link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - GOING CONCERN MATTERS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - INVENTORY link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 11 0001145443-12-000721-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001145443-12-000721-xbrl.zip M4$L#!!0````(`+!=KD"J^):WN6P``)AO!``1`!P`8FAR="TR,#$R,#,S,2YX M;6Q55`D``YPHL4^<*+%/=7@+``$$)0X```0Y`0``[%U[;^.VEO__`O<[:+/` M10O$B=Z/9&8N/'E,W9 MS-P+=&*)Y/F=!P\/R4/JS;\?)X%TCTB,H_#MGG(@[TDH]"(?AZ.W>S_=GO?L MO7^_^^<_WOQ'KR?]^O[ZH^1'7CI!82)Y!+D)\J4'G(REL[][[&W>DF0D6K[]T86H$ZK`'U0,G?/=Z1`!_1 M_TJ`,8R/[L8D>;LW3I+IT>'AP\/#P1V.QL@E"0Z]`R^:,"JRIBE[>84`AW^6 M*M#&#B(R@I*R=DA?WP'QHCA]Z^-Y!;ZP>9B]G!==:?I!8V45QW$.V=MYT1A7 M%81&E<-?/WV\\<9HXO9P&"=NZ)6PX!KLR^5Q'.FJ8M75R$H4%7PT)B`!T.72_IH<=IX(9N$I'9.?PN&O*B-$S(K"RV&'D'H^C^,'_)--.3 ME=Y"-UY*"!C:NGKYVXJ*/L+5=>!%17'TZ(VKR],W%15P>(_BI+I*]JZB4NAB M+ZZNPU[1*DJY2HR]Z@KPHJIX,B5KRL.;B@IIW!NY[G1>9^C&=TRS^8L*+AZ# M&OOY]2,U:MHQJ74?Q M3(/YLS%!P[=[M-_WBKY]\!C[>X>%[SB)P@0])M(-\A+J=DJNP\M?8C#QO.#O M_?CWR^'OFM([11YM4]Y;E`>GAI/9XC?VZ9,A1D1BW):9*\1_,OAA[YT,O5FS M;4UQWAPN5Z8-'E93`%G@R.GY_0Y`Z1IY%9WEO0B`(K'OA`$@9Q[.$DPR+Y&-YGH5\^+!S5LK/WKBBV MPM>;PTH2G'PY-)^U2ON^C^EHXP97+O8'X8D[Q8D;O"KUUO+XY:CZ%`TI?WT/ MYCQI0*/ETY3`U.@4W:,@FM)ZT,`(O0K=TSCKJ!W'7XXE7$$HBF!2XK\^5U[% MVI>CV-.<>?H8!.A2KWN?9:!K\M4=7>]X)78P->Y[5?;^#H9?CF3X1=K.N>_?1[C,=U\ZLDVA"4O0&C+ MFP@O2VRE0&Y%!L+#]:]1R1,OH+\8E7X-,KX857^-&9YY`?W%6,+7!?17JMBO M"^C/NX#^8@SAZP+ZEZ'GKPOHGZ^6916T/'OY\">KNN>81C>[?^.WQV? MOWE[?.Z\43XX;\X5VQQ\IYQ]_YVI#-[:WY]9QV='YV??EQ)/4TJYH;"7!?[B7?&;ME'1XD\WIRO-Y9G=1_"N?6M7B#"4\U9]?`\: M?,<5O4@GB-"\[RT)K]2G#T]1&$UP6-5L4_&4FC@LHU_BFZK^+&`=OV05;WR$ MC\Z8;5ZC$8X3`F9VX4Z0E-O3-4U`7KL']7YP^=U9__IV7QI'<"*(@;#$(?/?Z`9LU(\?UL;5,%G5OBT@,<-[/)710T:Y]ZOJSE4N4EY"PM M'UJ:1O34Q8AZTS1N1N`WJLQ-397)_1P%:9BX9':.`T0:TKF(>#)+313MY]3/ M<>RYP6_()6?9"E\S$KULDS.CLZZI,BN,_`D\'D6DH<9O)FX`E:2YB"0Z6KGA MC.>OU.Z2LKAHA?6ERS2A;I0JMQ+!Z@@AT?[#RN2>3/*1AP%7_'9O<'&^]T[1 M3,#5B$E9RXA,S`"'YV@[1:.:O',Q8F2(<^SO[D MO7>:ZMAO#EM1%0QS?AB@#J9B@?.6GQ?H/&._5IZFK;X,@:JU.$W'T8T../L> M.Y<6+X+["Y3D?ER$&'6'0U='3`RH=3)[C/%1B(.W>PE)479FJB`V".^A61@R M@(8`CDW-DM4%RWSKVU%M9@:::IN;J5X1-'6Q?_9(EVH0&,IE,D:D'\FIB4#62CJ(HAM(>%6<[%U'H";,2QU%,?0&G MDDQ''(W$TA9']DZ``%33UIV5;M*65",>-9A=6O6D\D'JRIW1$4J<,U`UR[)E M:W78+%/JBJ69?S!!#KRR&V&!,=;_B-T['&!ZOEE@.&';*O3)$IQJ8@(0-1*0 M#A&MHILM$9VFZ#:Z1FQ+],HE8H6D&V8IQEY/3`2D9E+:#A+,]F.<%**<"121 M:93BI364.H-I)ISF8(HU^8CX=+$/^:?H+N'D6+V!$EJ'!32Z86N'%,5^5]@9[)-$H6WH+Z3D`W&^2Z@6;JX.M`''0YI#HY MQ3$;)D0(5M54RU1SY==2$X&IV:CHZ*:M64TQ%>+=R9"HJ*IE.Q:GQ?JA9R>C MH*(:FJ%J6E,0Y2P1MBC1;$6V1BHU4_PNY+984>`6?<6P5HZ^#5/E5WS6$Q." MJ9G^-=51Y=:@UB0&BA"2[<#4S>`CQ6I:G>$TG#&Q.-II!6>%\$TEQ\+9:;&\#KSQJ7+GDDC!=^VSB4:3T M;2/#>3H@!U;;>R>R:Y'9<&JA!PS9V*0'`=''*5J75;.<(EN[VRGK-K]Z M4FZ^+>7EJS?J-RET1U;,1K1/HCBY''Z((I]%H(C<8P_%-Q"$=A>`8O%:6$>G M`YHV0C$,1364MH`^D"B.KT@TQ"(,0C8YN^2:;D.Q#<^F8UFFL9'D-8J12SR: M3\O-`_,4P09L;\R$AIGB`D0M-9&P-NQ4F);J/`FJ5AK3-=NR=7D+8#3J8L)M9$3&.U&J#I'L)7GM$T^M[V&U%(:$8%6V#(RY6!"SS/] MS7YVMD';DCE`-93$`=I@:YJZ>T!M=&;;X/CEUI`NI_30)IA>;F)-#@IM."5@ M.IK*Y]`N4^A*?H/MFH["YYL+(-\J$I-EW50L?MAOAF`0>M$$?83ANK,&>FM5 ML"#2'<.&+0=#=60^&A:$H8TN>HYCF1"#55E#-0INO,V")IKV'15UNAN'8AFE M7-%:&#']&((\:\(2MS'[C)3#5GE)A)-"2\? M`(H3^CZ3\H#F%\"3SN`L4U7YE(!UA%;&25ZL6='.G4S3;&=IB%RE(@;()J/2 M2OY.+)(VZE%-7;&73T_40RDT)BQ6E1V+WS-<:K\;Z0T1@>HHICC2K?R*IJF: M;"N-B*\J1)3P>[IL:AJ'8BTI47@V^#)=*9\VV0&>5KZ5;L/KI2,5C1`MQJIS M$DTH91RF4"$?S*(P?H^&$4%9N5OW$<5GCS!SR'+)R6R0H`D[OP0U2<0F&K4N MN97.%=DR3#YI:(=H7XY0-@4>,!5UU%IYWWH/L^QFRWMM M,K&WI]+N2'=S*AO44T,%PCJ1\Y$5'U%JOPOAEOU0'-TGS+H1R$37#KN6])E+ M0F`O+K9!W[LQ]N@")@[29,TF6:T)56W(TCMYY`-^.K>!K%B$#;:,_!^(W214M.X'+)JW`Y6-]&N[J*QJ-E0+)V/'[?#\B3YW;[KN)Q5^S3/@/P#8G8#9)E=H-KRU3L9\/; M-!G[V0`V3,=N@H\RF65>9&-X=AT6R_JY0`_L3?=013'+2X.-J.X$IM@3,9JJ M?`9,;9_EK1BV8BWG0PM@,3/,IU+SB\'R-,,X>O;$;CM!Y M1(I4C.Z=B#]+WX[V+C$+[5&J\?EQV.$0A;4K=C.;?7J-KNEJJK'9=M=";NHR M@1L(@.E5V9?#[.\$PZAX@SPH28\DL#/^??^/--M5Z=XC-=N2^;/S0M$]*]MB M.[5E\?NU7XR4MG<,FN%H30*62OK+PYM%00XI:G_KO&^--GL M+M)]V7+E#)=>4O,+3L8+NSY';I*N.1G2RK8LV5"-=D)H`NRYF-V=L3R!H/@, M-_@[0$^;>+B.Y`X@;IN*N%.(HI(3FX"\(M$]9F80D=,HO4N&:5!SKB75"5*KA`[3W`H4+[_R95U7!$UP.NDN+,U4;?Y6W4T416J:`J"G]#P2J%+>BW$HCCR/P%;]4`V*2X M+*I?7$(_NY(?B1N$W*SX(\04-,VVGS42!,A+4AAK\BN.NV?'ZXJF&&8^5Q<% MJR&?`#C,OFQ#QT?^?K[.7=M1%7I?=B<03\'%!NW(EJF\2"Y:V9@&TUM+%\!' MM:C`/I(?BN@^AFFSHZYQ:F91`2!M.>_%WX.\,4;M#FJIM*5N@HHJ& M5^ARR*;QX$`*$^#6`"_)2>#B27>8JFV8!I^DU8;ZO.=D\PDN4[S:6J_]_HB@ M[(M=78%KIBQKQ6VJ[>FWA7Z#DB3[UIA`%C1;,>DAQ8Y`YKQPBT?5E9';+M[BD?<.TE6*T[(ZGCK5=[RDU(RD"82N_HAN6HZK","XI9,+TP:XU_Y"Z MM.-')+XM<1W*5N@HLE" M.PL?'?B?U4A9C3'->:P/#9;Z5O>>;BEL]N^`2Z01D)M;_GY6+;%NJ-K% M:*884,5GJAKN`6TZQV+6@>)H=0/5REMK$,T*095_H*I(@:O\4%5GAY!/"[NA M>!(^-FVH&X[S0OEHYX\TI]:HN_/!"LX/_`K"K=HV/]5M1K4>9Y-AN=5DW-0, MI=;6:\9C$?`V2-#0%:/6S@[6*%EUN/Z!YQ*[96OE%X`T71\-K=Q?($\-I-KW1%URU#`,!K M-$V)-X:QXG)8^9<]&\.J,CK6,R_9,;3X[!$1#\=K3KFVFH4ZFJ6OZ7Z5%-?!$YI` MH!IK^]ZZ7>E66-I=M648EF6TA`.N*X\3LIXJ3C3T7CAN4KF.T-9@VET_J6DF MG];8!,W5O`3=51&U(ZXX*G]57@61!N'8?.=\Q],9W=)4_HORW>`\*6/M8J$7 MS5BK'2K5`1/3=L(:;0;F#?0?&N7E"\&?"W.[36A'-[IC+K(5:#YC]QM5+5,K[4HMVNY`O2"1;)08(C&D5S++4F76,= MX1V!;78,]=G`M@K/',6Q+'L[M(6579*1&^:YA0`BC@+LLQ_TCAN(KZZ@6T$# MV:,TQB&*XU,TOS(CR[NBNQSTK"!4]F!$O`5.W@=-%U_>_2M(CJ=2G,P"!)8* M17IN@$?AD42/`N'A[%B:N&2$X8$\?3R6AM#.D:3(TT1*\`3F;R%ZD"!6=\/] M[,&^%(/?'1[O_6N4'-/&[^@?%Y>W9Y(B_KRX^!D<'8CT;J'=T4KA]/BK]V!9>#`LST5P;X4IQ.H M/Y.BH92,D11#TWB(/3=,)'>N6&F::U9RI],`P\04AZSXE+..H@E:;3)UPQFM MF(9NZN/\PB:?[LRROW(S@Q_#+*!R`V`Q/V(6`Q-!$#W$1Z]5[+3QE/Z1W^.? M65KZFBWM5HQE@(V]Q]$8N239EV"$/-B7OJ%&5W1K53X^R6C,GRC'W^Y+8_<> M27<(A=1DIR[)3)@"(CY=EY$><#)FYDM2FA_DAKY$T(A>R<.8'K]:`75S=L(#8O7F)#'+W/4R2DDDG4=D`H+M_7@@]1E" MD%`$E2IC(/7:JN#S+E%4QSF?@T*NB/& M]3Z3N,O=;O`-M5K,ME5HT9#J(`"1@XW0`_14NB2%,?M;9MXPF:2*")$'`REU MO%3,KC1T,2E[TX7%YJKV#R3:B:!,&E`?"?"E:#$%INU0U,F8("1!*`#&-67S M#PE!__*E3_1;,9*F[$MTV)7H!_"H(15(,%@$#GUP_?3J]L*F"FK)V$U`"C-` M)*''*?)8#\U)SJ`[YD1@CL,._<[I9*"WZ^SQ.$H#GY*$>1/KL%#GCS1D/671 M?4H-+0-0JILN]P^:BH.@XQ62+H:W)5>B6,>Q!#UYWD%_>+5=8#Y"L3"0B>LN MC_[*9OKZ1Z[2>--DM)$>W)B:4D2F$6%&F8+-9UTE@IUG'GX1D%,2H>\2/X9V M?!;7,:7%Z5T"WLV3',7H*?*^Q%TW*['[9J4S:("-<-]PS/9O3O(J*X,9CK.^ M",1P=._&'@R=!,3H)>`DTP6,Q)5%'&J0$9`(!),@\P),[P.:- MT02[^Y(W)E$(?&=E%\]=+P553&81PP^N`L92<)>99Z48(@H)*M!KRT`QD42] MS3[O),!AQ\RA9@,L53L?3,?T0WO@QUCJ3;S/2H.-I#0AAWE4>N1SG]&BKV(0 MC,L4&D1Q3&G2R1D,XZ`A&@I@&@LMG#]UYJ#4/T#<-(!P,QE*!,=_4C+4O?U_ M>U_:W#:2+/C=$?X/6#_UMAT!T03`TST]$;(M]WB>+?O9FIF=3Q,@610Q!@$. M#LEZOWXSLZJ`PL5#X@%2V'@[+8-`'9E9>5>F%TD"`GB!%>B$,T(WX,:F`Y"< M;X;.%%`$0M9"3L<5?2Y)2.C`LAD9?RAK_/AFEA,M1;#8:7ECF&S":QXG7^-> M"D2-ZSHS#$,?]@:ZT1F>+*=]N'B4*J`TNF*A("O0YP2%`+Z;@4UU?^[?(4T! MJ8`BXMB8*`ML+;7$L4@4%3N\<%A@Q*:-3 M+\+)HBT1D)Q,(09*U@67/%\*T0O%A3Z?()<0#\$,(2IY@C+,`I$@(HX\# M8!*!8VMSU''!K)LS_`]V[DC6#Z>+&WQB9Y,WVDOC%>H?80R#P,EA&)#%S:'F M`KO%"X6"!;"?8(>'OVDOS5=2I^0*B#_FFA;\9+WBCD[>2!.9"@P%!W7J_$0N M@*>?P2I1H(U<]AL]>=E!XYUN4_)32_HX!O-\?.N>N$R`%OI[^:WDC\F><6(Y M%O(,*G>FP4LI"\O8F?^.)S><40;LQB8V0`OGZ_1XZ2[IM54WD^@`B\"?Q&-2 MK@@48GO<9,YLACY`[B&88$M+"@EQQ\)$%)N1CK$1L3[@N&/`I#\'Y.@)Y\'? M87%"<;;1DTL:A*XHTJK_!(&Q$&%VFDRPT-">)WHG=T5P!9)KTG;`B21`QTC% MT3NF8WT1<>\-_(#H8#8<)$7=TE5)9Z-%@$TH[V:,P$ETP1C^X&.U+*8X%Y5! M4C)'E"I4SMV18C#X#^B"3PC!X- M7THH6%E[2_N(AHHJ@U%PBU-FR^DFP$+L:83;B`/IB\N-'?!9'71MSM/H1:"- M78?QN`?H'DBSNKH3H8D((A7&WHCAN:L&:L*60X6EX<=B8(`#HYYZN'`@.L##CAJ,T\^FUD]4_5`&`4PE+Q$X4;2.KGSV@8LZNOF+9,:IM=56JWM/2Y]*NP4%6\B=[501-OL./= M^NXM$WXI(7#A;6#;%(L08GHNEIB()`(HKVH!VWP-7P14MP!%2AQRMG+"`8:_ M>7!.799C#_Q/@FV678QB>D)<&<\[NH`T'('8#(",3IV0Q-HB1E6)&T08?P^$ MY4#<#]BH)\TL6%(,%"@-'\&(DG%+-$FP_22'@V5)MHI>M`E&S71::9;/R6VA M3RM!><`DA2#O$B4Z,M[W.`\A_"8)/,#.1HD2(X0=?.1[(A9!BD?`TA'%"P)Z MITY>B86$Z6A/S"22,3:PD''S_`Q@>(Z4<7Q$L36O4FD\>F@DV$^JC*;%*)X" M,03VA$R#I-8']D(8IP5,6R]62 M0W/Z)^4"V25EKH12B;`S0)E(H*31!:^26&&DX(;+9B4PA4J$$.]A/,6X3^*J MA5-@2V]I9MK8RQQ).1_Z;C47XT2J+3P"K1.>A63R3-A_\(APKG^+?@;8(NB< M(UJEC*1]3K].M!END/$!QDDV7+JNY(#Q0X5G4KM#U\ZY/YWB01VCM7;#PM0Z M$H<+/=XQV48ED&NE]%8!3AS>OK$Q12BW)#"VO1*OE**@<34)%@?PXDHC&):V M0P;C!2TIGQ/BE210Z"NI`N/=9P.]WS5.P1.3<(BDDALE>24WSD^?,60VSI*- M4Y`YXD%<]`^A`/L'$F'`(LHNPT@_^G_N'##A)DZX\.'0Z!GG'&)4N]=N/CF<)`G,L)!"4EH!*`C..4,XLAY+!(1$?(/N^B3("N=.!#Z ML%PR2V@POCZ'.]?(WIH*:P*8$A/=6'D`O"1\A586;@\`MZB&EG102G@)][+8 M([J_0NG6#4%E0!/XW(6CBX[QF0\`O>7.M(R^`O8QGCXTMND,6WC.C2Y9/O6Q M:;9Q`#_YWLWY)P?Q+ZHRG?[94VT9D0:M?;CX_I:<-%:O?6[`_W7/+5U-0OI( M;)U[84&7(=KD9&>VW7`LV.YQ'!YUE=(J,:X5VTX MWL[T$'X13*.;8$^,`U+RV,2G3)`-PMC]3IO"V!G(Y3WA_*7E\>LD$"T)?2)J M:&F1_;.0PR'H7:9%IWG2,05K\9.QS.(3<5K!3WAB8R'C6X9"RQ00G`0&%+'6 MEO8WD6,*[(!K#_I:B\6CJ)@,B9U#'OU4EQJQZ`Y75IE,C5.0!V0):^?:#O-L MSF9P]13V0(6+9^5D,LKA,4=(=BUAP1>,/N(`LQ6OV1Q#*9A1JKPNUPX3"L=/)>>12XG,8$>*429&65#5N%%_B8RCR98 MR$:"Y[XB"4@5>;A)]"U)2)\^YT,V$#"0O93XP4_STV*`$Y]Q\4[,@1+!X=31 M(1MG@"/H$_TM7N*_X(I7DK%?G2EQ]#!+2.8*-*)//MY2`&[([\1J5,):%TE( M/+_/C?'D[XB6GC^K$62V($[-'A>GE$JUKX";`FH!:'*7\T(5;3781/2T$6R MC7EB@YZ]2I+-O)1B.+GW)VURPFPXX_&]Y,9;2WM+Z'4E[OD;N&,2J6/;'0LG M0R[SY(ZAW8V***K/-TS)DAAS^J&A8`UQA#H^)DNT-%Z]S5^D5P3N1&E[-3'Z MIY#C=IB,1=^QM$9$LI([:BK;W"D MTS18O_0P"9_;T6<]C!/)X!AL[1T/U7YSPA^KF<8Q$8S"'S)IS:FAY23]JI*< M)S#JR$6$5]C0NDJ!Q5.I"59XJ0U?)M>5""`4XVJ7)"E1-N8#6FWNR:(P/E=* M^#6TPM5E?M4;V,6Y#-B?8_B>OE'2)-,P!-#GE(0N;"T6U^V1G7Q@$ZKR$Z1 MSPP,&?B9XFGO1.X?<;\/[S^^>Z6+=&]72:@4=[#4`ALP84O[0R8E9&[<9<"= M`(G^R*D=A6TE6TG,#NY#U'!I?%>T$+SO%8FK,1F/@)I/#IH=X=B)8A$+#K,9 M#8FS%<`$6J`#ZD8:V#V%2.)URAX]OXQ,,4NWC*_RIR616*Z*I;DAA+)3@0'<&75U\=*=]M_L M'NW/$!N'N80`O!D=NY']-+)V\O9\GV3..5T"DDEE:ARDL#]';G/A8W()4+(2YWHGH@/[D!2A&\,0\O);?;T4!Q MTU0AX*"N/19>!G'Y#.^7`9X<<6%J$=/5>7KO*9RUD!$7XLE`Z;7\IW6T,C<[ M`A4F:JF",94W?MR=R[[5%G^7@,DA#M\$SPUW/G&!ROJ!J]9L,0@EODC$%/(ATYP<_4B=? MTY@[H6!%>"Y#7IE/?G#V>8>+@1"V>DM9IH3IW8YZ-)YOEMB1QG(<+ MO-T>T/6$I>N7:4_2$R&T-5Y^B$<%4UU"W:NLK\>5`Q5V"N^6Y4,J%R'KBE`Q MC6%/[YM#>N?,Z+=U`VLC/=+%QT?K=71KT-<'G3;7>F01&U"LL)"-]G(B"MTD ME4->(42R,ZS#6<=4FN2XF$K"6#^@T^CO%`4\?5:Z`?\;F/S.^8?$D%0Z61>8 M'W\[XQ-,O(%*\$`H$DKBB!)Y+?-!A+F4F_2C*@M:3V7$0E1T%=X([`.F!K[Y MS6?UJH`?!/X=!C-T?D=*23U4#?YPQAA-A/E6/RG_3]V2C`U(K2F=8([7PPN6 M>+)3K/C"+V*K]VE3L/#XO:X\R6#XT;4^A5 M(C2G7B9*;R46C0HPEP99JJ)=Y^'&N7LIZ%+QH^1<*'$OK%"0IM#Z'G+86]N1 M%_+2[6/&J>.)7'J%)!)1F`QX&AKK\V<5^MKXX3&(@5] M6@FFA!458IWXR1Y9GRYF"S:AA<@9CY6=,"K%GQ3:$[=E_,^3OB" M.XJS1FD&=J005TN[$@7T]81W21FF[-955CG'.W(810HHZ+:*B5?Q\+1YQTY;$"2=&;ZQ1%@]IC_!V'?]X(WV7[QK M'R>A\ZD]=]S[-]JO.2KZ-4=&_&T:Z8TH3B.>(4'92(R9ISPU*7WHL@A0>!X" M^F"ORG.`R?DL][(?+&:V%[[1S-\T]2C`J*,?#OPSCGSQBT-^7W$HZ`D%.)&9 MXG@>HZLB$:.9E:7?.1,LTX\SW/G!)%T8#20GH@%#4/_/>=FG-QJ?.OM[%/@_ MV#F,&,V4TTG?\2.:/;LES1W,3'.';Y??KR^N+S]?7ET3T2WKXW#$2#TJU)V# MVOM&&R@/`KX]^D@\&OE1Y,^SSUPVS>PQQ]4?V&'@>YI,/]64;F+K>L4,14D) MF+@:27H(,79^"0`L_2!)\E/X>]9<_C4DT6'+>P&\+KGT*TSB0*9/KER35&?D M_21U,1'8QU1U3=Q,%.O@0BLWIT/IB[RQ`0)$5GNA2Q`C^.$<,`!5J7]-,?J M.(^5<+.*4D7R$+U+#M&[-0X1L>9`>ZV&XZ^)=C]SVKTLH=V&CDZ6CJJT]8B8 MC4"TLNMR6!5A*K9EM-N_;$H8*K*JL%R`U/:Q\8)JWHLAL;%7`II`PD5914;W MB9!IWP7VXO<7_+_)+Z^CR:8OT9)^?]']Y44SZ*KW7T=!BB5ED%NB_-]?\$-2 M.5(NFXV?NVZK:UDE!TT^7WJ,UMIP:1+=!L/F=[<:9`M-?$*,Y$7E_!?DDKE% MFYH2`[F;Y;2VF)2\/:YM<29>O:]O3%QW/*UM782)2E^Y@H8+K`OT9J/-1IN- MKLL_Q)0C>_P#JZ5XDW-I`8W'C$VGH#(^C,5DV#8E#R^#UAK+V!&>'@"`[0GJ M,TU9Y![^.F]PL`<[:J@RF;?B0`F==LX$E&]'AJ7 M<7WP+6F$* MX#\"JD,1^%-GJ<-BOQL\E%C9*9;VQ`RJ-OG\68.K;>*JKELYMO4^`="?^E'8 MF5AM/*Q/=:./7W/-EW=:M+,S^U1DFF`]47')\4T#[5IMM#FI1T4[APU&E%]@ M?I3R2S'?Q@J(/HLC\$U+ENMLC2XM9`>K.L*UWVX.3VE/C0:\1`1U2"WF?:3Z%!WF.G0#XQ;2& M[Q:6.-#[[6X#ET81:1"_SH%8Q=KJ&0>\]B/L)%;PMJR#A./QH!^%F[S7&^J6 MV6D@7Z,`Q7YA?FS@/>AZ&$=S3*:^%H-/*^UVNCCU[R-Y3U_=EK&<1W]]O7* M/,.^750)FBJ(^IE[Y/7(?SB4Q7(D21PO-U!/:XJP5T\+8X_S4S2Y:4UN6FTV ML7NV]JIRLXT.70,MJ%8;K8<.W6C0N]2@Q]N).7T1A:VIG.A+Z5Q]M327;8UU M'8*IET/D\'SAU,"UEYT_B4W6$KW'F8VKL+$C$2CKJ7^6;@V&)[6C)MVE-N1S MR&273]1US=-"%D4N4RM[/LJJ.\W`_DO#:.N#OKEOT%0;G8>&R&X!4A>R6%4D M[*7Q6`R=XFDY0+6*C[*7C["@3DJ(O.RTAWK?;&]U4VOZNAL]Y*1(:',OYI&% M$0N):^7^E4?QSL;]OD?W>]?HZV;;JL]>FZCB[C7#BJT^?]9$%X]L*PU[6R67 M>[IE+3$CFNAB#?RFM=KHX]=<\^6=%NT'-D_FPL?AY`. MAFX,>GK7[-<=^!OJN$ZW4:YK+6"4*N- M-LKE4='.(2/('Q7E4'LY8AZ;.E$3#]M?/8`&)O6+'&]U_J>%^$89J8%`J=5& M&V7DJ&AG;YXN^1-?:-EHXI?2`<5O._">75YKG[Y\_[Y7$W(WL#@6`WH_E+`] MZ5?>0NA`?KZ:D,ZA?(?'3#N'\$WNEUP:IG),,'C^K!$LM6$.Z_ZUH8?X=62/ M7%;`6!YPU*M^:L\=]_Z-]FODS%FH>>Q."_RY[?VJ:_1$UT(6.%/QMH"AYP=S MVQ7/;NW`L;TH]_2.(1C2ARZ+(H!WN+#'CG>C/'<\=C[+O>P'BYGMA8#&W[2( M_8S.'6_"<`J$(G\2!?#"%-['KSSVFW8W1G_\]"OP?3-(7?<]!`M^]T8SV(DK4CV:!=&;;[Q=-KYS#?.\=?WQCS\_?_:G.#R_L>W%FT_.?V)GXD3W M[YUP#./&`4O>T\:P:?C'-S;]_<4[_O>_K,^7_[*,\\]V<&ZV#?/%GS-T5[87 M33T7!$@.0RU'ACDJ3$[;B-3X+]>7FB7.T\`TC-^T/[Y\O/I#>_?EZMWEMROM M\\7U]>4WKN:/DM.Q*)R,K:^P@A7N;,+K&=/L\=B?+VSO'@DB]NP8,,@FB*\) MIM+27\3\L%.Z-G4\VQL[MJLEM!!J,_N6:2/&/&T1L(4=P'M(4=J-CV/"]V,6 M>-K(#AV8'@[<>,;)8;YP88Q0BV9(E+`O7HD7"1#(D<'(6*07?PWAAW!JC^7/ MKF./'->)'/C:\>@5?G9AX!AI'-X9Q2$PB3!L:1>A%L[\.T^^^O@MZ]HD#O#K M:!8PILUA-[-08_#]1/M,C0XL0]>0J'6:\1V?#_,MX@#AXXE$#%B_'46!,XJ) M^6J1#Y//YWAO:P:`G/DNB)L0MW,V[/3TP=`DF,2XRK-!1[<&%NYJ;($/3)GCU8=`RH"0MT@]NRD3Y"G[\/6W3\"2X/*;IURH=30"QA5?W?@,I^ M.F'$`#::$P*N%HR$G!8O@&A@*/N&2#3S"3\L]PAIT7Q#-'XD>*:UN/AY\S5_ M%-E`5?8$#@8\!YJ8QAY)C!".UQA)"E87,"`9#Q'I^7A@8Y"MXR*Z,RL1APGK MS$X!L7#$B1@"%L9NA)1%*.82#P4!SOMSLL5?8U\2' M#>#D8S>>P&M`H5R@\Y]I/W,4Q7*9P$QB=Y(AZ76IN:5*U74$IRI@/WJWL"(_ MV)*`;12[72MV*UE"B6+2R2@F'Z_^?GEU_>7;/U.Z(-,^?/SP19NS M:.9/6EHZ`TAJ$CB@;G'9Z/IW+,!QQWR"`-?W`Y3"EV!DD;[%=42A%J-@N;7= MF+TJ%2#+!(,J0+X&*%.C^Z\N4,J%-[D$N4-]N!J!!*,EJR:1BDL^B15"TQ/&5]VS, MYB.0">*I03(CGL/`,/<$/YSZKHL;/3W,"VA*5'#$'`E-F*G#=HUSRBU;@;'4 M'_!:>*]6HDFLPK!X0D[R^L8LCO(8Q(X;>/Y4QE M'*@$N\4SG'#I"H9[K/M"F;-^K'6;A-/0[*YQJZH1IT>V:[:`72%!M"6)T45: M%!0V'`[E0C[90&*`Z9K4^IWLBBLHA=:0JEMXS]7:GR!%.$PI/<^JCP?UN),VAV/E@ M.-`'[7J)F`>MZ?AD3!AB1D@\CUV*MDU6-H>O!?F?ZM15_.?E8-#7>]WVWL'P MZHD`OIXXMW3+[!X M3N3K%+!5?YQL(4(=R!LB/(T?LY4H=5]F*[6T#WY0EA6O+>)@X8>(K(48&_[" M5*.2*1)U*Y,^!;NS$0?GB`^11Z7YP''Q5R?0TN2H.&33V`6\W;*P*@7\B"GM MF/E"N^$+]<3)>GSA$FOH3QSN&\?+%WBG!\X>Q3ILQXN81WG^_"*/2)Z7J9'N MO0:3,'%M1SVDR#X6U2QG/(-U,'[[(,G[;VG_F-&M(O&9KWB"*3\&?81XZP5O MG=PY(;`5)T06A+=#^,T;Y%@T7<"XG5=M\Q'CFP.WF?`>Y>+&P8+A31I^?2#V MZ,9"-),_QBY=MKG!ZQ*P$+I-%["I"]_`,/A0V`0.\X?-7HB7)K?/+6XC?30NZ]3.;IQ;MWW_YV^5Z[_']?+Z^^ M7ZZ^7MD0QND0AF`>LGU3*'/NV43>Y.+9C71S<>T\^47/02Q(UG3$J MF]S\]^]M%PSH*6/%3**=A#KTGM'6.V8Q_UZI?#T+5/O=O>+K=*C_'?F3;!^#YK_='$> M#A9Y:_=,OT97-RRS5CC"-5G&AFO:S8FZG"]<_YXQJCWEA"&ZJW7\!SIKR'NM M:RP:[Q<^EF'IW5Z]<&:90[UO]0][KG:=!?.E]'R>9@I2#;.?C(ZAF_W])S\] M.034$/?G]=G_T>:^J?#LZ$:_K1LE^>L'6(RE#P:F#F+_P>(CF_\V<6Y+/A1/ MTPCP`R.Y&`RFLJ]7J%J+C[<3\=U:$==^)L"(C[YK7R_^>?'VTZ5&P%CF<=EE M+NN^B#7%,(-!,T$QS!!/*T[>Y(;*(7E!@MCX@&/CR84>;)+AFM+!PQ"K37 M^'>6Q=9GC04^OPZZJM4U;>-8,07Z21'E*J>J7*H^5G+12;G6TJY9,,?RQ>$X M<$8@V48,)-HJ[7?97.LK\LM&V42IT]88;SAHZ^WVRMM+N]_8TP//FI3/W2MK MT#W^]=:-V3OR/;\3Q=(_.#P;-DO=G^'@SMQ[?,"+2%/RJ^.-G05\HT874(/+ MG0*=*G_"%[$G[B#"+^DVL3<#YKF25D^5X3L=O6NU:=BS84\WC8&2M^K>[]=% MUAD^P$6V:W>X8>B]]G`+;KM'<4YBB3/`Z#E6CLV0S'[A8>C6H*,/^_5RKCYP M50]42)8@H_0`%H]=7^]VN_S4`7U90Q#`ZK%;5\;M%*9F7^]T-G0X['I)5LW/ MXIKH[^A]T]A4D7FH7O_0[S;V,^Y[@5O>6%\?=*O3&O9BZ3R>LGIMO=>S&M*J MU\;Z0[W=JRZ$L@7:*F=HXWTQM`'(,[.ANGIMK(/]^ZK]#?OE:-J#2:N+181: MZ<*.D\JZ';TWL&JSRIJ>H>WSMC)WP)WC3?P[W,JCG1WU&6J%%V79Z*9.#>)* M+.]Z;[D>T+-TTS+U?DFZT=;6^0CF2\6JJ',@7AU&-EM2DFJG1MO+:O+"OXK% MDG:[FFITE:WF\`PI&]15@]8N=DU$L5JGL_9@-^_J]<&NS>/E,`<%X,KDH*WP MIHH:2S)-P&Q9,&9[\3.3,&!NG#!0]I<;;3M!P179(OB'0VJL$I&B^9QDW_O. M%<&6ZD6:V$;GT"^>]F4<^1@5-+L4%6QGV]!2>)'J4T2^9FN?\,K$1?;*A`34 ME2TZ@%(,#YV=UP$L471E/1,!'''K(M(Z+;/["U:W@%>]>)Z&.:B+YIT=4J?, MD!?Z"-A41$^67N:@]=C86_C6\>.P<)L#7^(=/OT1`)%7\\"I;OB%$8;FQ7VA MH:XRY\GVD/WH87J6QWCCY*1PR3*$Y_`L()2EG[D]X;>J)@QKNR`I(7Y\S!W' MLOAD(8IFRTK8:R[M0=X!S_9$;U6;UYK!#^Y\[9[90=C"[GFE:^??X45M6_EE MD]5GJ=]#.J+&S?B9Z'$^X2#B]X1`\<)FLCEXI:'`O\,SV$`2"OQLAUBS_`.H M%MHG9XZ]I5M[Q_P&#';K4Q>X;G78%!4C[:L2`UN/'Q_]P006_=?88QHE;;3[ M60+%%$O90_VLVVK+EMLP@.=0E2&@32I15`E87?O4^MJ2K)/<-G#NK)YL52>^1:LH=AS,71*F#:(%0"%"CX\B(.QC,[9%JOJ[>M-I[]\>87(L!RG[R8(QEJ>"78T9#QZV>D.2D_0AAYD87D^P,[;G3'XL;KHQ MXH]*!BCN9<+;K"UEV MYC/'_519]+54-N8V]7=?4!T\PO@=J)%,&\61QAO'`X$%D>`Z+I:6"P"M`.H0 M=0?&,*LR)CNB'==:+@RQ9<%;B(3RI)*'63Y)3`6FS7778_&NB+(4FQ MG_+&,W[LXD'E?%=4FL/=I;>BN2;GCT&7#KGHP26&MDO'"/]>,F7I!/R8$H"1 M0XWA&1;1PUT`DZ2*>Q'%")!\\6P"C4:ALB1@$_"_=$)#/?T.P2K*EI9NG\[1 M/6*'SK#*PX1XA?\#?#KG"P!5K&'UGQ'@P4,?'/5I_L$4L14HDBH53I[@'&&, MICDR604[`>ZA]I2MYJ=QF MGX!.XTU>E2MD.(C10:6,;"1)OSJ=PM@C'B6G1=@!#?X;SIX.OT4.%]2Z1G8_ MH.\6]1%>>Y-XAR>M-*Z%8>4%,,G@P&)*LO;2_.657$)FII9V>2OS'"66^4D% ML98]J%4'$]0/%YDE3@G4Y=[SDU:>07F'94&!$*J'D\17'!9&Y`R+3FA*=X1F ME?"6,.?,5++VJ38*F`VJD@!0@,5%@:5$@MXUTS2_X99$8_$R=D=T3K^-,]F#B])'$9L+T":_J2*V/#)F3$P")/( M(=$"(5C#;Z2()@L9E*TD8&/F))5OTS,`^HVP6"*T&`JL/&\6OA?/K^@[54^L MU$];VEN`@MF&Z/[T;QA1 M=J*B+[JO&8EJGT"E%3%A`,^C;D:F!=( MV5W;HBRG8H8K#"_5M21\0SV1F#?`!6[P<;K`,PP2]O5VI]O27J)VE]DEWWP9 M)K)$HXM*S%-&!A9R!\Y&%#+C;X;KV"''Q"\RAFM&K`SHKJ6X4-V MR(.NG*J`U)#C:2_L5(AF9LQ#EZ6$'G7#N M1-2*P>-V[B1G*V4,0AAL]$I"3@Z5]-?2PO&,36*7)8XZ6@KZV0+_%AW[5.I< M<*ESHJIR+RL)ZI]X8F5]'1E\?(-X,? MO!R_PO7,G!&2:T:0(U63P2YIVG48:G.@X:&5$548P30L?1?FC)[L`!M9UB+6 MQDT,V`%89=.I*&+OY,TT2?(Y6Z+H(7W^++.\,E>HH5M&5^]V3,4;6K7RO)?T MK-WJ6GF':-8EB4,);ZV8G6.L:PWU7K]'+LH)0ZJ;7,,/61'!JCIO&:"3<:4`/"^H MEXEAP^SI[7Z_RA&:<2A)/VB7JS:7":5DSU-4*9F(RT^XI8W>PW4E%+XUEXTB MMLT+A*YKR.#WP]F!`<35-P>\$`-YB3E'J,`N3%2.3T&XJX[064]:8ZN/#C]C MW!7B3!1DFD.]8W4W.D)].+?FL'9'Z%2]9>DQR]W?7G[6-M4"=WK&$OZPE0/6 M&I@/.6.EL;S]'+(VYYA%'LLAJ"Y#A&%)I,.@J`Y\5"7WUXQ/?,TCV^Z#95L_ MJ7>J1_9Z30M=,;_RM1G:!&RPDLU^#]0DJ]6V,JZ9/J_@H!>E:Z([J'SALWWC MV=H?@1\O=.W3IW>96!W]F+%[T$>WF-),+1R8BWH\^455:5^ M(=\IA\#(=GD$,UDG@I+FX"'=);E`@@$,@0'H.1.CS!\F?%M99D>NT[S]=P5+ MP/228FY"D@CT$_B!=R/LD8R;AHD$-^`^E`V,CGEZ3#ODD.>AWUR2@9VL='0O MWLLH]MD=M[2+)/SD@HW$/Y","MG-F4F:67$A28LJN9O\_M\I7Q3A0`DHR,$' MDNA*&&E/3)ZJ\\BZ,JJ[@UDI4>0RZ303D9+L8G,-N#*J["9F].9YION-%8?R M3/&40X0%DB%':QXA/++%:=FC'#B>/I*^19PX.R*5M_-I=]AA-<6*3XR MR"N3?,CU+J))`R5;4T]C:B(KSY$MQW`H=39B$QE"R,I2"EV)=!>2V$ZH==N_ M:"YZ!N"!L%Y@//LF$7.8]R08RUCTGJL2SX(BY2M35*5>=E]I$_L^Y/%QJ1)] MXD$/Y6N-N4*A0*-%IN9PRL8=8OE;[HS:A83LH^2JXO.M+8!@]X10?V);BOPT]+0N]CLF MEB=Y//9Y5%NF6PJECQLCIFI/;4`6*VZ;'(-A<(BH\F<;-+?>KLT%\CXW1@,W M&N0O/!-6)FG"OMW<#[=S4K79'[QG=QV/?,-I/5P]/KM1U-].+/_E1'-*E%Q1L M%?HQO=2XTS?3C#ED#Z49GZKY)W79):JL$VZJM-)UC35T5GU+VNHV?,GBK49# M;334(]$:CEA#'5@]O=_?@H[2>:B*TGB0#Z6?=H<=O=,=/![WPX=:)Z>BG@+< M!YMIIW\$[!Y`#$=57A=7U=+DU^-03>'L6X-VRS0.KIJF8'VP>JILIE%/&_7T M9-13HH7?7_`>1"^RK):7F,.N\()$1&-)3BF))*JO^OEB)R+2T@?F$-0:8RLA M5H6U/#T9*>JE&'N1DK4/<`[JX,;9@JQ4-M/(RD96GHRLW!V//5;!*?CW!J+3 MZ@[T0:^W)=&9WB9Y-_(3M];I'+S]W5X'V MZ.(CZ\K9E-FOGP2N]WM#W>BV&U&[K?+JC:!M!.U*07M,M-U(U!U)5*R__-)H M'X-%>OK",^F.0;S[CE5>G-&'P[[>&?2W)#&-KFYT.CL)>J^Y\RO_5M4:JK?> M%242'I^3:.IX\_V`>U9NRYG+MCRT^KJYC4MR,$VWWWUZ6E%"7(U:U*A%]?$_ M-+I2HROMU?MP8B[]=>6GI7?:'=WJ6=O1ECJH?0T/J3BH-ZV7[KRG][L]?=!^ M_,[/AAV];VVD+E7H#D?/7D&A2`HH-0I%HU`T"D6C4!R'0M'H#IN+4"RZW-4' MW2TI#Q9/QSN@\O#9#L:SE=ONZT;'A&T_WL-$?3RP4NU)N!V>/WM(DPU+%P!O MU(1&36C4A$9->&IJPBZ-L424]S;FLC?:?WO`[#BL:LP^A[P*?KN]>^ZI<48& M5#^BNLVT7*7WT%F7QU_P:&;/1AB/L/L)U7/>.0]6(-*PX(8%'RL+UD4[4^SS MPWN?N/X=53`'H)\!?1M*ZY''TE!=BQ1_D4:)U4XXN.//@)8`/A^]<:ND`EP& M89QO`>5<^4$T`^8;X``1&\\\W_5O[JN*IR2OJP-Q%LM;`Q+U$]]2JTA?B&9! M..,W)GK"?4W/`AVSE]=8@/X"AIO0[T4I)2PO<3XE/0M.IZW="5G/20Y7D0]G MW4Y'-WO]EE'LLI5G_+K:,>5GA-T9>$,%JNG(%TWS.)X3.6E76=[D>RJZ-%)5 M?M=->ZI+Z90VKKHB5D%-`.G$1C/9E5W`=XJ&9DZJ*5W:LR/)?D*%]JL^5:,4 MZY;+0AD%X^"RDX'5`7QL;2^G'MFA$ZJB1?1_0`[BRZ(^$ILDA7R0=)BAJD(B M:=T%#UX#E%BA(6EA0R!Q`?L+X"%)`TNYVFRA>/J2E(V0PS(]``ZV#A5=/+$+ M--*9[&4\`3B.(S^0O<.=D)07XC)*3TR%+-6>>^^#EO8/@)ECS[6O+>US'"QF M]]I?@Y9./WVWYS%SM8L9[P+X#@;%/@]_H=/,ZZV+)H34CR!_N*Z2$I"IP"_K M_^VK/IPAQT*NZ46&(8B"B=@^(@Y#:GR:-'';OAXL(:TT<4YZHH1253>L5C>CK8-`D:+5P6Y!=(1 M^-7][=,FL'Y9QUBY&IA%MH`2_8=)_W%X:6G>TVD&(+UE&=4=OP,31/-'@%S2 MMV3OXEQWJ%PC*MH4'(92`,@9Z&"D'!"FX"/T2[ MQ!^#"I?M9@YPP(Y7"'_N??#!Y%@PD$G1?;$Q?`7A9-DDF9AI1Z<09)L6W2^( M<)0]"PU7Z*>BWWL1@BWM+1O;<SAC+->*:V8#C%W4.Z8.-=AQ0M'A'&T^8&ET]D"-$:M%\U,(<\`7E^:A M+D\+:LDP)Z]Q;&,?HKDSB0$$+6D6X(=;,4Y`5D":.04W2B]D:^ MSEO$(\*XLKW`[E=I<"FUND4G&QPF]GA_,*7+N2V5S.KV.7081)=>WKS-0*R!YAHA;E=V&$E3=+ZW0-O9T)R^5; M=Z(;1!K?W$.`GB/LYVENTZRNJW!"75@`3G+7$9PS;+NJ\")GCBV->2=Q8N"( M!NZIG%'7-?1\W&.'9'XNKO'`2'S,;.H\E^D+!ZRIJ_>&'3DG^?[&U+--^N1" M52\F\L33)4)=W$28H@=%-GY#_@L"1W9XSW>!@P5Q%VK:#LX.T]/`?@*S"]G# M6\35M';\151HY&80/`KMW8H<$+W7O&>VROO)G_W\62+GB4FHOCS5?\<-[M1U MQXVOQ"VN:V<]@R[UD6YNF5B+QB0S;%TU@AA5CA>()H9`@@$V>?9$E_G'*05% M=22C&-39*GM$++J$]]I)=5OM;XG66>@]0)X&KIB1+SD[LH6/I!.>SCN"=DR@ ME>%LZAG@R)^D#F6IQ:0+VH:+^)A(%=M]C['M)U$( ML:"+[^^T3K]];N8X&;8'O?$XPP>:`YXW01?""/3EJ3-&'Z6"URGCI@1HPB%" M$2!:;%J2\1\!6QKSSH!Y34OJV1HH9S"+4%F`_`#/H3-6FZ0">CDP>,U*2DC-&AYJ#@C:^>14P# M#@M&"+&[+2FN85$[(-Y$*D*),M'2UG9AY?HF)RK*F=G7V\:`#(PX",@ES9F! MLJJRJ4\`^:51^W)YQ`.]FXBCW,B-/&KD42./&GE4.WG4'>B=GKDE<:1R5+-4 M\LC6R7I_T-7[1J?*<5+:.+F:_9X"[A\ORP4NGZ@L5VK^+.O:C3W_-I;FF7I" M9MV$,G<=H?CCKD70-A+AAUY:16CO6TK/'<^9`PA*5KWMQ**ZDN8>1;>:8E=7 ML9VL[U3Q?0";LJM;G8P,APD>+L9/%3&/%["6/K!Z3U*^/AIV2,UW@4^L?UJX MZ'5F#@V]W^D\2=@6LUIX*HMP`>A)T)*R-)Y29DMIWE19<"FGZ@&)@48C,@O3 M/,.9?4HT=%'B!'PXY-EMA?1`_"&04$U%,BY38;\!4(>$QRD0<-XY&/:)8TL8X6& M29:!SJ^+HHW`4_I$5R[0L$G=NG7\.`1Y*G)UDWIIIF2!2:DGF4M.XU"J;D>$ M2$5JK7/+L#&YI*4DRXHO=5P=0GS^+!-$+"06N=7QPS^]'LV"Z`TQ&9$N]QZ4 M%#`&8.9KH(.WH"O^^//S9W^*P_,;VUZ\^8[ZA\C)O?Q/#*#$CTL^0CT&*>D; MF_[^XAW_^U_6Y\M_6<8YD,,YPN+%GS.$-_9=/WBC_5>;_I^XL2U[AOV:H[1? M\UW#>&(GCO0&0!3,;5<\N[4#QT:"S3R]8WC?(7WHL@A(YUS>.QX[G^5> M]H/%S/;"-YKYFZ8>%QAU],.!?\:1+WYQ0#+BY'1PZ`D83EX(%M8Z<)H(#D1#8C9K.?V!,_J&XU/G?T]"OP?[%Q<2T^; M"RI9L)GSG15%5U^N+[5!DJEO&+]IWZ^_O/OOOWSY]/[RVW?UFLGE__SMX_4_ M5PJC!L^'QC-O3V2UNLJC@&^]7=&S2#YSV33*D4F,?[Q3[!/">]Q00,TH8%!^ MT%?I`T>,K-JCA!_*E1H7(>J]XG_;S/:JJN.I6Z:A=ZQV93Y=,DLT"YDIUKX]J=96V>\3$UG"&(T)6[5%R4,Y@=O-%C3-\84I7 M"8);BA4$=-T8!B'O\(1N*1G<;&[(YC`G>3VJ:8[WDSW>?;UOFOK`,M<.NI]9 M@[[>MBPN]5._3+Z(%G>TR0L?B3OF9% M-_F'4%,>XW](W5JO.3VL)G*)*[-E+2+$&$=T_N244V"14JN(OH062\E7/0<* M*3^2;DO\`<.B/T#[\O7ZXY>K[]K%U7OM'Q??OEU<77]?Z0O@,!\T("\#^2H& MW1#L"H(E'P0Q"HUSBG"E:Z(AR%H09*ED/$60YLH3C.SQ#[":8V]R+G9+*TKR M1])*S\/A4"<#_*UO!W3K\WVFC$:F>H8]\1=4I2+F7VI?U+C8Y7SA^O<,\*2> M%>VKBP$=8?;+=\134>2*#Y:=&(1M&+L1.0VJQY/?T%,>X\A,D9%"(P`8 M5P9,\&H>"_A]5`TKHSAT,E+)-3X="$75I'D;?%I>&421ED>]I@JF?`[A'@!%?_U@U'&5(BE2EU< M!//&@!C[AHJ>\*)2=QZ\,',6,L*-*)T)W1F\?]G M\$*PI)N0HG906F1'WD3$@!CN6KW'3)_!J_EZX[ER%`UGK3%G/47H;<)$RS() MLE;3Q&<\RDI9`K8\DIR)+5QY,;7Y&?.$`P%3`WCB*"68NO[=FZV3]*FB8MTR]'+.=;=Z;:O?+1+1DD(%\H+OZB;)4+3;PSQO,4O"C+0EQ*.=EE5LRH;'OM";^3I^\! MDRDP6GNR?Y"#EDW.R6T4:*^);_%K@NJC2UD/Y2M>/*C9XKY1W351CT\^1%7)@E?5>ZDBK2DY@+G$`YLY"_.\]Q2^4DVF,!CJCP6SO;0 M=YT)_%!0@OYK/&9L.H6CN18A5X%/>%(R;F"0/K+J@C`)EN&R%ILM.T.4`U-- M.*9NX,6J3G^]PUN+;3[D@)PI^]OX+[/5'YXD5'JMP<;'^E$'[0^,:+#)EN3# M"MKNZ#VSK;>'YJ,$TTZIK=UJ=_N/7-2:HG<5F]X5;Y7R<"G2'[Z(!]#%2T,? M#DQ]..Q6"[5'K6G7)-->2Q0];MV/I*I'DTNIHBXRR6@-VO5@'+75[YX_6ZGA%:YLU%[,/TP.6CW=,@:-CK?L/)E+ MS]/10F70JB;JX]?QSK>FVSW:@]'H9&5X7!^L>]5;&CVI.7-'ILZL5&:RP9+: M"[-&DVDTF8V@TF]5>^%VPE_E.5.+>6]TSK;IIQUV.KK17Y/RZT.+_>Z>UMEO M=1[)\_DBJDZ#^+7D0(A?]L3\+VYMQTUZ7-Q0D?A',/]#;_H!9Z']$.Y_Z'T^ M3D<]VCU4=AR?.+'`5,ZI[[K^'>\4BAOAF8_V8N%BVQ@J MH56B1%*ONB7";GD:#38P:Y*;]IY18UE6/;5?J\MQ,R63;EA3^ MXPZ$M;>YW4^U4A-NY((15F'`&0BH)0;<"U2507$",VV0\58I/4H/O,*:@JN; M`==E:N]LLL+GS_8-L%,Y"@HFS'P:]P%FWU7J=-WW(V/`ZK,T9;TA@\.!;9.# MOLR-5^E'5&(^67:E1'P,7DFQ*N;#0P.8BY@IFP%/^NU5;LQM3;\&YO<_HXIM M\F-GAMS&(BR],^SH5J^!\V[A/!2)4_78[[:/[@$!VVX9P].%;"UHU]`'G9YN M]!H*WA4%#PX.V0?:`T)P]XVLX#9:9G%+*S#[8'+G"5-? M8\)-B$U02+^_9W`:V'/.W-?N>IM-M'V=EA;>;9G=+!UW6[T]`[[?;^L#8\]T M;+7V@^ENJ[MGMM#O#G5CT*WI[A[#=/NM7E'OV2V5#/5N_T&$\O`Y.R(/:]>X M.R9H[F%S.V*P@U9GS^RTI_>'&PJ7QT[9;3V(>V^,U2,"YA[V]DA_]BHU>YE; MOE(%S_GKEZOGVXA]-+NHSRX>8#?68&/IG8C3QLYI[.(X::S?*NKCIX67(]C% M5AU>-=A/]OMXQB^KO3K!3R`=IJ.RD>5?_-"5BY7V= M;5SU>&H7/+9QA>GI75RRG8`WWL):P+;K)C>5;EE(I>?SA7]YS=]"*1^ZS83U MXZG93Z<]!".IPWL>FYV!WNGV]5RC8JP>/YX!X'GU^,I>[55=P!Z+YA/$Z"Z/ MQA.]W8?@HW8OLD$4079U`Y@&Q@W9UJ7$>]*"=7\UWIO+J0E,6&S8@&+:$<'8C>S9WN^CGSW<1>@ M'CUW'I>;7Z]X`D#9ZZV/DX;G;B]381\*]9G2DF+'['5WEW&$HM$=#C=7D(HN MQCO0OOP[1/)#$XV_K&Y^409KN8T'J'F[V,4:)T$M@G%<*^:Z=(G+_/"[,"Q] M:+;UOEE]M4..UCLVN!\A;1\=C(V:P+@Z4O700R@"1L/J!)VC94A'=#`>S#2? M/]OERKNM:K*HCQ:C]!K=XA*3OSZ&82R*5^_-6-ZY9?D0R&U3K_UL"4[6;=']XJ#/&=\X[2ZYRGC(&ZHSKNJN6^W#LE_<\?#1\#^78 M.8I%UM)E;YEZSVCK[26I[(=?Y*E00+/([5=U.OQRVZU!]?VBPR_O*%!^M.RS M<=TWKOOL/$/=,@V]8YV"LZ0F@^[>L[6DDQ._ MI-WST7IWCF*1M71!=0Q]"#30;3<>_&:1-5GDT7GP2^K%UP>:1X'R8V6?5FM+ MP9NC-@(OES5\/RT%>?.'4];8ZXSZG8<+2AJ?G#(&M@(U:TGYX-WP MV:9V81TJ73VI^E94N]!W7?\.373'PXU0N4#-7BQS]7OV=X2-R.K MXEIR-:N75.CSWBPP6>`6RDT^8>@U"WSL`I=6HLPL_J$U M*6NZ\=ICIEG@_FE[-_5KGS`*F@4V"D*SP+5X5"E#VDJ-[9K$G`^0CRKLX4ZO M)G5>\1J=]G_E;2'C-^VLW>I69T6(DT/9NZ?L3J^VE&TN22P\5G@?'TDO+2F^(EOL"-@GR-R5M?8;*FL8 MYVJ:?OZL/E1MF#IHD/IPR9668P7\\2RXIOS.L+9CM34W-6I<90@,1S-O2O:: M$BTRE5H?M+%DWRD`I+Y0[K:VQ&F.#+X[OSW1?6R!H>.$:\,=#@00M:K.SOXZ M:K*N2;NJG17]1JNWI>(&QT_+IMXS>[HYV,M=JF,<=$MWU;94#_O(X+O[ MBY/'RR./@6Y/B3L$I^%VWPSK;7;U] M$ET7:PSCUM-LL;QCJ=]I#?;4#1GKLM<*L@UW.%W!OS^RKI_@WW4-PFZKU\_J M`OVGUC:SY"!L:7)3'Q@#W1S4H9ACG6L'[H]YMQI4'%1#Z2^[G'**&#@%-F;H M9M_2!];3.CN[@^=>E*9^R]Q+C>4Z*DVU[B>Q;4@VBSRV?.JF>42SR",@TZT5 MZ6]07^M%'EW?D*;S=[/(&A/H<I#K_(A@)VRE'WDP'7\,$]W,I;WM&BM')] MV=A;K7UOMJQ%A.6Y3[8[QOLXP`X-T8S!_P\8T^8`K5FH,5C_)->E0=<<#V#@ M>6Q,;1_NG&A&7X:VRS1_"K_-X7.`NS_^H=,O[_SYPO;N-2<,8QC/]C3[YB9@ M-W9$'PQURS3TCM5.^T9$OK:(858[9.H(OX:9T;&%!`PFFDHP;8%EE$)M"NC$ MZY1MHX,#X5^6MF"!%E(M+OD^5IN'K83.3[E=WJ%BX0A@("#NF1V($7'UMC=F MK2R%39S;$@(43__T>C0+HC??<;5?%@BO"V\BJ_->`T;>NO#+GY\_^U,GB^O*]]O7BV_4_M>MO%U??+]Y=?_QR]9U(:Y3PRB*7:_!;$_RN$D<-HFJ" M*$!*C']\8BAK_HAM9,V,%^.+FY-6?P0N5^`;Y-49>=>I:I<(P/YOH&_!HD%? M>S>S'5B]ATHB:H%O?3N8Z/#885-L;3".(^>6:5^F4]#[`E+?^&_7;#SS`,`&R#DCQ&&0W#!G: MKAWZ]NG3.^TK(,,)0Q]XSQ6\OJ0#R`-O-=]#^,0-\(0UC_',`M-9F+.5V@4, M-Z'?/[!1$*/^TDMT$AZ;@RE4]0BTB;=N#/\&X1]I?X=IXX!I'QP/`V$`)]3) MM`\Q3/W)F0.&)Z3PD$Z$VA.N'X%BNR[H+O^)G0!&([W, MO1<.'?P>)X9C%(\QBFE']&SJ!&$"X*D?!\EW8I8P'3$[$M`T3#=BV@2@AK/# M!]37VD>RNA?KELL*XU$(XS!2-<7`Z@#PD9U,/;)!!\:)`F9/$>X8"F4>GAA\ M\:^QQ[1$Q<09`')W-CK(5$A,V-2.W8B"G:\!2NR69H6]BE^*&XIF4O?#(0E2 MDL[$;XP4![7W0TOX!4'/LN?:UI7V.@3_=:W\-6CK]]-V> MQ\S5+F:>\!#:@0N\]"]TH/$)S,T`3#PP73A?!`12O_$D\(-00OB(@N14F4/5 MF)#`R?($V)I&6P_',4R*7D8,B0>T)0D8O`*!>CW:''C..8F010*6!ISI4%VF MHI7_Z?4#`LIJ'!H6#?NB^2Z\"4:785U(;:P)19^@J9"-1V>K5+W[\OGSQ^O/ MEU?7W[6+J_?P[ZOKCU=_7%Z]^WAYTB'I$\3S"6NA)X@M:1=^\^]M-[K7O@JQ MJUA]3R+H>8*H;;!U1-BZSB0QRL@P-TY`%08DX/G$*+#O<;4\&*--@BF1I*%) M?6X1^)-X'`GE>`Z?HJ8/.KCK+X0-%X*^*W1P1)8?AP#V,?-"QK5C,HN$'HB# MS&S0\$>,>;`LG*-@Q#6^VB.@L(8?'!.V5'Z`^1W4=I9,6V`(V5.+UEQZ9)-\ M#C)>>6[S`BPWCUP8Z+4(A*B7%K:.P::I[[JXX88VZD0;YI,[R?7'R891%P?_ MD+ZCM\R.T=FF_<4/%TYDNX1`YS1MV]-"97/FC@-1'X6?VJ3,`S72D!&A=*D' M)&2(WFNA_:92%+5NS(!,E&H[(G58IDRXSI1)MZC\#5Z;QA2\`!7\WVPL7-?) M[W3MAXG,C&Y+^YCZ7G$Z.PDO4!B#JA)FEC^W49K#BV,*"XAUT,+S=Z#2T(&P M'M#M['F85R*W.F6T@3.C31.1DSHQ,0#[-ZA5D$_:_`5'Z?R"KWLL2BV.K*6! MSN:Q?TL0%M:!V#EME6[MX4!S@"?!%-\HHH#N?(9\0RDZ;#?TM;'MNAP%MC9W M/&<>S^6NI$J#F3$ANO,YZ.5;A9]YQHK9YIO'(3%;AF>CY)ZV<2@`Z9*Q'`K_ MX,;@:R/S-0_$I!&5EG9!L,OGZT0Y=<_S(XYP?)`$;GP<",'ME<:ERHD#IHSR M"3NXJ/=LS.8C&$\\-3*KR"0\@>P:81)R&M0"@*38(6`:>J]MZ!V3TQ+\L]MI MZV8[E]6C9!L';.K"8[1)83"T:1?`:CC]V^-Q@+%".#/<+/7YCL>^1[<]R3(> MV2[%",,98P"JY:VR7U#6G$!`JA!QT&0606>3%/O4DZ3_$-LMP>( MQ]T_/(TJ&\I!*I!@<(ASP8!)RI8-_\#PW3B)H>!-13BJ>`)E='0.QPGG78A' MF6A.@K[BM,)TP+/0[>M#V!3&B?(HL4L(^00=`2'LDQY?+3BC)Z9.V]X_DP'*$8QT#13P#=)GXI$L M4*@^<]DTL\L<137G_0GA^9_,#K1+C^>J*'I=%NM4^$)B7E;5L"RK&H!%0%?A M["&$HT"I!!,[*D8!-AV8$7RFWU^T^;]%(5#\=UJGLEC@1(PS''1Q@>(C&+?5 MQ](DZY9)$:-8@[H,8FYGE,[F@VR_+B@OV&042]NNV$QYX33\RP`=N%O2(6!K M&RNNOMB[98W5K_A9&*:[V\9&^"FV"SF"'9:4GQ75B/@+YJTC7.^@E.744V!]OR;@[=M2_##5OABOW!X[AB116N1A^M MA_79&`['@BB9P)?F3]^3F_`;NW%@&O(/++O,JE8[:ZYZ'0O6F^-Y'(A27>LC MYCKLEHEXF<.3\RBW3MR,\A?6)LP4(X0?9$028PD85)PO7/^>(>ZR-UPP M4A*[D2TBD^]@I0!!S['Q7[>.[V880Y!A%H'VGQC?!WV#'E!M&7Y_!&,SBX4+ MOZ`K01DU9.,XX&5J7/LNI#B7C:$?6$0^K()7K4(>"_S!^%MCARZHX!UZ'B:$ M+T(F2MF$V1`%Q=OH4_)W)I_@W2/Q`5"(ST%KT[T1QXO1-4(>%WPUG3$)2$4* M?OPT>^K.3Q?QT1/`RBY7%^$1(#J*1]%U)@4T`(\L!&@#R;(#EB`;=Q![LMAD M2A""/O)@P9!/O_^+1")_.U>K4IL#`AS`6!J6]6)R#\%7X@M>M%+7%FX##_$`S#%NZ3H_X(V9[T]*5Y[7\.-+/&JXZP.@Q!?0F#H46LFF].O!6=?$[8Z)]/FS)P/*W$4310#S["*7 MW6!*4>"/&4-/?I+>A2J%D*D^7B'&6\AC/PY"4@]&<0B\,TRU)'_A>$+#!.C; M-Q22UDOEALCV2B[QH\9"<6]%]I1=$8=W`,J`46>JB0O;F%$&J\CIJ0[HP@'I M9I2A!HO!:@249$4REZH0"'4QD8L.P`@F$TI,F>DL]ZQK4RI70+E8?D@I?7HV M5XE+WI`K02P047N0EZ[SG]@!Z7M?5!O\.`+MGZ#K)BR%E'N.J;%K.W-4#D'U MQ])3*-K1=,#:CK!PO&5..CP`%=1+[X97D*2TNT3K`>%/UZS1#X`:`EV,+[WD MO=EM;?6>]_>D!,$E50)HKG0?W3V$0B3;XC[NAT:RRVZ$FYD;X=__]O;[Y?_\ M[?+J6KO\.]X+)YIL;H'7CC2:*RKUP\EFZ?(7B\!QI22^8U4]-"R]W>WJ`W,@ MFUR@+(N#K(?JUG;IV^C,ZND=3(_%_A<`;I?)W'8;9*E'X2P4S?DR0IAB:W5Y MV4"J?"B2?"E7'4=$61;<<&](XJL02:F-K5EO8FNXPI$@ZBNH];'-KQ2DF>/" MK\SOK"2)Y-^Q%M/H7KL$118T]??H2'9&,2FK%^D=`53@_PC8/?`)#SW'=/U- MPYI!'M9>XFKR%:CGY#TRY94$U5R9!(#Z"58GIV9`F`([Q1SUY`:+X%SDAJ.' MU9Q*%SYO,I&0;@*9Z/ZV4U&D+ M8B'D\TQX)-[Y(1\M;J/5-KMI"R'M)2^"13]/&,*?W[LGUZJP21Z-E5>EFGZE MO@Y*/:CU_^?\'&#E1QZRZ^^B1=/Y.6K\<%)^O)F*WS[!/[2?]"BZ7\#A9E1C MC4U>B*>!CT=^%D6+-Z]?W]W=M7Z.`K?E!S>OS7;;>HT_O\877^#0KPMCTU/\ MQ'F#_PO__/]02P,$%`````@`L%VN0&BD&])["@``"9```!4`'`!B:')T+3(P M,3(P,S,Q7V-A;"YX;6Q55`D``YPHL4^<*+%/=7@+``$$)0X```0Y`0``Y5U; M<^*X$G[?JOT/*?:9D,NY[$Q-=HM`DD.=;*!"9F??IH3=@&ILB95L`N?7'\G8 M"1A+EHDQPM1431)0R]W?UY):K8N__+[PO;,Y,(XIN6E*/UZG92];/WUQ^/0F8*/FICP`!'G74I6DR5W^>G3IU;TK2C* M\6<>R3]2!P61!;EZG2E+R+^:2;&F_*AY>=6\OCQ?<+5+MZ+,I@_%-8S1E@9"_O+JX7DG_TJ&$4P^[*`#W%GG2TN$4(."- M,UGIU^?>AN8C3*>`6(")<^Y0OR7+M-1UM*1R#O*!2J;"@)BP"("VZB MIJSO(P^,'((Z&\_P)`64;2(1/R+">8SX*`([Y,T)0K.61*@%7L"33R+,FA>7 M,>:_Q!]_;W,NGMH)&0,2)`_PT`B\Z+'?L\NU*M:R@_BT35SYX^[O$,^1)[3@ M[:"#&%N*YO0G\D+0:&\FG^:ZS38-1,Q)GB%^W2)ZT^/C$BT>^GY46Q,'X"?R M8T9]'<#)<^DN=IQ1Y@(3/8[H<$(NE*0SJ0#R&F>O@"?30'Q5.85MQZ&A4/89 M'!"*CSQX@L#`[W1B]A.FMSKFZ2L5!"5#V4YD8 MYPP@U38/.@,6+`12WJ)J27LAJ'DR,CF'_MSV-:1A0Y\>4>D(O+J>%F;VT+'4!&1DL[3&VQ?Z=ZCO4U*4*YW4 M41"E-=N^"4#;=?%*AP'";H]TT`P'4B'U]$PA<13L*,VU,>Z?@T>C3-TP0!.X M(P&P&<,!GP@5'.!XR.L6XFNUZJZH7*(?*`/XO^DH2@ M7SE+ESSHZG$&L%NM+&V9C9M@.I2+.>8#I6[4A0";8P?X4/0-VOA:*60[*3I[ M\[O`9O4$Q7T'F<1[$'1K^MMEJXTHGH&+/M&1&\+6(J!8&8W>>KD##K!*\--N ME6.Y?1/K(7BBSLD#$&&A)]1NNSXFF`?2WCGDO`!7.Y5,1-OXO^E.__J:4.@:2M%:7 MN0Q7\C#;(R*Q3,] M(B*;,$I-B&GI@$&`%KKD@&D5Q\2D.2[V!7WRY``/I)XK4WLR'2T^T7"H%#DF MSM1VVQ?S12'JMH5Y07F&Q#$QI+3:OG@O<9[\`3A=\I@(V;(R?R]6Y4'1>W!W M+PSN4"*L"X6![TGS6QA3!JMR+V@!_&XAIN:K'6=LV1.01;O@A:1`TXNP,>@1 M]_?4`WI(!6`J0^_U*-WRF<4!8-*T7?M"#!'_&,V#-\L=LF?,4GB[-]PCZ_;% M_F]FQ(YV"P3TZX`JB>,@-L-2TQR`9E7[8^O:_:=A_['7;;_<=8 MAOW[3GOXG_O'_K=AD67MW+KVM:J=^^"*E\3D@77$IV(*/L?"FMOE5PYNC[P- M1&U'3.=6&SDRVKB^._M(Q54O#>[:2Q]PA;80V;-8+/QUHH("'G/TCUE71J.@G'H)4]S=,9 M`P8^#GT-N_FR-:38`#`;;]"H-G5>.]8+9]CS0 MT2Q(S$X!FE*G.`>XV8%\0XPAX4$]SD-IU=W"F2(R`3&`/&(G6OQMKU3T/'"" M$'G)Y249#)9;?XU(+QEXLV.+>_438341:HGOON%@NG[,_T-1W6GZ@`S;F M_5>;!O9-:^XQ0<01&,B=P=H+LW1B-6+<#*:8V$\V$2L=4MY;VA]'!UQ$9Y2X MJNBBDJW>?=;Q$/9U3!>KIX;4%P3R+=^RU]Y]=5!I+83,[G^>W?:$073R1M6O M[U!3C4C>&0A!X$6*E45W5HTG2GLFN`G])679%/2OG7S/UBUU M;9G,!:[NRM+,T\JJN6[N4`;8B5N4E*,S=XNUZ4*LM9)RG["";C"SN`G[I)S MH==>6WQ7GL["HU`^^%D^LVC.IZSJ3\!1=H,]\9+]I@;UN8C4\*7RA6*5U(WQ M@A`FO):4RBOI-.L4,;A%`@OAOW(+4-YZND*@1MSF09/P:%5JKD<J[/Z MV2/OKZG09FRTHA%Q->NX`:VK;2B$HD=+O&!5WC,P*3L(1LJ%+B+?K M*IMM[?,#='/9DZ!;%8Y?6;5%+E/OU/L,BG*=%C\5NK=@2QBW:K/O5B=S=[#V0O3BBN^11PMH^6S%]IV_@XQ`^7[ ML;2[!HTK.>P!K!((W]Y+:`Y@_G&.ZB]RR0;E;9-,V:W`M.+*WX#G`+C1:T5TCF"MV#&?"V_O"V.Y!D0J16I'I!J<_(,VE6<_!F^JR@V!>>>FLDK7CK],2`S.Q53. MG;2]35SY0\Y,Y\B3:@^`8>JF<](:4@M5`L``00E#@``!#D!``#=6E%SVC@0?K^9^P\,>2;&T+1)IER'"\D,,VF3@?3: M-XUL+Z"K;'&2',B_/TG&!(-M"-@X]"4Q9K7ZOOUV)7GQYR]SG]:>@0O"@D[= M/F_6:Q"XS"/!N%/__G37N*Q_^>O//SY3$OQRL(":L@]$ISZ1#]T)^+A!`B%QX+Z.TF[2QME7 M5U>6^5:9"G(MS/A[YF)I&&S%5- MT2%L`IA+$KCG+O,MP_4-3@U\55*HP1982%8Y0)16.,\=32,;6`2A'?,5%N-.W%HGRVN(V6:!13Z*M+ M$<]"L0/4S(VRC5$SBE@5B)^P\YI/>6B-(;+7M>WR)&95&;&W19&\:=<9<>;O M$*YX2K8%;(UQE1:=NAH1"H6$335FK*J2AU"=2+?_A42^W#!_R@+U473G9*<,2QN'6F5(F+-LYTBZE&F+G!D\,M4] MME!K^'J),T"*0*GVR&Z6H4S6T21'EJQPIZN42>:WDP?U5H^*I,5"?2A>*0799X$Y4@U#1[B<&-?YPN0.0I>GHL,V&G'8 MVQ>%AWUUO@&X0)[USI@?];PQZ-.I!'T+BV7,6U5O(JI*@7/P-"^U4IMVSW"" M.?R-U0GQ$;_H.A69DNWC!GT\`17W)+84MO+30=?S2#3U(R9>/[C!4R(QW:ID M[CAT<4+2;6,2:]4Z8.$K1JN5)7JK/ANVZ,,):9*&/M;!KER'1[ZH]MVD2#-' M[1-2(X-`+$CE>O0#EX-:9WL0_>\'JUVQB.V`47K'^`QS+T>J-WI"=BD=H1UE M?$MO:`]BRWJK?(_:A)K;_EDW1G8I39\=5=HG\ED-H31F[Z;/8(X[XB&4^K=$ M_0MFGDCKMLBN4)\;WJ&V7E`0*O.4!VE0?\TA5.85O$`UM6]R,GS6[G[@0'8U!4 MAL"?B9LJWCYND%WEX_7A$N[+N<3N86XV':YDIA]D5]GO*E?*7-++!Y#WNNZ: M1+QAP>(-KX=1="V)0V$(KK*41"\T\F'4]?X-A31=HCWWWS?/@^PJF]/'V:?W M"DJ<5Q_?:UY%5;&5V[[[_%;'R*[RYZ4C[?\[12%.E4^5I\I*#C^QC)ZF(:;? MKTSTJ0>@0B:(A,7:&@5A`"X;1]J:2LKM!9<[-6J5\V[`L=/M&'&*$_+R)!)R MI:YZX,@?1$Y>R^X.L`SYH8FWRQ2H564?[[@)MFL\XD2ZJCR1U!:M0L1\N&DU1'_X'4$L#!!0````(`+!=KD`! M7,M9.2P``,)Y`@`5`!P`8FAR="TR,#$R,#,S,5]L86(N>&UL550)``.<*+%/ MG"BQ3W5X"P`!!"4.```$.0$``-U][8_C-I+W]P>X_X&8>_!D`GC>DKO%3FXW M![?;G36VI]UK>Y);+!X$LD1WZU:6'$GNF._ M_)\_!7[XS[V38$3:A\F?7SVFZ>F'=^^^?/GR]NL^#MY&\<.[[]Z___Y=T?!5 MUO*'KXE?:_WE^Z+MAW?_]>EVZS[BH_/&#Y/4"=T+%>V&1_?AX\>/[]A?2=/$ M_R%A]+>1ZZ1,@DZ^D+`%_=>;HMD;^JLW'[Y[\_V'MU\3[Q6=@S@*\`8?$!O^ MA_3YA/_\*O&/IX"RS7[W&.,#GX<@CM]1^G_8@FX.XCE?[#'ZKXWMR6=J3DEEACWF],+Y8B\IFT^M2?R,H-T':$_WY+Q:YSAKRD./6K^LM]2 M2HDMSVP@70/8TA2YM2>CSA,YR&! M?>JGSZOP$,5'MIC,]TD:.VY:=,189]W_JD[[[L="Z!J/,4ZB<^QB+8&S>:\S MX^PUF*&+*Z&D2SL.WWS>OOJQ($-.Z*&,$%4HT3\*VO__IVS\\<0A3L<^*I7= M$JGF<5V7G-@M>",_=HB5MWCG1L23.:5O:A_L$$='7>4I6(ETI^2=,BZJ7D:" MW;S0G??V^;B/6A.?"U!O M8TA#FXPUOW+^=Y0U@-#'81R:TC[N!ZYJ'>_K3FP?SW%,E'R#3U&TVHP*5*!NBK"6<,H_&LEGM%:A$6VWY^C"5ON8@N?$3UPG^ MCIUX&7K73BK:90F;&]):";M-+2B,6-86T<9DA^XAVAQ">R=BW906=RE*59$[ MM&1:V\M@LR"C/42Q?`]6;VG4[C:9%)@PU@P5[>!L[BCLFK6W7#5H6UN>#DSL M!4?'8Q1NT\C]Y_;1(9]M?4[IE21UQN6^L(S0K$AM#&MIDK/F5R[\CV@!"'X=Q:$K[N!^XJG6\KSNU?;SLW6[( M;T0G6*+6AFUDFUFAQ:ENJ5EC2#LY)M^F;:5`07C6DJ\=9C0XL]3J.EQM#Z+% M=8:[]"%?0"W1Y/%XA]%FCK*(];FM*;H:?7"2/>.ZB+AE:HV#M(S!;>IW_NM? MZ54&IJRL#S=^Z(2N3_B)$K\CF$R+W(#V:XK35*B2#*T/J"1$!25@2-EH@D6: M@IG`31\E+(P/-H6J>)#A-%/#3:&@0*2T66RXM:V"!ZG=SNMTN=UM(!>9_ M[Z:J,\].C_EK^=_2_S@AR%5+.);9JQ,).'E;9Q)^3#YK5`RDZ99R\XU3;6.D3/HB[AN="9\;+"+ M"4_[`-_A-%]/9"Z)C,RD9R)GO^6@Y,W1I?T,$8K290'S4WK*$5?D"/'X["O9 MYXF8-^IT*<"@Y7MU8\`AFQ4G;1PVF=XBMW;.!N2NCL`IV(&@TD$@P+(:D=UY^GQ/)I(E M%R`;W!.]"Y)[HU(RHPNIE/VVM'+TVA3*T>WY#^SM`9MF#/(=7J)AYE*FUZ7]&YH3"_ MDQ!N(6!W#D)'''ZKH,F:^;V!?%-@7/5O?6?O!W[JXX0LA^SEV6,4>#A.Z-*8 M/BN$O"AW81`^&F(UU:5"6CI`Q&V%CX\9(M-J?K6Z7>U6RRV:WUVC[6Z]^.M? MUK?7R\WV&W2]O%DM5CM(;.BJ81,]FCH(@B_U(#()$0R&NH.R*HUMBBG3DJ%@ M.[@0@4:7=>N.!`;0<6;%C>N]\TRO6]7#%!H$``$*+9:%M^)Y2_@#76W.3UE+ MV""$_A-MP3Y'KN"B``2N=AM%97S&7MM.R($IH#&+32'C'*VA;1%O30)$J#;_ M.+M[@]I/C33C=D!5KO4K046ZH;`VID;,_[ M*/;\D"+F&N_3"GAXF?RZ:4S5Q.A@O/6^M](DV':1I_=0J/D$>,4 M>:0)^;63(C]!M%Z8=PX(#5G8]ACE47M?_/31)Z.%&#W39!Y1C,@_:5\A+:X1 M('H_[+"DR^ZS2W><_@$%4?B`X[>H->GH%#@N/2=&`2UKP_HB/_LX1*?BM?@> MDP'SYH_.$^W908_^`[W`.\5^%-/392(/9?"9O3HGG03^;V??L'5Z,;B( MZPG7Q">COIR]V.:@,]]+'I(>@KXP"OH3K8'4[7!XKH:S]A MYUTBMT%.9,IOZ&)=B@<:#D4SGU`:5!"!N`[]Q"@U/\0LT0E;H+RIY%!R'W0% MV9Z/?+\AD?L(^5]RUX.UI$O\FQ3'1^('5&:'^Y&11SP3CB-!^VRX#Q7O`6QY M5@)H;7U602?D%:K6U2GLE:GB5:D]]Z/"`)HBR+YR.PISLC4NS[`7NNH7N0!) MSGK$`MD1_:,5&U-M7`3[S-,T]O?GE"T!NXAZO';$,_26[!NROA]\UT]!(QKT M`WLL"N6Y)WUA@L4LO(BE@)#7#E`D-/L*52X"Y[%C1E#DV6?LST?]^_??_^PW^@?Y^]?_^>_D>\159/P#FGCU'L_XX]XB=37\]/$GK1 MR5ZN7D;+W,?&:)( MZS]\]^^S[[[_0]%Z,";IZ4]RPF[J/^$`]/!'0;E;N8HZ-=M@>)'GL4-O)[AW M?&\5+IR33_QP67"1@,)D:)&0Z?8%?]$2T:9H%:*\,5A841_>V46('R)W(M[5 MPHMLY%SCX6A_K?%+K;'JK>@X`MGS/+3#%K5"OJ2&R&2L"%F#(O8FE>CA`UZ& M*8Y/L9_@ZVP#-W?=\_',#O6OSS&9[":%-*QD<.=&(U!&F(IVP$?9!+$VZ-+M M#.4=HTK/*.L:M0CA@ELFF99,<*(@?Z(`O3G"S04)C MV85V/-%(1@'R;%+K3!+V+'+0&:0]!X_"0_>$=^P(XV1:Q[6&@ZG$.[C7.(1+ MV)-G]1-GZQYEJ]U_\DDM>H0MOQNM/+ZVX'9458#,F`0-,2PRB69ELND-N<)= MJPPR4!=-9-U?QZQ@C\?.]^YQS&H#*U\X"3L`NWB2B-1Y`45HT3I&&75V)DY+ MF64%H.VXB^HE7NMX_+4?(B\*`H>XA&0YS@Z[O[7G^JA++^772!U*"06VK.KV MO+Q^4`99BQ`,7!P1.D&55T^_$-D!)"U1<@"U;I#L08Q(N>1($6@6+$)6[,I- M$QTY$3`R2M9549$1V(0(!1'J:/"G$4$UR_98W\""=ZC=8%!!=2$)[+DX5K82*G;,D3JS' M%EJ%&B9N3&-W68\?LW+G/$BP%[!GUM!"26"7-;OE"D\:6V49%0R(%':6=?!8 MLT/N)82->V,%59(@`GQ7W.*ES;!XTR\!?O? M#K7O1"S0SK?%A_:K`=`];P?[:CIDP7:WGQQ6;G3'_B16[7''%\Z>[:V**>@T M8Y`;VU7H1D?,=@-'M7SB(@JC165%3+>+H]*6J&QJP:O;29@W6^M5JC+MLJ\R M?3$8YND$.-G@)QR>L;PZ7;.ER0#/%I--I942&34SY6PWO8Z$I:;AS5G(6D% M`:(4<#ZNK@PTR2'5&:BMZ5C\FO7BNI2\[<-U:+@YA/X41TER'T<'7[:F55L9 MQ&"=N:8"L+^B[,]0"%/A\#0-ATJ(ZL^?201QE+`)F;8&&BR.6212RRN0)PK[ M'#&-R2*9$L9;91S+;'%%8PMV._T$*(I5@.87ZE2:5OW)#HTQI^\;G&":JH*L M397G=3E;$IV7TQG4^RX!V@Y]UCY/R7%Y:IF30*G_(#DJ3T9AUIZIN#>)8B4H M-)&L@@.#)QC$#UA6F%I&!5(8GL>\I'@YNK1'.0%\D7@5&2I\1P?DAT\X2:'7 M3045$M=?%^F/T2I),79]EB&(Z0R6RU)PCRGZE#9FB:= M.068E?I@*V.%=(;NHO`41][9I?\$+*?44[ALY:BT!RJ&-IT`A@M%=2&$4RRJ M`QZ`1SHZ1SF@1SA*1S?6G-=PN,V>\$>MTQH8.([),>CQDO*Q$AS6LKO\VRA1 M0ENE-03>:LR*$9='6;RF#5O1_<9A)V6:U@\)Z($_U:9"G:,0&GBC\`P"O;8^ M"\'74F:31<7"J,Y&;@D4;C&Z:8T6$.L6I%U?Z$)38C4G^]:""XX^,F5[5C\7 MIEB,O@6][5!6LG9],#4-`\EZFMTW)E4>I=L_*2%,ME*^"+),I#D%V^^5-!8D M&-67),X"GX`+ZJIHDR0/IEB5#`:).'Y(UZYU>(UC_XD=3JY"@D]61RTAB_1] MC%/GJRR"1+4+D^$EZF*U(B<(:>[TH76(+O2HT@&+LIRAK!.P")7^0E(R%(7( M?22_9:7J#HX?7\KA>A>IBXQL0!7F7ZR0>EF'ARKL14SR#WTQC88$:9J<5KR0 MGKTQ^62B.)_/W)T537%,?B.QG4(2HX\FA&RW'QX437./>X:*UG"O)C2XS_Z4 M.]BP3R7DJM)^*R'5$\,7B&W/ONORD$-A^N*0RS1_`\;96H+>%VJP#J_:'1K" MO1L4JH=)XYTAJCMHIMG2J*EN,BFT<<"Q+AJ/" MJ;VN\;!DP0EJGY-3*TY,=4]*K3L>%=_2\0]'8>S&9.Q;<;2K?:0+]#R=;@-O MB%B+*"0LG0E7Z_(>Z0H?HAAG[7;.5YPLOZ:Q$\6>'SKQ\RK%1WKR1F8J)5,6 M,($4MFO3C6K\F?Q4DR=XK9X?J=$1T65(=!D398,6%HH-.T.U@1$;F9U?5\:V M8`]JT8!T@38O-*7J=MP;S0K6Y9QA#K_=3\:UA;VW@NH^5 M'(]O\[9-"$Z^71(AT^`&%Z=*L7GU=B8WL@T&>6M=W8,T5+*0+`(*NU@%[NE* M#;;+AN)/;1/=Q=URAV[7VRWH'ID'H-:^F(,>=$I9T'?'<^[G&\/C#> M*IDGU:U)SPX-&IG>(CHI!&T,Z_^K*C(CD=A/8*!!"JR*RP M?1<28@8)$;QZ3R<*B/[+5$L(!XE>056Q_(2I"R348!E=;H19( MBI``*>S<\WQZ<^\$]X[OK<*%<_)3)^A47CF=047N$J"I(Y?VB!*\684H)P%7 M\8&BT,=H.0FD\BMI5!,(*NID\NEZMI)0KPB'"0MM*4Z1L7?O/+.W;YT8T>K& MZ+-V+?':3\-S]Z!*G]>(>L.Z0$4?X)":0E389_#ZFME^%*^MEBK0VS_&*0/4 M^^]S.-'?_+H][Q,W]D]TE`UVL?]$]]]"['33&`"*"N.M36*E.;JT!T/`B#*, MSKH7N>SY,#<19$_>*U/.% M44B6)HR/#,EN94.'7D=Q_1>5A@EA/'A&3HK21])=]GU)K_1?K.?XV[=H]^@G MR$_QD<9P!VRQQ.9K4?FP^R?&369"#]]?HONHA3_@'"`,\?F M0)BYW,+RND!9%[4R':P36+-H5%08TSE8Q$5&1W/,A'EP M%S%EQ'9%,976RZ2EQJM2_8,:W`<,9S'Z`;1F0GJA$^"*[]8/,7OJHG*O=VD, M<9E7955RR4N;9<\!X2_MAK,,NBCV_1*N3',M&>4-X59+'K"43V0T&, MDU1FP\^(^N@SYWE1#V4VN/"(:M[SUAU!K7LSRPZ'T98)SW=-E59@2XX"NU<. M^:=+<"&(JQW,ZPG'?N21Q2%.1^57'`H\$LO+L/.)XD@,&UW/15AK+><"H)GT M1XF16K%CE["L<_0,#2.4Q`'3\@Y;FM?U@=;4#!U.&\@%H:G8`#Z>V2#IX M*I9O:P'5+9X(4=8L05JJJ`@OOAX.N?>5P'CY-4N?3!SF+8Z??)>+G%[=&+L= MUA9/>U5"13]T+X6*GF#ND0=+6PW-*^YZZ!U*,I58:G?,@^7*][S^\>2X:7'C MY'*$);8#%]^S*CC@E70_A-9OJ7O!T.,30Z0MZ5M\UU<05V)?_2UIF73J2JV)S&BS@T40:(UF&**CI, M/O8J+=0N$CRY8;SO:01D]7W`A@8<)GZ*@A9+TP.RFQ(Y,/;?3) MV>33V'[J50Y)LS`V7WY='K'5W^'47^B4HQ<;OMR=IFZBE&^QOOT%S]]O-CL&^RDYWBH25,:PC+3I3@M`TQ4 MU4^B0R`Z1M67RD>QV1CUG*4L-;'KDVFI>$V'K#W]55@)^V=.UN4JZC)IU,6R MW4SIH*N/.=*`%DB6MX63/-X$T9=$+[E;FPPFIQN/?6DJ-TJ`&(5=&=ST!(D4 M!0%*UR94*DF6-I%&&U?-GXD2LPG51W6A.3-X3VQ+Q:DHH MX&>D`;^6YU]Q.:+W:KGU>[U7+[`W`F]!$APTFA/AY>@)QZ MNL4(73_`M7SPNTA1,`6K,LEP4,[^>-/5X?B7`Z%V-0GR9TW;9($1`IC&-$)Q M.8W%&S_Z6_JS2V?PG&0Q)9=:DTXY"*CAFA*CTFW"N``UF6SH1+ZUSTPK^3G` M](=YZ,V/$=G=_,X-*ZAEA%$@-YI<2$F<]K/="]D,E83LR7R5%"Z1T&"QF"S. ME+(H59`P(8G9E$CJ^&FG0E(&C\EDJ,18L4.,*+Z.SOOT<`[FKAN=Y1$B4C*C MR5&E[+>SC>;-621:08`*"KA\NA)I@75P%7TIYT\M5-Y#+KY%?2M M#_1P[]I/&"_W,3[ZYZ/,9^^D->F`*PC2<@,K-/18C9V/%V3H=4XX0?4AE0IL M?00J>2\#!;(S;`H7,)=^8CF,.MRJ:&EYSXI0,;CRL?/]O_JAIU`>G-/8Y"K' M8[6UMF4)9M_09N!ULY4XOJ/*3?>7IRP-),O,)6#LBUG*JR_72A&8'N2ZABH&`3D58.I&2+X_%+,D."E45"=(;\Z0Z>I M9DCI3<2$4[1[Q,@I,P[F/CD[4GL(_=^S.6(/M+LHP%Y%=.BGHKX%RD M@'!O,,8V7+6W&2-;K2_NRPOU*!>]C;2W]9 MH`[K$=WS'P9,NQ&95'J^+6W&Y$B?15BPMKQL^4=8.;0F8.*50@H=6]>%;H.I ML0YT6DNHA)00Q4$#G4 M)'$$@#MSX6N2_+B%JT8&,SWF@:5Y#4_BF16XK3RF7<>+P/&E:4SU^C&9Y5%3 M0&$2F*)(+=L]E1:^^FH>K6.4]0.6WW&@L+]T["!%23J,YG+LH[&M3(X]U'7` MOB1+#K(*DS1F3HU@4=QX<^*`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`&>X>F&Z9I[Z`-IP`=2K9F922=B:@,!T*50> MR]QZJ)QTOJ!%49485TRO.YAQI:P7H[-MO.BH4+^YE4=%R@U93/R2=2=)<*J2 M@4N]#]`"XF+!%$N'5S)?L1XLR'HU1,K7!?&WR,O)R5(*FI9*6QN[BX#+51$2 M:!OL8O^)+L72V&TI'2B@Z@(H@JA"9`]HY)),R;+2LF@%PQ\SAD/FAG<6#1^1 M95@#Q$%IM]%I0Q32T*S")TP/B.4UA.1TH(:F+H"BH:D0V6-HNB3)_CK^T61/ M,V.=USC0"]C1Y MUHLWU$0:$A#6I.K8HVY;JV&,0$]N*#>-_:[>L0VO`]@S&[Y(J@R(M45.-8VFQCD)BL3N"1)T6%''=X04"D$''B`P1 M:3YUW$=/IV$XY[#0[XC!T(4$,,#I,[&*]='%>),<&N9M<=21SEX15HBM`GNW M8(4$>6R4-9N$49@'A[P`)TJHYX,$$OC%(<8&/^%06@R^FQ84\FU!%/%>$**< MTAZP=XM4\A[S>8<%BT"WNI'"5ZR74OI4@J&!';^84J<<51VOQ.G+K&LJF)+. MNH`PB[<=LKZ?5W<_+[0NH^=P3,HKVHQ]>3-:$>LX+O,[=W\Y^C(NG;O?DXZ;ST*,)P4Z" M=(,].C%:0TI#M'9MJ>>RY').7CZ1G"'6PXQ=J9>=P!6>&B`F(TG\S#A%A_*) M+1,-3R::DF?SH@33N]D$$,UL.3%=H](N,Z9I45Z*YS69Q_5R/*U)/:R7Z59U M;L/V-+EK,0F6;CD-R_IR7,=I7$9;#%]9:F.J+:?N`/"&4']*-`WBI=C,"]YR M#I^EYI;S9G4WOUO8O^7L"1E%^]$/+P:WG''D8NPE-V2Z+A5#*AE:9#O-3EJ3 M&TP%0=K1V!D-HD2H6@:GFLD';"\Y1"*J_BRG"9.(;$S<2N*G&0HQ[)Y$5>M: M6Q%%E8,!T`:?B"X\.@GA*#B$0=+@BR''S^D)#H/-MGK_?!M3H"<,@ M\_I4G#4=HIC&31*33;.=G?>![Q(<'7!,EW050!DZF+%&7B@#(D:=S'H((0=E M.@)Z5G7OQ.GS-=Y+#WAE9&!FH\6^W&CD!(A1($IBA\%0%X/!)SGOH]@C/E[* MHDDRF4Y,)EH[UAZ(\+5+#A"N:@U(MY>?(ZX/M#)J1U8];EM3R?,$C`JN):B_ M2!N"YL'39)G8O8@51T3@]!](7E*'40`5X1+0#C$;%:-4K:E<-5!",Z)":\RLJ`DB7SAK5;7KRRB,X1DH%%M&:W769_6% M%,@V]1.KM%5^R$R5DR21ZS-A6"Y1FF&S_@6)=:I]1+C,F3HXJ\->'60CF8%J MSW/OB9X""&OG=-)!P%\@@([/7)"!HUY7%H;XNJ_L3"6+-M85A5'!.?]SV8%O M&8"$V):@!V;3S$[\UB=V@K[\BF.7N'N>XLZ93PNT?18)(K<'6?K6G`R5=#9L MI+4%8D8!YRVIYYM5*(A.W$`"J'VT5.%DFVF9ML%@I[I0*T*F1@*$E`;;&KZR M#;!0Y;[M%,,?+FOQ7IOY&=K1P6P!,4_S9=CEJ+TYR&YP<4"?[:H5("LD,0A9 M"=OMG*7E%41^D`8.V7[W./+#'843`D[]SD54^*'Z%!.A*7!X`#R MOIS`3I%5&P7XY@P@Y74>>O1_-)SER0FH2;YG5;R:J2(DYDZK&X/&35.\5G`R MU6'Z)(O]4.EAAK(^$"?-"935&B@KQ6PM]5\N&"UM5TP#^P%?.H]L-#5>=,0[YRL]=.M0QWI+LVGO&DQR MDMR1%H@U`59,1593QBJ\?G(_/R=7'>?;F]T<4>M]1Z0B/UX>]88>9S]W[2=N M$"7G&"LX+X.[-KR)&C@-W(T5[7.&\EXK"0*H+\X[)4*7KBUPAB:8%=)5M@GA M'96`/H(="PF\+K M.7\CSU1/;-Y]%/BN6@D6"9%!'T'*NJ#0`%W?BM86+.@3BF!RJ>Y6HN8BW*E! MYA"PCA^>P%:9KLIX[!;W,N(,L3'IVE$=E?PZ'Q=5!F9. M/Q=4='3$A@>S#*8G=;OZZ6YULUK,[W9HOEBL/]^Q'*SWZ]O58K7<0EH7(P!M M&B@3Z#1GX_YV=N(4Q\%SOL-Q@LKIL-8A@FY/!NV0OI!-$)0]H+*+VG6(58E]O= M?,?N`\$VDC(]J.T8)4HP0`U_BLABM*!\QN$G)R40D&WV.DE,*:6<[>9W9JU1 MWASE[0'-M0$1C.FO@@+5U+A;>\RY0+?^;V??\]/GBX%7V:5)R0PZ-QWL-U6H M;%Y;Q)DC^HPLV-YHBO/3FFY&%NN[Q7)SAS[-=[OE!G1/HJ)-3;=#095,WH8_ MD<4EBI^UO'\9E=%;]4I?8M>Y<>@2)!96&0DL%B M069)^7IDP8J@*\?=S\237V_^;IGF=ZX""GIC])D]OSR&PEK036OVX7VG()QW MX-6Z//6R/!8L$"9E,OS"74WI.$_=E33.`OSHK25:W=B`*C4;+5=&R]:?H;)N MUO?+S>[O:'YWC99_^[RZASII&J*;RHBS8O'*0B:2[*XE/CN!2NR"C,KLDW8) M\YPWUZQU<67)VMNP1$TJA>%'Y%W*Q'E,WJ%)QL-XBC"B@J5:,7J]-:EOC^8# M@'H(+0BMN>2Z+#44>ZC2FVV+UH@SL%AL/B_)TO5?]\N[+>R%_T!E%L0:]=1D M@XDA*G&`*F6O>,U-)G'@L]L.,*_FD(5?LD9FVVCV`(F"M'("B+5CP`UBM5>U MY42)S-1-8C?[CI.LP@SE4.4]O)S0Y#/X+A%:`8\5 M@KP05%8;`WZ)&B3+-XK"&'W=KJ1?K4?M*LH%#1*]395Z'^#043//0A19LE2. M(N-NO?CK7]:WU\O-]AMVMK<#O7725D0U8`U;B`0.8R6;--EW_>+$L4-V8DHQ M!WKTIEQ(#8&X6,F3H+,#AH+:CK@$8/&,.6RZ*EGSW#3U<73D=&ZUNLA@<=*Y ME'#U!WROU4,8NF:@]3W-*[1E=T*_S#>;^=VN=;!F9N.E+X%XXU7[4//*AX+; MA"F"10'*<)NP:LV2'>$EH7D8..6\.6YE)ZG1?.J=8K2?$U3+SU2)+-B,F9+' M;-9R-55K9R]7TC-XS.CMRG1ZL0!):KL6B1):MC<;*.?R=KY;7J/[.8V^V)$U M=CM?L&771H1I[-+TM=)@EJKH>/13EDJ=9OMD684?<.AJIZ32ZL=D_BE-`7F) M7G+Z+)EOM0<[]GL6B6HTK50?U6WED.JAMY:A4V5AU.S(-GS*E@UUK;5@A1PN M[?K3I]6.1B1FF]'%FJ5W6-Y!YW;HIZJ]X`AXO7;>)_BW,V%O^<1X5$DT+2`Q MFEE:R'8[E731%&5M+5C7)F+?;%9HN>*TTT!+M09.XY7NQH0T@#HO/>-K:XT% M:X66!)^OMLN_?2;+`EK2YU2@2T&GSG1I.YR!SR[1R"ITBD(:'!\=';]U%%L1 ME=_>H)J+&&XJ2'ZC6S9$_\B:@EI%Z6PWE40RU9D(MX3J1_(S^=_>23#YP_\` M4$L#!!0````(`+!=KD"D,001FA8``.YG`0`5`!P`8FAR="TR,#$R,#,S,5]P M&UL550)``.<*+%/G"BQ3W5X"P`!!"4.```$.0$``.U=7W/;.))_OZK[ M#BGO<^+(=F8G4YO=DBT[ZUK'TEF:S=T3BZ(@"3<4H0"D8^VG7X`4)8H"0("D MV!3O7A+'08/]ZV[\:W0W_O*WMY7_[A51ADGPY:+WX>/%.Q1X9(:#Q9>+WRJ=L(?[U/FWV7OSJ?>_J_77OPQN;70@94.*C%S1_ M%W_^MW"S1E\N&%ZM?<%V_+LE1?,O%],E#3E][^KC=4+]IP'QHA4*PGXPNP]" M'&X>@SFAJYCGBW>BW]]?'@^8GV*R1"X-<>!]\,CJ4K2YU'9S68W%.Q(PXN.9 M&Z+9K>L+98R7"(7,@C]U'Z=B;N12+H\E"K'G^K6PFNNQ1L;'(?]3J(\-Y\,U MHK':RO*LZ.P4[`[GXY!X?RR)/^/SQ`#-L8?#JFS+.ZW*_O!Y/'QZ'/0G]X/Q MA/_Y[?YY,AX^W/7'?W]X&GX?VW!=V%=%9L=X$6`.V^7CV?-(Q`=TL!AQ07D8 MV5B%OI^*3+X@EFK,@J4L544&OA*.AEN0AVCPS0U#;BP6C,BH*S+T&+QR6(1N M+-C8TU3\^(@2/M;#C5@`?D1X;:D7*7E%EKC-T0C-[M_6*&!6AINGK,C(,PD1 MG[TW[E2T->;B@*SJD,Y,:4+`H8V12(CK8&>XCE<&KO+O+J5\DK":6Q0]5)Y5 M?+$8\*4VW$QXC\SU;-="91>55\#5"H?QPLH!\ZE#S*9\1VPW)^MZJ:K4:,K0 MCXAW?2\F%2MMYDFM6)'MFWU*DZX#M!#J$+OFSV+7W/LE9G;[ZR=WBGPYH]DM M^.>#OA*BR[^^:X+#$:*8\$UU.59SU(WRS'=4-*S`=8:^(;XG)'3]4AQG*!OB M]1F5D^V.KBF9\D4#E9/IGK)&7L-C/JT%N9<@GZ76%#$^9\7'G"?.Q@&#Z"U$ MP0S-4A9%!Q5/T['/@W@'G_&%EX'0HAE:_,;1==Z?LI#R]2KMR!CE#^%*P+7Z(^7__L;=U=OR)_\I)OOR"%EA\,`B? MW162,*QJZO02_K)ZZ]-#7EWJI3WR'X^4=NB=V;:X7,?G\_?>$OL[?<\I6=G+ M+^6%%")Y1RC?E7VYX#01XTR2>$?D^HVHX(XCH:[_R`W\[1]HH]5!KJUS=;Y* M.(:2:J'7L!KX]E*X0\>;U93X"O$?M'&NSU'L>0BIN*]@K#ZB`NL+6A,Q;2^$ MXRAB>N.7DC@WYZB,`D2I;JY!=/-/XD=Z_\/W]CPH\>`;^84FE`U=WXY1V5HT*3Z^`0R+&*SN..<+&+O MH&90'+1T_GR.6I`#217P"\R:058K$L0^J_&2@V?#*!37BF)9TZ\<&D+GU_-5 M3P&N5%M_;EA;*:P)[U:AEVP3Y_,Y:B"'()7UKT"RWKFH-.N$M*W3^WC.XC_" MDBKB<\.*Z'-N9H*C!]]5S48';9S>61ZACS#LCVU`IK_?*3SPWZBVJXK63N\L MS]`:-#M]-'V./N0I&9CF&LFT=WIG><#6XMEI17'[]PW75B(,@/6?J;O*5L?^UD(D4><,#YP%QFA.$"!ZH->6D?:GE4 M?<:X+`WX/VP(Y$VU%&;.YI50E.[4=QS?'/'C77*1IN$_9OX5T2G97UY`:')[ M8:*X]D(-6K1F=!H]Y[X0B[URV%)?T_"\1=O'J^O&U?7CG4KKA!Z5_NGXD MVS%;T0.YA`L5*->W*:1.Z'\;-,=>D(Y^O;FG+0VHFCMXC1$D$])PW")Z(%D-,HT MH`9R@9?4L1D@]>70.:G>5,F'Z&%\Z64GWASKZNLD2\6%V3BIID=L$F(\\MWD MC)S&&>OG71T9D`?>=I-<`*$;RVAFPGDF@5DKEWXI``ZN+$4%-Z]\0QE*ZH5F3!'8M& MKUTYC=.#]3R55;`:33K`/* M2FU&:&KS28&.RVR2=VX*\EW&\!RC6?%8M>C%Z<$ZK4J-7TM\ZFAKT#&=1?&, M^+%2F/4`LW@7J1K46B*G!^NPLA_5A7#4@=KG-*RM-LV2_>45K&^KU""5PU"' M)042Y:>34FZ"VAU5;0N8+UHI72OQQ&%V*#BG;$%6ZS MG:O6.-YJN,940JQMU%&Q^Q M5!V<=7*2,<1.G+P.T28U`?I1N"04_VL_E`LM(4\(G,94IP5(H'7C)":#^]@=>-D)H-8QJ]V7#<$^AQ>M^(/L4%?5-?N82NQ[!M0`^=& M5;,",WS=N/D^*@%DM-QKJ(`SIFK3O`07](7VB31>N,HK*("3J6K6]`Y3-ZZ^ M+6N=F9`!YUG5K&_34F>5E0[A.E&\_M-X3C5G#NUX,7"4*"@`?"-CUT?L!;VB M($+ZU,1<2V!OAUJ"*G?R$?N=\&3<$<8GBJ^$S&)O*:*OV$-L3'S]0J#M3IU0+KA57CABN!"%*6!,E?.6[@:%6OI@#T)6JW)%5T$IQ/KZQCYO,_% M5Q1P^?@<:G^VPD'\+$:(7U&QTLTZ`/8FE-"^,:YNK,+[(@B/J[6+J3#U.W[` M6B!=[0`-%;!7H83&]6"Z<5TP0)Q9?N*.M<%M>B4>G/C7]GUBI9HU5,#.A!)J MUH/IQ@I^)!:;C1EPV98R(U<"H0N!5#M4 M^4P"]6?'@JI(6N[F*M:"-$W;BHR1P>$B\`RX(W"XR6$$)7=#'3H&H- M+D+6B>_T5ZIR$F@2\%44;P.4S?.6_&9\EA$14?J8PKH M4C!5U*R!U(WC5FJWQ=ZR7$OH\B_5!N\1E.K;]#8D(RF%4F:##ETIIHJ&M:!J MVYL#'LGVA\P'+K@[$G"D$0>[#[6X17-"4=)NXKXA=O_&I994TJ&;1W[:B6O& M`SSJMSC/:;1^1WBQY(CZG`MW@9ZCU131X3P&G8E"-;>$ M(N0WY6LBRN*9`(@; MMB>]62M-5;A*'DLG'.@[5(D8[LAJ30+A$^Z_8=V&24O7EBSFG:8*-*K`T`D% M'R9J?D-B:=#H5=:\+1G**C7)M:M`T@FE9G)T"C5ZU+8M><=VZI3!Z,95E:*V M6:%BM71M22NV4W(1I&Y<60VVG`JIH(#%NDD/=J)0]":^E"W4OTTW;^C0WY*+ MJA)+;3<^/JPGXPD'*+ZU-'%?[!I#Q_=:.RT..._&2>@Q\"AR17G>Y._'X-A1 M]T)\_X'0GR[5.?XM>X*.]%4H57EI:XNM$TZ/JB6,@>-WRZA--07(L-6EXS6B MF(B+%!H"Z=FB"L]QA1K@8-T:M2R#5ML\#Z]E(9:DE%2RY1S%',6UXY[1S_A_ M]"NX`3UT3&_-8]X$;C=<9`JXR9BH8!ZY#J"C@T]N'Q*\;?62:0S\_LU;NL$" M<3&D!7J4CC.[;J"#AZL;0%G4+?6Y:>VXNATH^VE!7.\)#4$+&]J#=_K]Q!T) M.&^,@QK.DY]#S`_98^3QEN*9B/AEQ_[L?Z,D5ZKLOL/Z.RT(&&Y@?U)*+-UP M-&K'8Z%(SET(]`],WHF1'&-'@ME*JY.LQ>J+XB+F^$0 M;=>$1(`OR".+(.XE'L/:.(33?KH%\=HU&6L3DJHM]+_UYIP9T>)1YN\X7.X' M_`-RPTA;F[^N3[0@6KQ!\S252#<2$DJF#W7%T7P$ZY3I`F=TDP#\@NI);Q(R M+ZKV:O(RWP=0CUY6NDD`?O+TE#<)F6=->Y4=Q3(E-Y;[,WP>#Y\>!_W)_6`\ MX7]^NW^>C(AM_'@"D_=RY;/OCDITGM9AT90((/G_@%&R-*7C'7 MR>WF=[X??0QVM>/Z7HA?XQ.4+*'Z)VXU"^YPX*M M^%&;!HVV7;4I.N3K1AO.<^+8&GC81P=`)\10J`;3RRD^!YP%=6JC.Y'(NA&8 MEJUHS'_VD:2TL393HY@<."OK5.J7&YNA0#JQPL4"B[TCA`Y(-`WGD=_W/!+I M[YET9,#)7>M0%F,<8112L<6/@I+:&5R,9_);&4AU. MA=]=2ETNI.2R_#'(1`,]82]Y!R)!Y?O("R/7YP+C(I(ZQVOM'SAOKAD#JEMB MT%%;I6R.'TT#CH3_G[@X?"8A8B-WHR@B5*D_Z.2\UAB57D3=B+(ZE,#VS>-@ M(9[VU!VQ=&30Z8"0F^9C270C1DH,"0X,;>M_\;DU'2R9B-@AO?-=K$T>M>H' M.K6P64.R%@UTN))B&4NN5S.[?OET^C+K+RB*[X!4"YA]3]")B@TN7>6$`QU; M5,UFQB@,_:2P9TVV(^D1.@VR?3:D$!)X1%-Q[1DYGM0%NMW,">>YY]&XH?(, M7U//T%F5#1I7/<*J+Z#JY$9FD6)E1@V=8@EK+`J!U!=\U?2LLXJM?1"A"?D: MN6)G1R@;SF_=X(_AO+]"%'ON$W%EMZ$U?P$Z=;-5LY"-T';&U[(,8/WP&8B' MP?$TBK,A1+ES6V]E3=U#)XJV9CZSDMC.YEKF(M=[RW*+N\JRK#J!3OELT'ZL MY;*SDC-/1=Z5*,VF9]85VM\UI'U[Y<1ITB38TA![!R5&$;8C:.48JG M?L6V7U\W0$O7OLS%.M2?`U@]8+"=^A]1M';Q+*V9GCY"&LSBQX$3^5D9ADF' M[4N%K,-B3)%7CR-LIRG%,'."M-N52#IH7SYE'::B0MJ-R$"-S)ZP.\6^:4*. M74?.U?\%GW%YV>R6L/,N\G$,O-CA8DSK7+6MLE^A5DW-0X*T$YDR4J3B+BTC M,%N3R)$[5VTK\U>G54C`=B,]YAAMNC=[07QSKRU/54CK7+6M"%]M-B%!VHW< MEVK9L!IKJ=:Q M>H51A(!N#P3#NFE5[=$RA=A1ZZV$C]BWJ\G1W& M*-C]&Z(>9OO:TP4KNY36N8'UMC:ZO"LET(UZ(JIYT-`^#HJLW+32GWH:L\@# M[T;9$'[.V?J,DUV0@36H2)R;5KH\Z[,&'?#JI3[:X$P?[?")?,JB$D.2ULX- MK*/Q]#."''/UJAUM4'\UZ9W,B^W<=-PU65T\]57Z`+Q,$3+H!S/QEW"YO;J^ M&&G):W#Y\!^-L=ETX]S`^C3+78S8(JSM5>S6&4>?#QQ*-WP\%#WD:$3OW,"Z M,>LT!PFTVEP;R:M(G%L:=MH:8)V?)[6&&I_&AGX(+5JOD^)7KI_*Z3&8$[I* M%&;P0)59#\X-K'^TG#U8@.N&@R,M3B6J66M#I_?-G$^P3E`;'":!QW_!MQ'"`&!L@YE$<6TY2-30'9\(U>^OK0Q9/^EW@ MUU6U"E9,]*>6Q_D/_!<^86Z7T*:'^7]%G!E$_RC4?'0J+D?2I,>TB M$H!%[0G_B/`,AYN]?9BL23HRH%%@(%S%@E(`YOPM/RV.M6EZ-=A]V&KFUU`! MC!`)-R8C1$<&O$[HY:MTQ&CQG/\@25-$#[)MFX])DZ>I&HR:0EJ`L:/DR6XL MV70#/+9,M*`*J;%#>?XC;EO,9EMYKW&/Q-;7P]+G/%S?Q"6AH0(88,J723)% M9>S&6LD>H8>=5BN*`5<>ZOF/O0.?<=/A=9EOFZ1^2YK7<=K/]FLV1DS(@`>" M0EBR@WXQD/,W\]C;OR0^A\&V:;]-1V4<<2#D;A*,H24$6&OD#-FM+L9]``^C M0N&K@DPL\'5D=&TSA#*O@%;VJF7ZS71KY$.PHJ]C%9%_JW`5*2"#]*%92$^V MK!0C.W_#SZ903C@^YGI)Z'_C64MR/@R6ER)2@`5&Q9+=$F/1"_`B8Z`"Q3)C MA_'\QYL(W$C::D4Q M/JTQG_\0'4=3AGY$O-=[<5'0^+C,?]\HW%U.`G&VRK%B=)92T4"?G=1B59V: M-$@:'AF7@L&IRQ#_Q[\!4$L#!!0````(`+!=KD">K&XTS`@```Q$```1`!P` M8FAR="TR,#$R,#,S,2YXS'&,#('8#(LABC%?H`#?M.9"+*Y-\\>/'V<3 MDLPQ8H+0X"Q(8O/BO'-Q?GG9`8D1CC$5_83%/3Q%:21N6M]3%)$IP6'+`!4H MOY[,F6@H3S<?ZX/$O8#$C..^:7^X&GM"TD1X1^6Z-^FK"HH+\TY?`$<5R0 MR]%PI4J9^)V9#2Y)HQJY7P8@N"R4U!`3R@6BP4J)#:5S$SM75U>F&BU(*9XA M@<.MPJ],ED38S,D*KI2W9P@MEEQ3Q">*(Q]0<+?/.^TEX-=!DE+!GM>1X3@X MFR6/9CZH8TL9@S6UC2\?U3"&F.AY8$!#CI^"N9Y>CF@8"'W$7.A9LC$-$T4D MX'H>-219.NLLG`1Z!AC0D(,#Q/,"Q M0*V=*0I$&S\M(D212-AS'WXO`4DH36.]D%`P4VIL`E$;J#`CP9)O-U/.(.,/ MHC012$"4^O@!+1:$3A/Y6NZ#:ZFB#PR&?'@8.[511-G32X)41B2+AC851#P[ M((_%2G[+(`!)+<5RYA!/"25**X@\1MLHV,J/B(9&)L,H"?E@5B440E..0Y=^ M5,_@(PXR%(<,)SE73J+C6`EL1A^@*$BC[1.8:Q`?@'DWH3R)2"B7W"V*9+#S MYA@+G@&^?5B/]@5`[`$P.(>[ZPX]=^#T+-_N&;?6P!IV;C=<-G>#\<]UB?\Z:;\L0>/NU%U@IJ;7N&0+G=X;/]5Y MP_/AOWM[")YP^X8[LL>6[P#!7VZ0:+E33R3!MWD2A9`-0YI*`B)JW*&GU[OE M72.W2*]XOMO]]9,[Z-EC[Q]&S^X[7<<_/0>5\%FM6K??M;Q/_8'[V)%&4H62?G!(_,*!1H`8(D*%#9/=2$(]@'`<%YG*HGT8/_;YD:$1Y$ M"4\9EIYP[H8.K',+=H#5[;H/0]\9WADC\$C7L4\/]S'4'?G:S%`NO]!C^G,5 MT[&]7,8GA]]=`HL00G:`&;U'0D!TSG#4#>CQO*KB>>?*)0EQHFN/A\:]Y?L0 MGT\.60=J8BK+OPS/U4\MBIWS*HK.\#=8D.[XZ\DA-V()I&[B65:3WU.R6&UN M[8@>STX5S]%8)G'^5\,:]@S[/P_.Z"0W/'QZ6(I#^VF!*2\^3=67>D@OJI#" M!VC\`%F`_65D#[T3_/H,$X&A\GM&DPAG2*Z]T<-X685QZ/JV9XRLK];MP#XY M#,N%@=S4(@^8FO=Z/'_:R)'6R@*YU?W3"Z(*/G>AZE\(EY\18Y!X\A*VFD$] MP.^T`$--K`IB%4\_6^,QI*2G%P'&.)*%[@C>/_L`(D=!Z6ABZZ@>Z/>;F>E` ME5DC2WZX?(#8L[JG>@P1QT2HHQU8L9"8RNH)TU5Y54>@AWNCN.JZ]_>.GY6S M;CT(Q?+DQI:)[;'C M*?^1]Z!C/#74!>.UO(6Y:7$2+V0RD+V;,SR]:E]#*EOA=%I=3\(`6)(P85!MF\2V>_^LPV*0!$I,#8O\ MU2[XVO)5NW/1ONRBH8S%PQRRG<-)JOM:-@R MIYI/RVCB2/#B37LEJJG5-8T%=;IHV/+G`W30]6HT4:+,5_PX1`U=ZTCI@]LV^D2;3K[BRQ_9*P+X*5/M0FDQ?\,B'0Z:N=JE*!L'.^T,T:!@*2[.+0V>N;_!IJDU9BKT2 MLI]RM1U>359%P2,?]MN-]>U'C6"H_LU4LK0^ MR5M#E2[U75?6A`NFEJ4LVF1F^'LS\BR]5`V8U_`.:FA'X%B6/BT#Y50W+<%2 MF7PJ*DCW2!+ZBB],6=X61DD4R4/0@I9#W0B3IG+TCB7IHIB$@'BPSM@P#RK- MA(6$RIC1PQ-1/DPIF55/5C8G3B`&(/:L,VB*(JZU*$L=13$TR7I^;EH!PZ%L M>3C\>QQ/,UCU: M0Y;9F?517H=)C`C=R\S77*+RS"FAZC2UK/2&13OHWI))>6^.%4"P2-5.ZJ4R M"O3P(XX2=>/F"33;]-J^C&_):.49A_.T4'JD)OH-12FV(5U%=(;["?,P>R1! M<>"8K=5].0_>IBN[_[A]JC?*FR.&^8OPJ&%=^^`HLC]M&5@Q?.C)?Y4\=UK< MBF36.+2D_0!4EQ>E\"EUJ,!1A`.1HJBXGB[A\7HB_[B%$^+)ZZR;>F.[L-6Q MNO_X3,1\\^JT`5YU(HX`G^P:TX'O+%.9V!:[QJ$U8[C4TZ20>0GS_P\F'A8B MXSL`&ZV0(\"HE#[H#(?G.GEJJ%H71%=*]UTUSH<6)86@Y0=D%M/%'R MQF0V%PU2@5>3>`3HU7^X*Q&FA-&>?$>`!.B:_0&$S%8V#=8/'T.1`.LQP#CD M?9;$Y4QLRS%-,_)C<&C)D++R5O@H9^);;-:3'H&]FK"URJ.R=:O9R'MQO2(* MA]NK:7S7'*;64KV=,]0RSJMV'!\_B=L(7+/E=%%+N79>(XKW?^Z13=;"6.I@ M7&FN\5ESEK?C0+W..@?NI'QC#BS]H8[.'/WP+AOJU:BU:,/\BHE9$TMVJP./ M_P-02P$"'@,4````"`"P7:Y`JOB6M[EL``"8;P0`$0`8```````!````I($` M````8FAR="TR,#$R,#,S,2YX;6Q55`4``YPHL4]U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`"P7:Y`:*0;TGL*```)D```%0`8```````!````I($$;0`` M8FAR="TR,#$R,#,S,5]C86PN>&UL550%``.<*+%/=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`L%VN0!DO42DI!0```Q0````(`+!=KD`!7,M9.2P``,)Y`@`5`!@```````$```"D@49] M``!B:')T+3(P,3(P,S,Q7VQA8BYX;6Q55`4``YPHL4]U>`L``00E#@``!#D! M``!02P$"'@,4````"`"P7:Y`I#$$$9H6``#N9P$`%0`8```````!````I('. MJ0``8FAR="TR,#$R,#,S,5]P&UL550%``.<*+%/=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`L%VN0)ZL;C3,"```#$0``!$`&````````0```*2! MM\```&)H'-D550%``.<*+%/=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`&@(``,[)```````` ` end XML 12 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

GOING CONCERN MATTERS
3 Months Ended

Mar. 31, 2012

Going Concern Matters [Abstract]

GOING CONCERN MATTERS
NOTE 3 – GOING CONCERN MATTERS

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, during three months ended March 31, 2012, the Company incurred net losses attributable to common shareholders of $946,892 and used $84,383 in cash for operating activities. As of March 31, 2012 we had a working capital deficit of approximately $12.3 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

X

- Details

Name: bhrt_GoingConcernMattersAbstract

Namespace Prefix: bhrt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References

No definition available.

+ Details

Name: us-gaap_LiquidityDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\W9F0T,30T-%\S,F0Y7S1F-F5?861A,5\W83)A M83DW9&0X8S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/ M5$537U!!64%"3$4\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/34U)5$U%3E137T%.1%]#3TY424Y'14Y#2453/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I3='EL M97-H965T($A2968],T0B5V]R:W-H965T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W9F0T,30T-%\S,F0Y7S1F M-F5?861A,5\W83)A83DW9&0X8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-V9D-#$T-#1?,S)D.5\T9C9E7V%D83%?-V$R86$Y-V1D.&,W+U=O M'0O:'1M M;#L@8VAA2`P,BP@,C`Q M,CQB'0^0DE/2$5!4E0L($E.0RX\2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3,X.#,Q.3QS M<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T* M("`@("`@("`\=&0@8VQA2!&:6QE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^36%R(#,Q+`T*"0DR,#$R/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^9F%L M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\W9F0T,30T-%\S,F0Y7S1F-F5?861A,5\W83)A M83DW9&0X8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V9D-#$T M-#1?,S)D.5\T9C9E7V%D83%?-V$R86$Y-V1D.&,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XT+#,R-3QS<&%N/CPO'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E&5S("AB96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)FYB'0^)FYB'0^)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)FYB'1087)T7S=F9#0Q-#0T7S,R9#E?-&8V95]A9&$Q7S=A,F%A.3=D9#AC M-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W9F0T,30T-%\S,F0Y M7S1F-F5?861A,5\W83)A83DW9&0X8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@;V8@:6YT97)EF%T:6]N(&]F('=A&-H86YG92!F;W(@2!I;G-T'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E2!A;F0@97%U:7!M96YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6UE;G0@;V8@ M;&]A;B!C;W-T'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0^ M)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!O9B!T:&4@6EN9R!U;F%U9&ET960@8V]N9&5N#L@9F]N=#H@,3!P="!T:6UE&-H86YG92!#;VUM:7-S:6]N("AT:&4@ M)B,X,C(P.U-%0R8C.#(R,3LI(&%N9"!W:71H('1H92!I;G-T2P@=&AE>2!D;R!N;W0@:6YC;'5D M92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T97,@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU2!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@96YD M960@1&5C96UB97(@,S$L(#(P,3(N(%1H92!U;F%U9&ET960@8V]N9&5N3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE2!I;F1U2!D96QI=F5R:6YG(&-E;&P@=&AE6]C87)D:6%L(&EN9F%R8W1I;VYS(&%N9"!O=&AE2P@86YD(&ET3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE7-I2P@ M86-T=6%L(')E#L@9F]N=#H@,3!P="!T:6UE&5D(&%N9"!D971E M2!A6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ(&IU2!A6UE;G0@=&5R;7,@;V8@=&AE('1R86YS86-T:6]N+B!)9B!A('-I9VYI9FEC M86YT('!O&5D(&]R(&1E=&5R;6EN86)L92!A;F0@F5D(&%S('1H92!F965S(&)E8V]M92!D=64@;W(@869T97(@:6UP M;&5M96YT871I;VX@;W(@8VQI96YT(&%C8V5P=&%N8V4@:&%S(&]C8W5R2!I3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE2!A8V-O=6YT M6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$ M)W1E>'0M86QI9VXZ(&IU2!B:6QL86)L92!T;R!T:&4@8W5S=&]M97(@<'5RF5D(&%S(')E M=F5N=64@87,@'!E8W1E9"!T;R!B92!C M;VQL96-T960@=VET:&EN(&]N92!Y96%R(&%N9"!A#L@9F]N=#H@,3!P="!T:6UE2!C:&%N9V5S('1O('1H92!A;&QO=V%N8V4@9F]R(&1O M=6)T9G5L(&%C8V]U;G1S(&]N(&%C8V]U;G1S(')E8V5I=F%B;&4@87)E(&-H M87)G960@=&\@;W!E2!O9B!T:&4@86QL;W=A;F-E(&)A2!I;7!A:7)E9"X@07,@;V8@36%R8V@@,S$L(#(P,3(@ M86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L M(&%C8V]U;G1S('=A6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU2!A;F0@97%U:7!M96YT(&%R92!R96-O65A M6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!A2!N;W0@8F4@6EN9R!A;6]U;G0@;V8@82!L;VYG+6QI=F5D(&%S&-E961S('1H92!S=6T@;V8@=&AE('5N9&ES M8V]U;G1E9"!C87-H(&9L;W=S(&5X<&5C=&5D('1O(')E6EN9R!A;6]U;G0@;W(@9F%I3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'!E8W1E9"!F M=71U"!R871E3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@ M;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE2!D;V5S(&YO="!H879E M(&%N>2!I=&5M#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W#0H@#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)VUA6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE M'!O M6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE2=S(')E=F5N=65S(&5A6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE&5C=71I=F4@;V9F:6-E65E M2!C;VYS=6QT86YT6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$ M)W1E>'0M86QI9VXZ(&IU3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE2!A M8V-O=6YT6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3L@;6%R9VEN M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE6%B;&4@86YD(&%C8W)U960@;&EA8FEL M:71I97,L(&%N9"!S:&]R="UT97)M(&)O&EM871E(&9A:7(@=F%L M=64@8F5C875S92!O9B!T:&4@2!O9B!T:&5S M92!I;G-T#L@9F]N=#H@,3!P="!T:6UE65A3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!I'!E8W1E9"!T;R!A M(&AA=F4@82!M871E'1087)T M7S=F9#0Q-#0T7S,R9#E?-&8V95]A9&$Q7S=A,F%A.3=D9#AC-PT*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W9F0T,30T-%\S,F0Y7S1F-F5?861A M,5\W83)A83DW9&0X8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'`@6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!L971T97(M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#([('=O'0M#LG/CQB/DY/5$4@,B`F(S@R,3$[(%)%4U1!5$5-14Y4/"]B/CPO<#X\<"!S M='EL93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM=&]P.B`X<'0[(&UA'0M86QI9VXZ(&IU M6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[(&UA#L@;6%R9VEN+6QE9G0Z(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^56YA M=61I=&5D($-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT(&]F($]P M97)A=&EO;G,\8G(@+SY&;W(@=&AE(%1H#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`X<'0[(&UA'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[('=O'0M#LG(&-E;&QS<&%C:6YG/3-$,#X\ M='(@6QE/3-$)VUA6QE/3-$)VUA M6QE/3-$)VUA2!R97!O#LG/B8C M,38P.SPO<#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)2!N M;W=R87`],T1N;W=R87`^/'`@86QI9VX],T1C96YT97(@6QE/3-$)VUA#LG/D%S M(')E#L@;6%R9VEN+6)O='1O;3H@-2XU,S-P>#LG/B8C,38P.SPO<#X\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`^/'`@6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.SPO<#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0U)2!N;W=R87`],T1N;W=R87`^/'`@#L@;6%R9VEN+6)O='1O;3H@-2XU,S-P>#LG/B8C,38P.SPO<#X\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`^/'`@6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE M/3-$)VUA#LG/B8C,38P.SPO<#X\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0U)2!N;W=R87`],T1N;W=R87`^/'`@86QI9VX],T1R M:6=H="!S='EL93TS1"=M87)G:6XZ(#!P>#LG/BT\+W`^/"]T9#X\=&0@;F]W M6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/B8C,38P.T=R;W-S('!R;V9I=#PO<#X\+W1D/CQT9"!S='EL M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!B;W)D97(M=&]P+7=I M9'1H.B`R<'@[(&)O6QE/3-$ M)VUA6QE/3-$)V)A M8VMG#L@8F]R9&5R+71O<"US='EL93H@#LG/BT\+W`^/"]T9#X\=&0@6QE/3-$)VUA6QE/3-$)V)A8VMG#L@8F]R9&5R+71O<"US='EL93H@ M6QE/3-$)V)A8VMG#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)V)A8VMG#L@8F]R9&5R M+71O<"US='EL93H@6QE/3-$)V)A8VMG#L@8F]R9&5R+71O M<"US='EL93H@6QE M.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA#LG/D]P97)A=&EN9R!E>'!E;G-E6QE/3-$)VUA#LG/B8C,38P M.SPO<#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)2!N;W=R M87`],T1N;W=R87`^/'`^)B,Q-C`[/"]P/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<#X\<#XF(S$V,#L\+W`^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-24@;F]W6QE/3-$)VUA#LG/B8C M,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24@;F]W6QE/3-$)V)A8VMG6QE/3-$ M)VUA6QE/3-$ M)VUA6QE/3-$)V)A M8VMG#LG/C$W,"PQ,3$\+W`^/"]T9#X\+W1R/CQT#LG/DUA6QE M/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A M8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG#LG/BT\+W`^ M/"]T9#X\=&0@#LG/B8C,38P M.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E M969F.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24@;F]W#LG/B8C,38P.U1O=&%L M(&]P97)A=&EN9R!E>'!E;G-E6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL M93H@#LG/C8V.2PS,C0\+W`^/"]T M9#X\=&0@6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO#LG/B8C M,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P+7=I9'1H.B`R M<'@[(&)O6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)V)O#L@8F]R9&5R M+71O<"US='EL93H@6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@6QE.B!S;VQI9#L@ M8F]R9&5R+71O<"UC;VQO6QE/3-$)VUA6QE M/3-$)VUA6QE/3-$)VUA#L@;6%R9VEN+6)O='1O M;3H@-2XU,S-P>#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/'1R/CQT9"!S='EL M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!B;W)D97(M=&]P+7=I M9'1H.B`R<'@[(&)O#LG/DYE="!L;W-S(&9R;VT@ M;W!E6QE/3-$)VUA6QE/3-$)V)A8VMG#L@8F]R9&5R+71O<"US='EL M93H@#LG/B@V-CDL,S(T/"]P/CPO M=&0^/'1D('-T>6QE/3-$)V)A8VMG#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)V)A8VMG#L@8F]R9&5R+71O<"US='EL93H@#LG/BT\+W`^/"]T9#X\=&0@6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO6QE.B!S;VQI9#L@8F]R9&5R M+71O<"UC;VQO6QE.B!S;VQI9#L@8F]R9&5R+71O M<"UC;VQO#LG/B8C,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!B;W)D97(M=&]P+7=I9'1H.B`R M<'@[(&)O#LG/B8C,38P.SPO<#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0U)2!N;W=R87`],T1N;W=R87`^/'`@#L@;6%R9VEN+6)O='1O;3H@-2XU,S-P>#LG/B8C,38P.SPO M<#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`^/'`@6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)VUA'!E;G-E6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG#LG/B8C,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B`C8V-E8V9F.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$-24@;F]W6QE/3-$)VUA#LG/D]T:&5R(&EN8V]M93PO M<#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`^/'`@#LG/DQO6QE/3-$)V)A8VMG6QE/3-$)VUA M6QE/3-$)VUA6QE/3-$)VUA M6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA M6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG#L@8F]R9&5R+71O<"US='EL93H@ M6QE/3-$)VUA'!E;G-E6QE.B!S;VQI9#L@ M8F]R9&5R+71O<"UC;VQO6QE/3-$)VUA6QE/3-$)V)A8VMG#L-"B!B;W)D97(M=&]P M+7-T>6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO M6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO#LG/B8C,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!B;W)D97(M=&]P+7=I9'1H.B`R<'@[(&)O#LG/B8C M,38P.SPO<#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)2!N M;W=R87`],T1N;W=R87`^/'`@#L@;6%R9VEN+6)O='1O;3H@-2XU,S-P>#LG/B8C,38P.SPO<#X\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`^/'`@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)VUA6QE/3-$)VUA M6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@#LG/B@Q+#$X-BPU,C<\+W`^/"]T9#X\=&0@6QE M.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO#LG/BDF(S$V,#L\+W`^ M/"]T9#X\=&0@6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO6QE/3-$)VUA6QE/3-$)VUA M6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@#LG/B@Q+#`W-2PV-34I/"]P/CPO=&0^/"]T#L@;6%R9VEN+6)O='1O;3H@-2XU M,S-P>#LG/B8C,38P.SPO<#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`^/'`@ M6QE/3-$)VUA6QE/3-$)VUA#L@;6%R9VEN+6)O='1O M;3H@-2XU,S-P>#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/'1R/CQT9"!S='EL M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG M/DEN8V]M92!T87AE6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG#LG/BT\+W`^ M/"]T9#X\+W1R/CQT#LG/B8C,38P.SPO<#X\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)2!N;W=R87`],T1N M;W=R87`^/'`@#L@;6%R9VEN M+6)O='1O;3H@-2XU,S-P>#LG/B8C,38P.SPO<#X\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`^/'`@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R M+71O<"US='EL93H@#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)VUA6QE.B!S;VQI9#L@8F]R M9&5R+71O<"UC;VQO6QE.B!S;VQI9#L@8F]R9&5R+6)O='1O M;2UC;VQO#LG/B8C,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M=&]P+7=I9'1H.B`R<'@[(&)O6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO#LG/BDF(S$V M,#L\+W`^/"]T9#X\=&0@6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@#L@ M8F]R9&5R+6)O='1O;2US='EL93H@6QE/3-$)V)O#L@8F]R9&5R M+71O<"US='EL93H@#L@8F]R9&5R+6)O='1O;2US='EL M93H@6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@#L@8F]R9&5R+6)O M='1O;2US='EL93H-"B!S;VQI9#L@8F]R9&5R+6)O='1O;2UC;VQO#LG/B8C,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P+7=I M9'1H.B`R<'@[(&)O6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[(&UA#L@;6%R M9VEN+6QE9G0Z(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B@Q*2!R979E M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3L@;6%R9VEN.B`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R M9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!I;F-U&EM871E;'D@)#$R+C,@;6EL;&EO;BX@5&AE M6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU&ES=&5N8V4@:7,@9&5P M96YD96YT('5P;VX@;6%N86=E;65N="8C.#(Q-SMS(&%B:6QI='D@=&\@9&5V M96QO<"!P2!B92!U;F%B;&4@=&\@8V]N=&EN=64@87,@82!G M;VEN9R!C;VYC97)N+CPO<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$ M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M M86QI9VXZ(&IU#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y M.R!M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J M=7-T:69Y.R!M87)G:6XZ(#!P>#LG/DEN=F5N=&]R>2!C;VYS:7-TF%B;&4@=F%L=64I+CPO<#X\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'`@6QE.B!N;W)M86P[(&9O;G0M M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M M#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O.R`M=V5B:VET M+71E>'0M#L@9F]N="US:7IE.B`Q,'!T.R!T97AT M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X\<"!S M='EL93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#LG/E!R;W!E6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L M971T97(M'0M:6YD M96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@ M;F]R;6%L.R!W:61O=W,Z(#([('=O'0M#L@9F]N="US:7IE.B`Q,G!T.R!M87)G:6XZ(#!P>#LG/B8C M,38P.SPO<#X\=&%B;&4@#L@ M=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E M6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-EF4Z(#$P<'0[(&9O;G0M#LG/C(P,3(\+W`^/"]T M9#X\=&0@6QE M.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&9O M;G0M'0M86QI M9VXZ(&-E;G1E#LG/C(P,3$\+W`^/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Y.3EP>#LG/DQA8F]R871O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,S4R+#,U.#PO M=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B0\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,3,S<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^ M,S4R+#,U.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,W!X.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT'1U6QE/3-$)W9E M6QE.B!S;VQI9#LG/DQE87-E:&]L9"!I;7!R;W9E;65N=',\+W1D/CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,S8R+#`T-CPO=&0^/'1D('-T>6QE/3-$)V)O M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,S8R+#`T-CPO=&0^/'1D('-T>6QE M/3-$)V)O6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)V)O M6QE.B!S M;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ M#0H@#L@=&5X="UTF4Z(#$R<'0[(&UA6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X M="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU2P@<&QA;G0@86YD(&5Q=6EP;65N="!A6QE.B!N;W)M86P[(&9O;G0M=F%R M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M'0M:6YD96YT.B`P<'@[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W M:61O=W,Z(#([('=O'0M#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X\ M<"!S='EL93TS1"=C;VQO#L@9F]N="US:7IE.B`Q M,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#LG/D5X<&5N M9&ET=7)E2!E>'1E;F0@=&AE('5S969U;"!L:79E2!A;F0@97%U:7!M96YT(&%R92!C:&%R9V5D('1O(&]P97)A=&EO;G,N M(%=H96X@<')O<&5R='D@;W(@97%U:7!M96YT(&ES('-O;&0@;W(@;W1H97)W M:7-E(&1I2!R979I97=S('1H92!C87)R>6EN9R!V86QU92!O9B!I=',@<')O<&5R M='D@86YD(&5Q=6EP;65N="!F;W(@:6UP86ER;65N="X\+W`^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W9F0T,30T-%\S,F0Y M7S1F-F5?861A,5\W83)A83DW9&0X8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-V9D-#$T-#1?,S)D.5\T9C9E7V%D83%?-V$R86$Y-V1D.&,W M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#L@=&5X="UTF4Z(#$P<'0[(&UA#L@;6%R9VEN+6)O='1O;3H@,'!X.R!M87)G:6XM;&5F=#H@,'!X.R<^/&(^ M3D]412`V("8C.#(Q,3L@04-#4E5%1"!%6%!%3E-%4SPO8CX\+W`^/'`@6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T M97(M'0M:6YD96YT M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(#([('=O'0M#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`S+C5P=#L@ M;6%R9VEN+7)I9VAT.B`P<'@[(&UA#L@;6%R9VEN M+6QE9G0Z(#!P>#LG/D%C8W)U960@97AP96YS97,@8V]N#L@=&5X="UT#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET M+71E>'0M6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O#LG/CQB M/DUA#LG/CQB/C(P,3(\+V(^/"]P M/CPO=&0^/'1D('-T>6QE/3-$)V)O6QE.B!S M;VQI9#L@<&%D9&EN9SH@,"XW-7!T.R<@8V]L#LG/CQB/D1E8V5M8F5R(#,Q+#PO8CX\+W`^/'`@#LG/CQB/C(P M,3$\+V(^/"]P/CPO=&0^/"]T6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6%B;&4@=&\@=&AE($=U M87)A;G1O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^,2PQ-C0L,S`V/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT6%B;&4@;VX@;F]T97,@<&%Y M86)L93PO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^.#`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`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Q,#`E M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL6QE/3-$)V9O;G0Z(#%P="!T:6UE6QE/3-$ M)V9O;G0Z(#%P="!T:6UE6QE/3-$)W=I9'1H.B`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`Y/"]T9#X\=&0^ M)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^-RPX-30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`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`P<'@[(&9O;G0Z(#$R<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M6QE/3-$)W1E M>'0M86QI9VXZ(&IU2X\+W`^/'`@3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE2!M861E(&%N9"!D96QI=F5R960@ M82!P2P@=&AE($-O;7!A;GD@96YT97)E9"!I M;G1O(&%N($%M96YD960@86YD(%)E3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU2!C M;&]S960@;VX@82`D-2XP(&UI;&QI;VX@6UE;G1S(&]V97(@=&AE(')E;6%I;FEN9R`S,R!M;VYT:',N($%S M(&-O;G-I9&5R871I;VX@9F]R('1H92!L;V%N+"!T:&4@0V]M<&%N>2!I65A3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE3L@;6%R9VEN.B`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`D,RPV,#`L('1O9V5T:&5R('=I=&@@=&AE('!R:6YC:7!A M;"!A;F0@:6YT97)E2`R+"`R,#`Y+"!T:&4@0V]M<&%N>2!R96-E:79E M9"!F&5R8VES:6YG(&%N>2!O M9B!I=',@#L@9F]N=#H@,3!P="!T:6UE2P@*&(I(&%M96YD960@=&AE(&%M;W)T:7IA=&EO;B!S8VAE9'5L92!F;W(@ M=&AE($QO86X@=&\@<')O=FED92!F;W(@:6YT97)E2!P87EM96YT M2!P M6UE;G1S(&]F("0R-C(L-CDR('=I M;&P@8V]M;65N8V4L(&%N9"`H8RD@<')O:&EB:71S('1H92!#;VUP86YY(&9R M;VT@9W)A;G1I;F<@86YY(&QI96X@86=A:6YS="!I=',@:6YT96QL96-T=6%L M('!R;W!E2!I2!O=F5R('1H92!T97)M(&]F('1H92!L;V%N+B!);B!C;VYN96-T:6]N('=I M=&@@=&AE($)L=65#2!P M86ED($)L=65#2!A;'-O('!A:60@ M0FQU94-R97-T(&$@9F5E(&]F("0Q-2PP,#`N($5F9F5C=&EV92!*=6QY(#$L M(#(P,#DL('1H92!#;VUP86YY(&%N9"!";'5E0W)EF%T:6]N('-C:&5D=6QE(&9O2!O=F5R('1H92!T97)M(&]F('1H92!L M;V%N+CPO<#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G M:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UEF%T:6]N('-C:&5D=6QE(&9O2!I M28C.#(Q-SMS(&-O;6UO;B!S:&%R97,@86YD('!A M:60@82!F964@;V8@)#(P+#`P,"X@5&AE($-O;7!A;GD@86QS;R!P2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&ESF5D(')A=&%B;'D@;W9E M3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2`W M+"`R,#$Q+"!";'5E0W)E2!P87EM96YT(&1U92!O;B!T:&4@0FQU94-R97-T(&QO86X@*'1H92`F M(S@R,C`[3F5W($YO=&4F(S@R,C$[*2X@5&AE($-O;7!A;GD@97AC:&%N9V5D M('1H92!";'5E0W)E2`H=&AE("8C.#(R,#M#;VYV97)T:6)L92!.;W1E M)B,X,C(Q.RDN($]N($IU;'D@,3@L(#(P,3$L('1H92!#;VUP86YY(&ES3L@;6%R9VEN M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!T=V\@=6YS96-U6%B;&4@870@;6%T=7)I='D@ M86YD(&5A8V@@8V]N=F5R=&EB;&4@:6YT;R!C;VUM;VX@28C.#(Q-SMS('-H87)E7,@<')I;W(@ M=&\@=&AE($QE;F1E6QE/3-$)W=I9'1H.B`Q,#`E M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL6QE/3-$)W=I9'1H.B`R,'!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2`R,#$Q+"!T:&4@0V]M<&%N>2!I6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W9E3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!A;F0@36%G;F$@1W)O=7`L($Q,0R`H)B,X,C(P.TUA9VYA)B,X,C(Q.RD@ M=&\@86=A:6X@6UE;G0@9'5E(&]N('1H92!";'5E0W)E2!T=V\@=6YS96-U6%B;&4@870@;6%T=7)I='D@ M86YD(&5A8V@@8V]N=F5R=&EB;&4@:6YT;R!C;VUM;VX@28C.#(Q-SMS('-H87)E7,@<')I;W(@ M=&\@=&AE($QE;F1E6QE/3-$)W=I9'1H.B`Q,#`E M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL6QE/3-$)W=I9'1H.B`R,'!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2!I6QE/3-$)W9E2`R,#$Q+"!T:&4@0V]M M<&%N>2!I3L@;6%R9VEN M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6UE;G0@9'5E(&]N('1H M92!";'5E0W)E#L@9F]N=#H@,3!P="!T:6UE2!T:&4@3F5W($YO=&4@:7,@:6X@=&AE(&YA='5R92!O9B!C M;VYV97)T:6)L92!D96)T(&5V:61E;F-E9"!B>2!A;B!U;G-E8W5R960@8V]N M=F5R=&EB;&4@<')O;6ES2!N;W1E+"!B96%R:6YG(&EN=&5R97-T(&%T M('1H92!R871E(&]F(#@E('!E2!A;F0@8V]N=F5R=&EB;&4@:6YT;R!C;VUM;VX@6QE/3-$)VUA6QE/3-$)W9E6QE/3-$)W9E2`R,#$Q+"!T:&4@0V]M<&%N>2!I2!P87EM96YT(&1U92!O;B!T:&4@0FQU94-R97-T(&QO86X@ M*'1H92`F(S@R,C`[3F5W($YO=&4F(S@R,C$[*2X@5&AE($YE=R!.;W1E('=A M&-H86YG960@9F]R(&$@;F5W($-O;G9E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ M(&IU&5R8VES92!I=',@8V]N=F5R6QE/3-$)W=I9'1H M.B`Q,#`E.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL6QE/3-$)W=I9'1H.B`R,'!X.R<^)B,X,C(V.SPO=&0^/'1D M/DEN($IU;'D@,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D(&%N(&%G9W)E9V%T M92!O9B`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`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M6QE/3-$)VUA6QE M/3-$)W1E>'0M86QI9VXZ(&IU7-T;VYE)B,X,C(Q M.RD@=&\@86=A:6X@6UE;G0@9'5E(&]N('1H92!";'5E0W)E M6UE;G0@8GD@=&AE;2!T;R!";'5E0W)E3L@;6%R M9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6%B;&4@870@;6%T=7)I='D@86YD(&-O;G9E28C.#(Q-SMS('-H87)E7,@<')I;W(@=&\@=&AE($QE;F1E6QE/3-$)W=I M9'1H.B`Q,#`E.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL6QE/3-$)W=I9'1H.B`R,'!X.R<^)B,X,C(V.SPO=&0^ M/'1D/DEN($]C=&]B97(@,C`Q,2P@=V4@:7-S=65D(&%N(&%G9W)E9V%T92!O M9B`T+#DY-RPT.#<@6QE/3-$)VUA6QE/3-$)W1E>'0M M86QI9VXZ(&IU2!P87EM96YT(&1U92!O;B!T:&4@0FQU94-R97-T(&QO86X@ M*'1H92`F(S@R,C`[3F5W($YO=&4F(S@R,C$[*2X@5&AE($YE=R!.;W1E('=A M&-H86YG960@9F]R(&$@;F5W($-O;G9E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ M(&IU&5R8VES92!I=',@8V]N=F5R3L@;6%R9VEN.B`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+7-I M>F4Z(#$P<'0[)R!C96QL6QE/3-$ M)W=I9'1H.B`R,'!X.R<^)B,X,C(V.SPO=&0^/'1D/DEN($IA;G5A2`R,#$R+"!W92!I6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU2!P87EM96YT(&1U M92!O;B!T:&4@0FQU94-R97-T(&QO86X@*'1H92`F(S@R,C`[3F5W($YO=&4F M(S@R,C$[*2X@5&AE($YE=R!.;W1E('=A&-H M86YG960@9F]R(&$@;F5W($-O;G9E6QE M/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU&5R8VES92!I M=',@8V]N=F5R6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT M+7-I>F4Z(#$P<'0[)R!C96QL6QE M/3-$)W=I9'1H.B`R,'!X.R<^)B,X,C(V.SPO=&0^/'1D/DEN($9E8G)U87)Y M(#(P,3(L('=E(&ES3L@;6%R9VEN.B`P<'@[(&9O;G0Z#0H@,3!P M="!T:6UE&-H86YG960@9F]R(&$@;F5W($-O M;G9E6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)W1E>'0M M86QI9VXZ(&IU2!A M="!A('!R:6-E('1H870@:7,@-C4E(&]F('1H92!A=F5R86=E(&]F('1H92!C M;&]S:6YG('!R:6-E&5R8VES92!I=',@8V]N=F5R3L@;6%R9VEN.B`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2`V+"`R,#$R+"!";'5E0W)E2!P87EM96YT(&1U M92!O;B!T:&4@0FQU94-R97-T(&QO86X@*'1H92`F(S@R,C`[3F5W($YO=&4F M(S@R,C$[*2!A9G1E6UE;G0@;V8@)#4P+#`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`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`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE2`V M+"`R,#$R+"!T:&4@0V]M<&%N>2!I2`V M+"`R,#$S(&EN(&5X8VAA;F=E(&9O28C.#(Q-SMS(&-O;6UO;B!S=&]C:RP@870@ M82!C;VYV97)S:6]N(')A=&4@;V8@-C4E(&]F('1H92!A=F5R86=E(&]F('1H M92!T:')E92!L;W=E2!R96-O9VYI>F5D(&%N(&5M8F5D9&5D(&)E;F5F:6-I86P@ M8V]N=F5R3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE2!I6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@;6%R9VEN.B`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI M9VXZ(&IU'!E;G-E+CPO<#X\<"!S M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N M=#H@,3!P="!T:6UE2!A;6]R=&EZ960@)#,L.#,V('1O(&-U3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UEF5D M(&%N9"!W3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6%B;&4@9&5S8W)I8F5D(&%B;W9E M+CPO<#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ M(#!P>#L@9F]N=#H@,3!P="!T:6UE2P@ M86YD(&%R92!U;G-E8W5R960N(%1H92!C;VUP86YY(&ES(&YO="!O8FQI9V%T M960@=&\-"B!M86ME('!A>6UE;G0@=6YT:6P@0FQU94-R97-T(&QO86X@:7,@ M<&%I9"!O9F8N/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A#L@=&5X="UT6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O M.R`M=V5B:VET+71E>'0M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;BF4M861J=7-T.B!A=71O.R`M M=V5B:VET+71E>'0M#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J M=7-T:69Y.R!M87)G:6XZ(#!P>#LG/D1U2!I6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O.R`M=V5B:VET+71E M>'0M#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M M87)G:6XZ(#!P>#LG/D1U2!I6QE/3-$ M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B#L@=&5X="UTF4Z(#AP=#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[)SXF(S$V,#L\+W`^/'`@6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T M97(M#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O.R`M=V5B M:VET+71E>'0M3L@;6%R9VEN.B`P<'@[)SY$=7)I;F<@=&AE M('1H7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA"`P<'@[(&-O;&]R M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z M(#!P>#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E M>'0M"`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M'0M:6YD96YT.B`P<'@[(&QE='1E"`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;FF4M861J M=7-T.B!A=71O.R`M=V5B:VET+71E>'0M2!R969E2!T:&4@0F]A"`P<'@[(&-O M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET M+71E>'0M'0M:6YD96YT.B`P<'@[(&QE M='1E"`P<'@[(&-O;&]R M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z M(#!P>#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E M>'0M'0M:6YD96YT.B`P<'@[(&QE='1E M65A#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M#LG/B8C,38P.SPO M<#X\=&%B;&4@#L@=VED=&@Z(#$P,"4[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[ M('=O'0M#LG(&-E;&QS M<&%C:6YG/3-$,#X\='(@6QE/3-$)VUA6QE/3-$)VUA6QE M/3-$)VUA6QE/3-$)VUA65A6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@ M#LG/C(L,34X+#0T-R8C,38P.SPO<#X\+W1D/CQT9"!S='EL93TS1"=B;W)D M97(M=&]P+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M=&]P+7=I9'1H.B`R<'@[ M(&)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V)A8VMG6QE/3-$)VUA#LG/B@Q-3DL,C(V*3PO<#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y-CX\<"!A;&EG;CTS1&-E;G1E#LG/B0F(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LQ+C@P M/"]P/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DV/CQP/B8C M,38P.SPO<#X\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M=&]P M+6-O;&]R.B`C,#`P,#`P.R!B;W)D97(M=&]P+7=I9'1H.B`R<'@[(&)O6QE/3-$)VUA M6QE/3-$)V)O#L@8F]R9&5R+71O M<"US='EL93H@6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@#LG/B0F(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LQ+C(P M/"]P/CPO=&0^/'1D('-T>6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@ M#LG/C@N,3PO<#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0S-C`^/'`@6QE/3-$)V)A8VMG6QE/3-$)VUA6QE/3-$)V)O#L@8F]R9&5R+71O<"US M='EL93H@6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)VUA6QE/3-$ M)V)O#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@#LG/C6QE/3-$)VUA#LG/C`F M(S$V,#L\+W`^/"]T9#X\=&0@'0M:6YD96YT M.B`P<'@[(&QE='1E"`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M6QE/3-$)W=I9&]W'0M:6YD96YT.B`P<'@[('=I9'1H M.B`Q,S,S<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-EF4Z(#$P<'0[('=O'0M#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^ M/'1R/CQT9"!S='EL93TS1"=F;VYT.B`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`P("8C.#(Q,3L@)#`N-S`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`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`P<'@[(&QE='1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M M#LG/CQU/E=A"`P<'@[('1E>'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET M+71E>'0M'0M:6YD96YT.B`P<'@[(&QE='1E2!D M=7)I;F<@=&AE('EE87(@=&AE;B!E;F1E9"!I6QE/3-$)V9O;G0Z(#$R<'0O;F]R;6%L("=T:6UE#L@ M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN M9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M#LG/B8C,38P.SPO<#X\=&%B;&4@ M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@)W1I;65S(&YE=R!R;VUA;B&5R8VES93QB3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W9E3H@)W1I;65S(&YE M=R!R;VUA;B2`Q+"`R,#$Q M/"]T9#X\=&0@#L@9F]N="UF86UI;'DZ("=T:6UE'0[ M(&)O6QE.B!S M;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,S-P>#L@ M=&5X="UA;&EG;CH@'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B#L@9F]N="UF86UI;'DZ("=T:6UE'0[(&)O6QE M.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U,W!X M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B'0[(&)O6QE.B!S;VQI9#LG/C4N.#PO=&0^/'1D('-T M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E3H@)W1I;65S(&YE=R!R;VUA;B6QE M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@ M=&EM97,L('-E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B6QE/3-$ M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F3H@)W1I M;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA;B'0[(&)O6QE.B!S;VQI9#LG M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/C,N.#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@ M=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)RP@=&EM97,L('-E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F6QE/3-$)W9E'0[(&)O6QE.B!S;VQI9#LG/D]U='-T86YD:6YG(&%T($UA'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/C0Q+#DS,2PU,#4\+W1D/CQT9"!S='EL93TS M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B'0[(&)O6QE M.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B6QE M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q,CPO=&0^/'1D('-T M>6QE/3-$)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA M;B6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$R<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE M='1E6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE M='1E&5R8VES86)L92!A M="!-87)C:"`S,2P@,C`Q,CH\+W`^/'`@'0M86QI9VXZ(&IU#L@;&5T=&5R M+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M'0M86QI9VXZ(&IU#L@;&5T=&5R M+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=V]R9"US M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&]R<&AA;G,Z(#([ M('=I9&]WF4M861J=7-T.B!A=71O.R`M M=V5B:VET+71E>'0M6QE/3-$)W=I9&]W'0M:6YD96YT.B`P<'@[('=I9'1H.B`Q,S,S<'@[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[('=O M'0M#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`X<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$ M)W=I9'1H.B`X<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@ M=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W=I9'1H.B`X<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I M;65S(&YE=R!R;VUA;B#L@9F]N="UF86UI;'DZ("=T:6UE'0[(&)O6QE.B!S;VQI9#LG M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`R-G!X.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B'0[(&)O6QE.B!S;VQI9#LG M/C`N,#D\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.'!X.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W=I9'1H.B`X<'@[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE M=R!R;VUA;B'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W9E6QE/3-$)V9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@ M;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@ M=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W9E M6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B6QE/3-$ M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$ M)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B6QE/3-$)V9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B'0[(&)O6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)RP@=&EM97,L('-E'0[(&)O6QE.B!S;VQI9#LG/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N M)RP@=&EM97,L('-E6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M'0M#LG/D1U2!I2=S(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P M&5R8VES M8FQE(&EN('-I>"!M;VYT:',@86YD(&5X<&ER:6YG('1H3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W9F0T,30T-%\S,F0Y7S1F M-F5?861A,5\W83)A83DW9&0X8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-V9D-#$T-#1?,S)D.5\T9C9E7V%D83%?-V$R86$Y-V1D.&,W+U=O M'0O:'1M M;#L@8VAA2!4'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'`@6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!L971T97(M#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O M.R`M=V5B:VET+71E>'0M3L@;6%R9VEN.B`P<'@[)SX\8CY. M3U1%(#$P("8C.#(Q,3L@4D5,051%1"!005)462!44D%.4T%#5$E/3E,\+V(^ M/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X M="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU#LG/B8C,38P.R8C,38P.R8C,38P M.SPO<#X\<"!S='EL93TS1"=C;VQO#L@9F]N="US M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#LG M/E1H92!#;VUP86YY)B,X,C$W.W,@9F]R;65R($-H86ER;6%N(&]F('1H92!" M;V%R9"P@0VAI968@17AE8W5T:79E($]F9FEC97(@86YD($-H:65F(%1E8VAN M;VQO9WD@3V9F:6-E2!G=6%R86YT965D('1H92!# M;VUP86YY)B,X,C$W.W,@;V)L:6=A=&EO;G,@=6YD97(@:71S(&QE87-E(&9O M2X\ M+W`^/'`@6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!L971T97(M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#([('=O'0M#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO#L@=&5X="UT#L@=&5X="UT MF4Z(#$P<'0[(&UA6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B#L@=&5X="UT2!A;F0@8F]N=7,@9F]R('1H92!T:')E92!M;VYT:',@96YD M960@36%R8V@@,S$L(#(P,3(L(&EN(#(P,3$L(#(P,3`L(#(P,#DL(#(P,#@L M(#(P,#<@86YD(&9O#L@=&5X="UTF4Z(#$P<'0[(&UA6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU2!A;F0@86QL(')E<75I2!P87EM M96YT6UE M;G1S('=I;&P@8F4@9'5E(&]N(&$@;6]N=&AL>2!B87-I6UE;G1S+B!4 M:&4-"B!#;VUP86YY('5N9&5R2P@:6YC;'5D:6YG($1R+B!7 M:6QL:6%M(%`N($UU2!*7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M'0M:6YD96YT.B`P<'@[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z M(#([('=O'0M#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XZ(#!P>#LG/CQB/DY/5$4@,3$@)B,X,C$Q M.R!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO8CX\+W`^/'`@6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T M97(M'0M:6YD96YT M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(#([('=O'0M#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XZ(#!P>#LG/B8C,38P M.SPO<#X\<"!S='EL93TS1"=C;VQO#L@=&5X="UTF4Z(#$P<'0[(&UA2!087EM96YT6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!L971T97(M'0M M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C M93H@;F]R;6%L.R!W:61O=W,Z(#([('=O'0M#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XZ(#!P>#LG M/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO#L@=&5X="UT#L@=&5X="UT MF4Z(#$P<'0[(&UA6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B#L@+7=E8FMI="UT97AT M+7-I>F4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M2!H87,@96YT97)E9"!I;G1O('9A2!P87EM96YT6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M'0M:6YD96YT.B`P<'@[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z M(#([('=O'0M#L@9F]N M="US:7IE.B`Q,G!T.R!M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL M93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T.R!T M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#LG/CQI/E=I;&QI86T@ M0F5A=6UO;G0@2&]S<&ET86P\+VD^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU M6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI M9VXZ(&IU2!E;G1E2!T:')E M6%L='D@=&AR97-H;VQD('=A2P@=VAI8V@@:7,@2!I;F-U M'!E;G-E2!H87,@86-C#L@9F]N="US:7IE.B`Q,'!T.R!T M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X\ M<"!S='EL93TS1"=C;VQOF4Z M(#$P<'0[('1E>'0M86QI9VXZ(&IU#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`R+C-P=#L@;6%R9VEN M+7)I9VAT.B`P<'@[(&UA#L@;6%R9VEN+6QE9G0Z M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X\<"!S='EL M93TS1"=C;VQO#L@9F]N="US:7IE.B`Q,'!T.R!M M87)G:6XM=&]P.B`R+C-P=#L@;6%R9VEN+7)I9VAT.B`P<'@[(&UA#L@;6%R9VEN+6QE9G0Z(#!P>#L@=&5X="UA;&EG;CH@:G5S M=&EF>3LG/EEE87(@16YD:6YG($1E8V5M8F5R(#,Q+#PO<#X\=&%B;&4@#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1EF4Z(#$P<'0[('=O6QE/3-$)W=I9'1H.B`S.'!X.R!P861D:6YG.B`P+C6QE/3-$)W=I9'1H.B`R-'!X.R!P M861D:6YG.B`P+C6QE/3-$ M)W9E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W9E M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P M<'0[('1E>'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU28C.#(Q-SMS(&-O;6UO;B!S=&]C:SPO=3X\+W`^/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@ M+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M M3L@;6%R9VEN.B`P<'@[)SXF(S$V,#L\+W`^/'`@6QE.B!N;W)M86P[(&9O;G0M M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M M#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O.R`M=V5B:VET M+71E>'0M&5R8VES960@;W!T:6]N&EM871E;'D@ M)#,W,2PP,#`N($AO=V5V97(L(&%S('1H92!#;VUP86YY(&)E;&EE=F5S('1H M97)E(&ES(&]N;'D@82!R96UO=&4@;&EK96QI:&]O9"!T:&4@2!O9B!T:&5S92!P97)S M;VYS(&EN(&%N(&%M;W5N="!T:&%T('=O=6QD(')E#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G M:6XZ(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M#L@=VAI=&4M'0M#LG/CQU/DQI=&EG871I;VX\+W4^/"]P/CQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P M<'@[(&QE='1E6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&IU#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!A=71O.R`M=V5B:VET+71E M>'0M2!I2X@2&]W979E'!O7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;BF4M861J=7-T.B!A=71O.R`M M=V5B:VET+71E>'0M6QE/3-$ M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA M;B#L@+7=E8FMI="UT97AT+7-I M>F4M861J=7-T.B!A=71O.R`M=V5B:VET+71E>'0M6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!L971T97(M#L@+7=E8FMI="UT97AT+7-I>F4M861J=7-T.B!A=71O M.R`M=V5B:VET+71E>'0M3L@;6%R9VEN.B`P<'@[)SY);B!! M<')I;"P@,C`Q,BP@=V4@:7-S=65D(&%N(&%G9W)E9V%T92!O9B`S+#`U-2PX M,C@@#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J M=7-T:69Y.R!M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C M;VQO#LG/E!U2!%<75I='D@1&ES M=')I8G5T:6]N($%G2!%<75I='D@1&ES=')I M8G5T:6]N($%G7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC M&UL/@T*+2TM+2TM/5].97AT4&%R=%\W9F0T,30T-%\S,F0Y ;7S1F-F5?861A,5\W83)A83DW9&0X8S XML 14 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

RESTATEMENT
3 Months Ended

Mar. 31, 2012

Quarterly Financial Information Disclosure [Abstract]

RESTATEMENT
NOTE 2 – RESTATEMENT
The accompanying unaudited condensed consolidated Statement of Operations for the three months ended March 31, 2011 have been restated to correct the errors in the accounting of the Company's issuances of notes payable during the three months ended March 31, 2011. These changes correct the treatment recording of issued notes payable in exchange for payment of debt obligations.
Unaudited Condensed Consolidated Statement of Operations
For the Three Months Ended March 31, 2011

As previously reported

Adjustment

Reference

As restated

Revenue

$ -

$ -

$ -
Cost of sales

-

-

-
Gross profit

-

-

Operating expenses:

Research and development

170,111

-

170,111
Marketing, general and administrative

490,508

-

490,508
Depreciation and amortization

8,705

-

8,705
Total operating expenses

669,324

-

669,324

Net loss from operations

(669,324
)
-

(669,324)

Other income (expenses):

Other income

3,389

-

3,389
Loss on settlement of debt

(110,872
)
110,872

(1)

-
Interest expense

(409,720
)
-

(409,720)
Total other income (expenses)

(517,203
)
110,872

(406,331)

Net loss before income taxes

(1,186,527
)
110,872

(1,075,655)

Income taxes (benefit)

-

-

-

NET LOSS

$ (1,186,527
)
$ 110,872

$ (1,075,655)
(1) reverse recording of loss on assignment of debt

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: bhrt_RestatementTextBlock

Namespace Prefix: bhrt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS (USD $)

Mar. 31, 2012

Dec. 31, 2011

Current assets:

Cash $ 69,945 $ 36,828

Accounts receivable, net 3,495

Inventory 63,286 63,702

Prepaid and other 88,427 49,828

Total current assets 221,658 153,853

Property and equipment, net 11,151 15,476

Other assets 99,164 99,164

Total assets 331,973 268,493

Current liabilities:

Accounts payable 2,631,964 2,377,807

Accrued expenses 4,170,146 3,882,115

Advances, related party 456,000 456,000

Deposits 465,286 465,286

Subordinated debt, related party 1,500,000 1,500,000

Notes payable, related party 365,000 365,000

Notes payable, net of debt discount 2,946,837 3,232,762

Total current liabilities 12,535,233 12,278,970

Stockholders' deficit:

Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding as of March 31, 2012 and December 31, 2011

Common stock, par value $0.001; 195,000,000 shares authorized, 132,919,498 and 95,625,236 shares issued and outstanding as of March 31, 2012 and December 31, 2011, respectively 132,920 95,625

Additional paid in capital 99,631,969 98,915,155

Deficit accumulated during development stage (111,968,149) (111,021,257)

Total stockholders' deficit (12,203,260) (12,010,477)

Total liabilities and stockholders' deficit $ 331,973 $ 268,493

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable Net Of Debt Discount due within one year or the operating cycle if longer.

+ References

No definition available.

+ Details

Name: bhrt_NotesPayableNetOfDebtDiscount

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The portion of the carrying value of subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle, if longer. Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets to related party.

+ References

No definition available.

+ Details

Name: bhrt_SubordinatedDebtRelatedParty

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended 152 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2012

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (946,892) $ (1,075,655) $ (111,968,149)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 4,325 8,705 887,650

Bad debt expense 1,266 166,266

Discount on convertible debt 248,776 136,288 1,391,763

Gain on change in fair value of derivative liability 25,026

Non cash payment of interest 21,169 199,070

Amortization of warrants issued in exchange for licenses and intellectual property 5,413,156

Amortization of warrants issued in connection with notes payable 50,761 92,158 5,393,074

Amortization of loan costs 927 3,054 1,228,717

Warrants issued in exchange for services 285,659

Equity instruments issued in connection with R&D agreement 360,032

Equity instruments issued in connection with settlement agreement 3,381,629

Common stock issued in connection with accounts payable 756,816

Common stock issued in exchange for services 10,000 1,457,922

Common stock issued in connection with amounts due to guarantors of Bank of America loan 69,159

Common stock issued in exchange for distribution rights and intellectual property 99,997

Warrants issued in connection with accounts payable 7,758

Stock based compensation 19,051 105,347 9,893,379

(Increase) decrease in:

Receivables 3,495 (1,265)

Inventory 416 (63,287)

Prepaid and other current assets (38,599) (50,761) (98,396)

Other assets (28,854)

Increase (decrease) in:

Accounts payable 254,157 363,511 3,189,572

Accrued expenses 288,031 109,531 5,534,834

Deferred revenue 465,287

Net cash used in operating activities (84,383) (306,556) (71,953,185)

CASH FLOWS FROM INVESTING ACTIVITIES:

Acquisitions of property and equipment (898,800)

Net cash used by investing activities (898,800)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock, net 117,500 518,300 63,414,475

Proceeds from (payments for) initial public offering of common stock, net 1,447,829

Proceeds from subordinated related party note 3,000,000

Payment of note payable (3,000,000)

Proceeds from notes payable, related party 505,000

Proceeds from related party advances 140,000 456,000

Proceeds from exercise of stock options 293,749

Proceeds from notes payable 25,000 11,557,750

Repayments of notes payable (210,042) (3,533,605)

Payment of loan costs (1,219,268)

Net cash provided in financing activities 117,500 473,258 72,921,930

Net increase in cash and cash equivalents 33,117 166,702 69,945

Cash and cash equivalents, beginning of period 36,828 3,298

Cash and cash equivalents, end of period 69,945 170,000 69,945

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Interest paid 128,696 67,635 1,909,160

Income taxes paid

Non cash financing activities:

Common stock issued in settlement of notes payable $ 387,033 $ 139,729 $ 3,919,778

X

- Definition

The aggregate expense recognized in the current period that Amortization Of Warrants Issued In Connection With Notes Payable.

+ References

No definition available.

+ Details

Name: bhrt_AmortizationOfWarrantsIssuedInConnectionWithNotesPayable

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that Amortization Of Warrants Issued In Exchange For Licenses And Intellectual Property.

+ References

No definition available.

+ Details

Name: bhrt_AmortizationOfWarrantsIssuedInExchangeForLicensesAndIntellectualProperty

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that Common Stock Issued In Connection With Accounts Payable and accrued interest.

+ References

No definition available.

+ Details

Name: bhrt_CommonStockIssuedInConnectionWithAccountsPayableAndAccruedInterest

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period thatCommon Stock Issued In Connection With Amounts Due To Guarantors Of Bank of America loan.

+ References

No definition available.

+ Details

Name: bhrt_CommonStockIssuedInConnectionWithAmountsDueToGuarantorsOfBankOfAmericaLoan

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that Common Stock Issued In Exchange For Distribution Rights And Intellectual Property.

+ References

No definition available.

+ Details

Name: bhrt_CommonStockIssuedInExchangeForDistributionRightsAndIntellectualProperty

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that Common Stock Issued In Exchange For Services.

+ References

No definition available.

+ Details

Name: bhrt_CommonStockIssuedInExchangeForServices

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the Common Stock Issued In Settlement Of Notes Payable.

+ References

No definition available.

+ Details

Name: bhrt_CommonStockIssuedInSettlementOfNotesPayable

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that Equity Instruments Issued In Connection With R&D Agreement.

+ References

No definition available.

+ Details

Name: bhrt_EquityInstrumentsIssuedInConnectionWithRdAgreement

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that Equity Instruments Issued In Connection With Settlement Agreement.

+ References

No definition available.

+ Details

Name: bhrt_EquityInstrumentsIssuedInConnectionWithSettlementAgreement

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

No definition available.

+ Details

Name: bhrt_PaymentOfNotePayable

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the Notes Payable to Related Party.

+ References

No definition available.

+ Details

Name: bhrt_ProceedsFromNotesPayableRelatedParty

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the Related Party Advances.

+ References

No definition available.

+ Details

Name: bhrt_ProceedsFromRelatedPartyAdvances

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period thatWarrants Issued In Connection With Accounts Payable.

+ References

No definition available.

+ Details

Name: bhrt_WarrantsIssuedInConnectionWithAccountsPayable

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 21

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of net cash from (used in) the entity's financing activities, excluding cash flows derived by the entity from its discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of net cash from (used in) the entity's investing activities, excluding cash flows derived by the entity from its discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-Footnote 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of net cash from (used in) the entity's continuing operations, excluding cash flows derived by the entity from its discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-Footnote 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for loan origination associated cost which is usually collected through escrow.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfLoanCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow resulting from the entity's share transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromRepurchaseOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 18 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended

Mar. 31, 2012

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES
NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

The accompanying unaudited condensed consolidated financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated December 31, 2011 financial statements and footnotes thereto included in the Company’s SEC Form 10-K.

Basis and business presentation

Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2012, the Company has accumulated a deficit through its development stage of $111,968,149.

The unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. The most significant estimates are those used in the analysis of potential derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.

The Company accounts for Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.

Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.

Cash

The Company considers cash to consist of cash on hand.

Accounts Receivable

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

Allowance for Doubtful Accounts

Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of March 31, 2012 and December 31, 2011, allowance for doubtful accounts was $8,751.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.

Long-Lived Assets

The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

Income Taxes

The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of differences in carrying value of certain debt liability and stock compensation accounting versus tax basis.

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Net Loss per Common Share, basic and diluted

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 124,077,413 and 40,950,819 for the three months ended March 31, 2012 and 2011, respectively.

Stock based compensation

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non employees be recognized in the income statement based on their fair values. (See note 10)

As of March 31, 2012, there were outstanding stock options to purchase 4,636,318 shares of common stock, 2,944,178 shares of which were vested.

Concentrations of Credit Risk

The Company’s financial instrument that is exposed to a concentration of credit risk is cash and accounts receivable. Effective December 31, 2010 and extending through December 31, 2012, all non-interest-bearing transaction accounts are fully insured by the Federal Deposit Insurance Corporation (FDIC), regardless of the balance of the account. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

There were no accounts receivables as of March 31, 2012, as of December 31, 2011, three customers represented 98% of the Company’s accounts receivable.

For the three month period ended March 31, 2012, the Company's revenues earned from the sale of products and services were $40,485, from two customers. For the three month period ended March 31, 2011, the Company did not generate revenues.

Reliance on Key Personnel and Consultants

The Company has 7 full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $96,729 and $170,111 for the three months ended March 31, 2012 and 2011, respectively and $64,387,840 from August 12, 1999 (date of inception) to March 31, 2012.

Fair Value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Reclassification

Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.

+ References

No definition available.

+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)

Mar. 31, 2012

Dec. 31, 2011

Statement Of Financial Position [Abstract]

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 5,000,000 5,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 195,000,000 195,000,000

Common stock, shares issued 132,919,498 95,625,236

Common stock, shares outstanding 132,919,498 95,625,236

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

COMMITMENTS AND CONTINGENCIES
3 Months Ended

Mar. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES
NOTE 11 – COMMITMENTS AND CONTINGENCIES

Royalty Payments

The Company is obligated to pay royalties on commercial sales of certain products that may be developed and sold under various licenses and agreements that have been obtained by the Company.

The Company has entered into various licensing agreements, which include the potential for royalty payments, as follows:

William Beaumont Hospital

In June 2000, the Company entered into an exclusive license agreement to use certain patents for the life of the patents in future projects. The patents expire in 2015. In addition to a payment of $55,000 the Company made to acquire the license, the Company is required to pay an annual license fee of $10,000 and royalties ranging from 2% to 4% of net sales of products that are covered by the patents. In order to maintain the exclusive license rights, the agreement also calls for a minimum annual royalty threshold. The minimum royalty threshold was $200,000 for 2011 and $200,000 for 2010. This minimum royalty threshold will remain $210,000 for 2012 and thereafter. As of March 31, 2012, the Company has not made any payments other than the initial payment to acquire the license. At March 31, 2012 and December 31, 2011, the Company’s liability under this agreement was $1,601,420 and $1,540,204, respectively, which is reflected as a component of accrued expenses on the consolidated balance sheets (see Note 6). During the three months ended March 31, 2012 and 2011, the Company incurred expenses of $52,500, $52,500, and $1,610,420 from August 12, 1999 (date of inception) to March 31, 2012. The Company has accrued interest for the past due commitment at 2% over the prime rate per the terms of the agreement. The Company has included $257,920 in accrued expenses as of March 31, 2012.

Approximate annual future minimum obligations under this agreement as of March 31, 2012 are as follows:

Year Ending December 31,

2012 $ 157,500
2013 210,000
2014 210,000
2015 210,000
Total $ 787,500

Contingency for Registration of the Company’s common stock

The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2012 or December 31, 2011.

Litigation

The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2012, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, consolidated results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
3 Months Ended

Mar. 31, 2012

May 02, 2012

Document and Entity Information [Abstract]

Entity Registrant Name BIOHEART, INC.

Entity Central Index Key 0001388319

Trading Symbol bhrt

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 136,975,326

Document Type 10-Q

Document Period End Date Mar. 31, 2012

Amendment Flag false

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q1

X

- Details

Name: bhrt_DocumentAndEntityInformationAbstract

Namespace Prefix: bhrt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 22 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

SUBSEQUENT EVENTS
3 Months Ended

Mar. 31, 2012

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
NOTE 12 – SUBSEQUENT EVENTS

In April, 2012, we issued an aggregate of 3,055,828 shares of our common stock valued at$36,400, in settlement of a Convertible Promissory Note of $35,000, and balance of $1,400 charged to interest expense.

Pursuant to the terms and conditions of the Standby Equity Distribution Agreement with Greystone Capital Partners dated November 2, 2011, The Company drew down the sum of $25,000 and issued 1,000,000 shares of our common stock, registered on a Form S-1, declared effective February 10, 2012, to Greystone Capital Partners. The shares were valued at a price of $.025 per share (such price determined based on the terms and conditions of the Standby Equity Distribution Agreement).

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 152 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2012

Income Statement [Abstract]

Revenue $ 40,485 $ 1,249,016

Cost of sales 417 551,251

Gross profit 40,068 697,765

Operating expenses:

Research and development 96,729 170,111 64,387,840

Marketing, general and administrative 468,099 490,508 35,127,583

Impairment of investment 58,695

Depreciation and amortization 4,325 8,705 887,650

Total operating expenses 569,153 669,324 100,461,768

Net loss from operations (529,085) (669,324) (99,764,003)

Other income (expenses):

Development revenues 117,500

Loss on change of fair value of derivative liability (25,026)

Interest income 762,277

Other income 11,353 3,389 264,184

Interest expense (429,160) (409,720) (13,323,081)

Total other income (expenses) (417,807) (406,331) (12,204,146)

Net loss before income taxes (946,892) (1,075,655) (111,968,149)

Income taxes (benefit)

NET LOSS $ (946,892) $ (1,075,655) $ (111,968,149)

Net loss per common share, basic and diluted (in dollars per share) $ (0.01) $ (0.03)

Weighted average number of common shares outstanding, basic and diluted (in shares) 114,974,051 40,517,481

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income recognized during the period from participation in unconsolidated joint ventures engaged in real estate development (such as the building upon or otherwise improving property).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_DevelopmentProfitsNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Audit and Accounting Guide (AAG)

-Number AAG-BRD

-Paragraph 80

-Subparagraph Exhibit 4-4

-IssueDate 2006-05-01

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Paragraph 5A

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

ACCRUED EXPENSES
3 Months Ended

Mar. 31, 2012

Payables and Accruals [Abstract]

ACCRUED EXPENSES
NOTE 6 – ACCRUED EXPENSES
Accrued expenses consisted of the following as of March 31, 2012 and December 31, 2011:

March 31,
2012

December 31,
2011
License and royalty fees $ 1,610,420 $ 1,540,204
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest 1,183,086 1,164,306
Interest payable on notes payable 806,671 732,556
Vendor accruals and other 115,132 115,312
Employee commissions, compensation, etc 313,562 329,737
Other 141,275 -
$ 4,170,146 $ 3,882,115

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

PROPERTY AND EQUIPMENT
3 Months Ended

Mar. 31, 2012

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT
NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2012 and December 31, 2011 is summarized as follows:

March 31,
2012

December 31,
2011
Laboratory and medical equipment $ 352,358 $ 352,358
Furniture, fixtures and equipment 130,916 130,916
Computer equipment 53,481 53,481
Leasehold improvements 362,046 362,046
898,801 898,801
Less accumulated depreciation and amortization (887,650 ) (883,325 )
$ 11,151 $ 15,476

Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.

Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

STOCK OPTIONS AND WARRANTS
3 Months Ended

Mar. 31, 2012

Stock Option and Warrants Disclosure [Abstract]

STOCK OPTIONS AND WARRANTS
NOTE 9 – STOCK OPTIONS AND WARRANTS

Stock Options

In December 1999, our Board of Directors and shareholders adopted our 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.

As of March 31, 2012, the Company does not have a stock option plan.

A summary of options at March 31, 2012 and activity during the year then ended is presented below:

Shares
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual
Term (in years)
Options outstanding at January 1, 2011
2,158,447
$ 2.79
6.8
Granted
4,620,092
$ 0.057

Exercised
(1,982,995)
$ 0.001

Forfeited/Expired
(159,226)
$ 1.80

Options outstanding at December 31, 2011
4,636,318
$ 1.20
8.1
Granted
-

Exercised

Forfeited/Expired
-

Options outstanding at March 31, 2012
4,636,318
$ 1.20
7.9
Options exercisable at March 31, 2012
2,944,178
$ 1.75
7.4
Available for grant at March 31, 2012
0

The following information applies to options outstanding and exercisable at March 31, 2012:

Options Outstanding Options Exercisable
Shares Weighted-
Average
Remaining
Contractual
Term Weighted-
Average
Exercise
Price Shares Weighted-
Average
Exercise
Price
$0.00 – $0.70 3,494,360 9.1 $ 0.19 1,846,161 $ 0.18
$0.71 – $1.28 324,780 6.1 $ 0.77 315,712 $ 0.76
$5.25 – $5.67 770,810 3.2 $ 5.58 759,185 $ 5.58
$7.69 39,572 4.4 $ 7.69 39,572 $ 7.69
$8.47 6,796 5.0 $ 8.47 6,796 $ 8.47
4,636,318 7.5 $ 1.20 2,967,426 $ 1.75

The fair value of all options vesting during the year ended December 31, 2011 and 2010 of $409,314 and $248,457, respectively, was charged to current period operations.

Warrants

A summary of warrants at March 31, 2012 and activity during the year then ended is presented below:

Shares Weighted-
Average
Exercise
Price Weighted-
Average
Remaining
Contractual
Term (in
years)
Outstanding at January 1, 2011 13,920,729 $ 1.98 5.8
 Issued 20,817,034 $ 0.07
 Exercised — $ 0.00
 Forfeited (2,127,688 ) $ 0.69
Outstanding at December 31, 2011 32,610,075 $ 0.86 3.8
 Issued 9,321,430 $ 0.018 2.9
 Exercised — $
 Forfeited - $
Outstanding at March 31, 2012 41,931,505 $ 0.67 3.6
Exercisable at March 31, 2012 20,660,810 $ 0.76 3.5

The following information applies to warrants outstanding and exercisable at March 31, 2012:

Warrants Outstanding Warrants Exercisable
Shares Weighted-
Average
Remaining
Contractual
Term Weighted-
Average
Exercise
Price Shares Weighted-
Average
Exercise
Price
0.01 – $0.50 32,548,150 2.6 $ 0.09 12,821,905 0.13
0.52 – $0.68 3,800,078 5.3 $ 0.59 3,800,078 $ 0.59
0.70 – $1.62 2,626,285 3.1 $ 0.79 2,626,285 $ 0.79
1.81 – $2.61 33,710 0.5 $ 1.90 33,710 $ 1.90
3.60 – $4.93 105,000 1.4 $ 4.87 105,000 $ 4.87
5.67 – $7.69 2,818,282 10.2 $ 7.50 1,273,832 $ 7.26
41,931,505 3.6 $ 0.86 20,660,810 $ 0.76

During the three months ended March 31, 2012, in connection with the sale of common stock, the Company issued an aggregate of 9,321,430 warrants to purchase the Company's common stock at an exercise prices from $0.014 to $0.03 per shares exercisble in six months and expiring three years from issuance.

X

- Details

Name: bhrt_StockOptionAndWarrantsDisclosureAbstract

Namespace Prefix: bhrt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for Stock Option And Warrants.

+ References

No definition available.

+ Details

Name: bhrt_StockOptionAndWarrantsTextBlock

Namespace Prefix: bhrt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

NOTES PAYABLE
3 Months Ended

Mar. 31, 2012

Notes Payable [Abstract]

NOTES PAYABLE
NOTE 7 – NOTES PAYABLE

Notes payable were comprised of the following as of March 31, 2012 and December 31, 2011:

March 31, 2012 December 31, 2011
Seaside Bank note payable. Terms described below $ 980,000 $ 980,000
BlueCrest Capital Finance note payable. Monthly payments of principal and interest as described below, net of unamortized debt discount of $44,530 and $96,218 respectively 499,737 711,609
Short-term note payable 1,384,972 1,384,972
Short-term note payable, net of unamortized debt discount of $7,555 and $11,391, respectively. Terms described below 27,445 23,609
Short-term note payable, net of unamortized debt discount of $4,721. Terms described below - 7,854
Short-term note payable, net of unamortized debt discount of $60,663. Terms described below - 79,066
Short-term note payable, net of unamortized debt discount of $8,552. Terms described below - 45,652
Short term note payable, net of unamortized debt discount of $85,046. Terms described below 54,683 -
2,946,837 3,232,762
Less current portion (2,946,837 ) (3,232,762 )
Notes payable – long term $ — $ -

Seaside Bank

On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was be used to refinance the Company’s loan with a previous Bank of America loan. The obligation was guaranteed by shareholders of the Company.

In connection with the Loan Agreement with Seaside Bank and Trust Company, the Company made and delivered a promissory note in the principal amount of the loan that matures in two years.. In connection with the loan transaction with Seaside Bank and Trust Company, the Company entered into an Amended and Restated Loan and Security Agreement with BlueCrest Venture Finance Master Fund Limited.

BlueCrest Capital Finance Note Payable

On June 1, 2007, the Company closed on a $5.0 million senior loan from BlueCrest Capital Finance, L.P. with a term of 36 months which bears interest at an annual rate of 12.85% (the “BlueCrest Loan”). The first three months required payment of interest only with equal principal and interest payments over the remaining 33 months. As consideration for the loan, the Company issued to BlueCrest Capital Finance, L.P. a warrant to purchase 65,030 shares of common stock at an exercise price of $7.69 per share. The warrant, which became exercisable one year following the date the warrant was issued, has a ten year term. This warrant had a fair value of $455,483, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan. The Company also paid the lender a fee of $100,000 to cover diligence and other costs and expenses incurred in connection with the loan. On August 31, 2007, BlueCrest Capital Finance, L.P. assigned its rights, liabilities, duties and obligations under the BlueCrest Loan and warrant to BlueCrest Venture Finance Master Fund Limited (“BlueCrest”).

The loan may be prepaid in whole but not in part. As collateral to secure its repayment obligations under the loan, the Company granted BlueCrest a first priority security interest in all of the Company’s assets, excluding intellectual property but including the proceeds from any sale of any of the Company’s intellectual property. The loan has certain restrictive terms and covenants including among others, restrictions on the Company’s ability to incur additional senior or pari-passu indebtedness or make interest or principal payments on other subordinate loans.

In the event of an uncured event of default under the loan, all amounts owed to BlueCrest are immediately due and payable and BlueCrest has the right to enforce its security interest in the assets securing the loan. During the continuance of an event of default, all outstanding amounts under the loan will bear interest (payable on demand) at an annual rate of the 14.85%. In addition, any unpaid amounts are subject, until paid, to a service charge in an amount equal to two percent (2%) of the unpaid amount. Events of default include, among others, the Company’s failure to timely make payments of principal when due, the Company’s uncured failure to timely pay any other amounts owing to BlueCrest under the loan, the Company’s material breach of the representations and warranties contained in the loan agreement and the Company’s default in the payment of any debt to any of its other lenders in excess of $100,000 or any other default or breach under any agreement relating to such debt, which gives the holders of such debt the right to accelerate the debt.

On January 2, 2009, the Company failed to make the monthly payment of principal and interest of approximately $181,000 due on such date. On January 28, 2009, the Company received from BlueCrest notice of this event of default (the “Default Notice”) under the BlueCrest Loan. By reason of the stated event, BlueCrest demanded payment of a 2% late fee of approximately $3,600, together with the principal and interest payment of approximately $181,000. On February 2, 2009, the Company received from BlueCrest notice of acceleration of the outstanding principal amount of the BlueCrest Loan and demanded repayment in full of all outstanding principal and accrued interest on the loan, including late fees, in the aggregate amount of $2,947,045. (The acceleration notice, together with the Default Notice, are referred to as the “Notices”).

The Company and BlueCrest entered into an amendment to the BlueCrest Loan as of April 2, 2009 (the “ BlueCrest Loan Amendment”), that, among other things, includes BlueCrest’s agreement to forbear from exercising any of its rights or remedies regarding the defaults described in Notices (the “Forbearance”) as long as there are no new defaults under the BlueCrest Loan, as amended.

The BlueCrest Loan Amendment, (a) increases the amount of permitted unsecured indebtedness of the Company, (b) amended the amortization schedule for the Loan to provide for interest-only payments until July 1, 2009, at which time monthly principal and interest payments of $262,692 will commence, and (c) prohibits the Company from granting any lien against its intellectual property and grants to BlueCrest a lien against the Company’s intellectual property that will become effective in the event of a default. In addition, the Company issued BlueCrest a warrant to purchase 1,315,542 shares of the Company’s common stock at $0.53 per share. The fair value of the issued warrants of $539,676 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan. In connection with the BlueCrest Loan Amendment the Company paid BlueCrest accrued interest in the aggregate amount of $126,077. The Company also paid BlueCrest a fee of $15,000. Effective July 1, 2009, the Company and BlueCrest agreed to enter into an amendment to the BlueCrest Loan to amend the amortization schedule for the Loan to provide for interest-only payments until January 1, 2010, at which time monthly principal and interest payments of $139,728 were to commence. In connection with that Amendment the Company issued BlueCrest a warrant to purchase $600,000 of the Company’s common shares and paid a fee of $29,435. The fair value of the issued warrants of $575,529 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan.

Effective December 31, 2009, the Company and BlueCrest entered into an amendment to the BlueCrest Loan to amend the amortization schedule for the Loan to provide for interest-only payments until July 1, 2010, at which time monthly principal and interest payments of $139,728.82 were to commence. In connection with that Amendment, the Company issued BlueCrest a warrant to purchase $600,000 of the Company’s common shares and paid a fee of $20,000. The Company also provided BlueCrest with a lien on its Intellectual Property. The fair value of the issued warrants of $507,606 was determined using the Black Scholes Option Pricing Model and was recorded as a debt discount and amortized ratably over the term of the loan.

The outstanding principal amount of the Loan as of December 31, 2010 was $2,276,543.03. On January 7, 2011, BlueCrest agreed with the Company and Magna Group, LLC (“Magna”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The Company exchanged the BlueCrest note for a convertible note with Magna in consideration for a payment by Magna to BlueCrest of $139,729.82. Additionally, Magna purchased a $25,000 convertible note from the Company (the “Convertible Note”). On July 18, 2011, the Company issued 625,000 shares of its common stock in settlement of the convertible note and related accrued interest.

The loans evidenced by the New Magna Convertible Note are in the nature of convertible debt evidenced by two unsecured convertible promissory notes, each bearing interest at the rate of 8% per annum, payable at maturity and each convertible into common stock of the Company at a price that is 50% less than the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.

• In January 2011, the Company issued an aggregate of 538,542 shares of our common stock in connection with the conversion of $87,729 of the convertible note.

• In February 2011, the Company issued an aggregate of 421,392 shares of our common stock in connection with the conversion of the remaining balance of $52,000 of the convertible note.

On May 16, 2011, BlueCrest agreed with the Company and Magna Group, LLC (“Magna”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Magna in consideration for a payment by them to BlueCrest of $139,729.82, and thereafter exchanged for a new Convertible Note. Additionally, Magna purchased a $34,750 convertible note from the Company (the “Convertible Note”).

The loans evidenced by the New Note and Convertible Note are in the nature of convertible debt evidenced by two unsecured convertible promissory notes, each bearing interest at the rate of 8% per annum, payable at maturity and each convertible into common stock of the Company at a price that is 45% less than the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.

• In June 2011, the Company issued an aggregate of 338,834 shares of our common stock in connection with the conversion of $29,729 of the convertible note.

• In July 2011, the Company issued an aggregate of 2,304,615 shares of our common stock in connection with the conversion of $110,000 of the convertible note.

On June 15, 2011, BlueCrest agreed with the Company and Lotus Funding Group, LLC (“Lotus”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,729.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Lotus in consideration for a payment by them to BlueCrest of $139,729.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.

• In June 2011, the Company issued an aggregate of 836,775 shares of our common stock in connection with the conversion of $40,000 of the convertible note.

• In July 2011, the Company issued an aggregate of 2,594,458 shares of our common stock in connection with the conversion of $99,729 of the convertible note.

On July 8, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $140,380.21, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $140,380.21, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.
• In July 2011, the Company issued an aggregate of 3,829,001 shares of our common stock in connection with the conversion of the $140,380.21 convertible note.

On August 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 50% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.

• In August 2011, the Company issued an aggregate of 3,358,866 shares of our common stock in connection with the conversion of the $139,728.82 convertible note.

On September 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the five (5) days prior to the Lenders’ election to exercise its conversion right.

• In September 2011, the Company issued an aggregate of 5,769,150 shares of our common stock in connection with the conversion of the $139,728.82 convertible note.

On October 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

• In October 2011, we issued an aggregate of 4,997,487 shares of our common stock in connection with the conversion of the $115,144 convertible note.
• In November 2011, we issued an aggregate of 500,000 shares of our common stock in connection with the conversion of $12,010 convertible note.
• In January 2012, we issued an aggregate of 937,242 shares of our common stock in connection with the conversion of $12,575 convertible note.

On November 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

• In January 2012, we issued an aggregate of 3,404,363 shares of our common stock in connection with the conversion of the $44,999 convertible note.
• In February 2012, we issued an aggregate of 6,756,803 shares of our common stock in connection with the conversion of $94,730 convertible note.

On December 1, 2011, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

• In February 2012, we issued an aggregate of 2,695,853 shares of our common stock in connection with the conversion of the $39,001 convertible note.
• In March 2012, we issued an aggregate of 7,142,857 shares of our common stock in connection with the conversion of $100,728 convertible note.

On January 3, 2012, BlueCrest agreed with the Company and Greystone Capital (“Greystone”) to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $139,728.82, the amount of the monthly payment due on the BlueCrest loan (the “New Note”). The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $139,728.82, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right.

On February 6, 2012, BlueCrest agreed with the Company and Greg Knutson to again split the note evidencing the Loan into two notes aggregating the outstanding principal balance, with the new note being in the principal amount of $95,000.00, the amount of the monthly payment due on the BlueCrest loan (the “New Note”) after combined with payment of $50,000 by a common stock subscription. The New Note was assigned to Greystone in consideration for a payment by them to BlueCrest of $95,000.00, and thereafter exchanged for a new Convertible Note.

The loan evidenced by the New Note is in the nature of convertible debt evidenced by an unsecured convertible promissory note, bearing interest at the rate of 8% per annum, payable at maturity and convertible into common stock of the Company at a price that is 65% of the average of the closing prices for the Company’s shares for the ten (10) days prior to the Lenders’ election to exercise its conversion right, but in no event lower than $0.01 per share.

On March 30, 2012, Bioheart, Inc. (the “Company”) and Northstar Biotechnology Group, LLC (“Northstar”), the holder by assignment of the Amended and Restated Promissory Note (Term A), dated February 6, 2012, issued by the Company to Blue Crest Venture Finance Master Fund Limited, in the principle amount of$544,267.19 (the “Note”), agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company understands that Northstar is owned in part by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart, and received an assignment of the Note from BlueCrest Master Fund Limited on February 29, 2012. The Company and Northstar are in discussions regarding
certain additional amendments to the terms of the Note.

For the three months ended March 31, 2012 the Company paid $263,560 in principal and $11,641 in interest. As of March 31, 2012 the balance due under the Loan remains at $544,267.

Short-term Notes Payable

On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term. Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Noteholder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.

The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan.

At December 31, 2011 and December 31, 2010, the Company has two other outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the BlueCrest Loan is paid off.

On January 3, 2012, the Company issued a $139,729 Unsecured Convertible Note that matures in January 3, 2013 in exchange for Bluecrest Capital Finance note payable. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of 65% of the average of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, but in no event lower than $0.01 per share.

In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in Convertible Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the Convertible Note.

The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $112,063 is charged operations ratably over the note term as interest expense. For the three months ended March 31, 2012, the Company amortized $27,018 to current period operations as interest expense.

On February 6, 2012, the Company issued a $95,000 Unsecured Convertible Note that matures in February 6, 2013 in exchange for Bluecrest Capital Finance note payable. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of 65% of the average of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, but in no event lower than $0.01 per share.

In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in Convertible Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the Convertible Note.

The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $58,462 is charged operations ratably over the note term as interest expense. On February 21, 2012, the Company issued 6,785,714 shares of common stock in settlement of the Unsecured Convertible Note.

For the three months ended March 31, 2012, the Company amortized $58,462 to current period operations as interest expense.

On September 28, 2011, the Company issued a $35,000 Unsecured Convertible Note that matures in September 2012. Note bears interest at a rate of 8% per annum and is convertible into shares of the Company’s common stock, at a conversion rate of the lower of $0.13 per share or 65% of the three lowest closing prices for the common stock during the ten trading day period prior to date of conversion, minimum conversion rate of $0.01 per share.

In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the New Note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital and a discount against the New Note.

The total debt discount attributed to the beneficial conversion feature and common stock issued in the amount of $15,342 is charged to operations ratably over the note term as interest expense.

For the three months ended March 31, 2012, the Company amortized $3,836 to current period operations as interest expense.

For the three months ended March 31, 2012, the Company amortized and wrote off an aggregate of $291,744 to current period operations as interest expense.

Notes payable, related party

As of March 31, 2012 and December 31, 2011, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at 8% per annum and are due upon payoff of the BlueCrest note payable described above.

At March 31, 2012 and December 31, 2011, the Company has outstanding three related party notes payable with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The company is not obligated to make payment until BlueCrest loan is paid off.

X

- Definition

The entire disclosure for notes payable.

+ References

No definition available.

+ Details

Name: bhrt_NotesPayableDisclosureTextBlock

Namespace Prefix: bhrt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

STOCKHOLDERS' EQUITY
3 Months Ended

Mar. 31, 2012

Stockholders Equity Note [Abstract]

STOCKHOLDERS' EQUITY
NOTE 8 – STOCKHOLDERS’ EQUITY
Common stock

During the three months ended March 31, 2012, the Company issued an aggregate of 9,321,430 shares of common stock and warrants for the purchase of our common stock, for aggregate gross proceeds of $167,500.

During the three months ended March 31, 2012, the Company issued an aggregate of 250,000 shares of common stock for services rendered valued at $10,000.

During the three months ended March 31, 2012, the Company issued an aggregate of 27,722,832 shares of common stock in settlement of $387,033 of outstanding convertible notes and accrued interest (see Note 7).

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

RELATED PARTY TRANSACTIONS
3 Months Ended

Mar. 31, 2012

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
NOTE 10 – RELATED PARTY TRANSACTIONS

Lease Guarantee

The Company’s former Chairman of the Board, Chief Executive Officer and Chief Technology Officer has personally guaranteed the Company’s obligations under its lease for its facilities in Sunrise, Florida and has provided a personal guarantee for the Company credit card, which is for his own use only.

Sister-in-Law of former Chairman of the Board

The former sister-in-law of the Company’s former Chairman was an officer of the Company until March, 2012. The amount paid to this individual as salary and bonus for the three months ended March 31, 2012, in 2011, 2010, 2009, 2008, 2007 and for the period from August 12, 1999 (date of inception) to March 31, 2012 was $42,934 $108,892, $106,000, $77,165, $86,209, $87,664 and $580,314, respectively.

Northstar Biotechnology Group, LLC Promissory Note

On March 30, 2012, Bioheart, Inc. (the “Company”) and Northstar Biotechnology Group, LLC (“Northstar”), the holder by assignment of the Amended and Restated Promissory Note (Term A), dated February 6, 2012, issued by the Company to Blue Crest Venture Finance Master Fund Limited, in the principle amount of $544,267.19 (the “Note”), agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company understands that Northstar is owned in part by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart, and received an assignment of the Note from BlueCrest Master Fund Limited on February 29, 2012. The Company and Northstar are in discussions regarding certain additional amendments to the terms of the Note.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)

Preferred stock

Common stock

Additional Paid in Capital

Deferred Compensation

Subscription Receivable

Common Stock Subscription

Deficit Accumulated During Development Stage

Total

Balance at Dec. 31, 2011 $ 95,625 $ 98,915,155 $ (111,021,257) $ (12,010,477)

Balance (in shares) at Dec. 31, 2011 95,625,236

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock 9,321 158,179 167,500

Issuance of common stock (in shares) 9,321,430

Common stock issued for services 250 9,750 10,000

Common stock issued for services (in shares) 250,000

Common stock issued upon conversion of notes payable 27,724 359,309 387,033

Common stock issued upon conversion of notes payable (in shares) 27,722,832

Stock based compensation 19,051 19,051

Beneficial conversion feature connection with issuance of convertible note 170,525 170,525

Net loss (946,892) (946,892)

Balance at Mar. 31, 2012 $ 132,920 $ 99,631,969 $ (111,968,149) $ (12,203,260)

Balance (in shares) at Mar. 31, 2012 132,919,498

X

- Definition

Number of Common stock in exchange for services Shares.

+ References

No definition available.

+ Details

Name: bhrt_StockIssuedDuringPeriodSharesExchangeForServices

Namespace Prefix: bhrt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the common stock issued in exchange for services.

+ References

No definition available.

+ Details

Name: bhrt_StockIssuedDuringPeriodValueExchangeForServices

Namespace Prefix: bhrt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment to Additional Paid in Capital resulting from the recognition of deferred taxes for the temporary difference of the convertible debt with a beneficial conversion feature. A beneficial conversion feature is a nondetachable conversion feature that is in-the-money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 05-8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=21917533&loc=d3e34017-109320

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 31 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

INVENTORY
3 Months Ended

Mar. 31, 2012

Inventory Disclosure [Abstract]

INVENTORY
NOTE 4 – INVENTORY

Inventory consists of raw materials. Costs of raw materials are determined using the FIFO method. Inventory is stated at the lower of costs or market (estimated net realizable value).

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 9

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 25 125 1 false 7 0 false 3 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.bioheartinc.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bioheartinc.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.bioheartinc.com/role/ConsolidatedBalanceSheetsParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) false false R4.htm 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bioheartinc.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://www.bioheartinc.com/role/ConsolidatedStatementOfStockholdersDeficit CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT false false R6.htm 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioheartinc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bioheartinc.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES false false R8.htm 008 - Disclosure - RESTATEMENT Sheet http://www.bioheartinc.com/role/Restatement RESTATEMENT false false R9.htm 009 - Disclosure - GOING CONCERN MATTERS Sheet http://www.bioheartinc.com/role/GoingConcernMatters GOING CONCERN MATTERS false false R10.htm 010 - Disclosure - INVENTORY Sheet http://www.bioheartinc.com/role/Inventory INVENTORY false false R11.htm 011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.bioheartinc.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT false false R12.htm 012 - Disclosure - ACCRUED EXPENSES Sheet http://www.bioheartinc.com/role/AccruedExpenses ACCRUED EXPENSES false false R13.htm 013 - Disclosure - NOTES PAYABLE Notes http://www.bioheartinc.com/role/NotesPayable NOTES PAYABLE false false R14.htm 014 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.bioheartinc.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R15.htm 015 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.bioheartinc.com/role/StockOptionsAndWarrants STOCK OPTIONS AND WARRANTS false false R16.htm 016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.bioheartinc.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS false false R17.htm 017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bioheartinc.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R18.htm 018 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.bioheartinc.com/role/SubsequentEvents SUBSEQUENT EVENTS false false All Reports Book All Reports Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS bhrt-20120331.xml bhrt-20120331.xsd bhrt-20120331_cal.xml bhrt-20120331_def.xml bhrt-20120331_lab.xml bhrt-20120331_pre.xml true true

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2012	Dec. 31, 2011
Current assets:
Cash	$ 69,945	$ 36,828
Accounts receivable, net		3,495
Inventory	63,286	63,702
Prepaid and other	88,427	49,828
Total current assets	221,658	153,853
Property and equipment, net	11,151	15,476
Other assets	99,164	99,164
Total assets	331,973	268,493
Current liabilities:
Accounts payable	2,631,964	2,377,807
Accrued expenses	4,170,146	3,882,115
Advances, related party	456,000	456,000
Deposits	465,286	465,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	365,000	365,000
Notes payable, net of debt discount	2,946,837	3,232,762
Total current liabilities	12,535,233	12,278,970
Stockholders' deficit:
Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding as of March 31, 2012 and December 31, 2011
Common stock, par value $0.001; 195,000,000 shares authorized, 132,919,498 and 95,625,236 shares issued and outstanding as of March 31, 2012 and December 31, 2011, respectively	132,920	95,625
Additional paid in capital	99,631,969	98,915,155
Deficit accumulated during development stage	(111,968,149)	(111,021,257)
Total stockholders' deficit	(12,203,260)	(12,010,477)
Total liabilities and stockholders' deficit	$ 331,973	$ 268,493

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		152 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (946,892)	$ (1,075,655)	$ (111,968,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,325	8,705	887,650
Bad debt expense		1,266	166,266
Discount on convertible debt	248,776	136,288	1,391,763
Gain on change in fair value of derivative liability			25,026
Non cash payment of interest	21,169		199,070
Amortization of warrants issued in exchange for licenses and intellectual property			5,413,156
Amortization of warrants issued in connection with notes payable	50,761	92,158	5,393,074
Amortization of loan costs	927	3,054	1,228,717
Warrants issued in exchange for services			285,659
Equity instruments issued in connection with R&D agreement			360,032
Equity instruments issued in connection with settlement agreement			3,381,629
Common stock issued in connection with accounts payable			756,816
Common stock issued in exchange for services	10,000		1,457,922
Common stock issued in connection with amounts due to guarantors of Bank of America loan			69,159
Common stock issued in exchange for distribution rights and intellectual property			99,997
Warrants issued in connection with accounts payable			7,758
Stock based compensation	19,051	105,347	9,893,379
(Increase) decrease in:
Receivables	3,495		(1,265)
Inventory	416		(63,287)
Prepaid and other current assets	(38,599)	(50,761)	(98,396)
Other assets			(28,854)
Increase (decrease) in:
Accounts payable	254,157	363,511	3,189,572
Accrued expenses	288,031	109,531	5,534,834
Deferred revenue			465,287
Net cash used in operating activities	(84,383)	(306,556)	(71,953,185)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment			(898,800)
Net cash used by investing activities			(898,800)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net	117,500	518,300	63,414,475
Proceeds from (payments for) initial public offering of common stock, net			1,447,829
Proceeds from subordinated related party note			3,000,000
Payment of note payable			(3,000,000)
Proceeds from notes payable, related party			505,000
Proceeds from related party advances		140,000	456,000
Proceeds from exercise of stock options			293,749
Proceeds from notes payable		25,000	11,557,750
Repayments of notes payable		(210,042)	(3,533,605)
Payment of loan costs			(1,219,268)
Net cash provided in financing activities	117,500	473,258	72,921,930
Net increase in cash and cash equivalents	33,117	166,702	69,945
Cash and cash equivalents, beginning of period	36,828	3,298
Cash and cash equivalents, end of period	69,945	170,000	69,945
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	128,696	67,635	1,909,160
Income taxes paid
Non cash financing activities:
Common stock issued in settlement of notes payable	$ 387,033	$ 139,729	$ 3,919,778

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Mar. 31, 2012	Dec. 31, 2011
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	195,000,000	195,000,000
Common stock, shares issued	132,919,498	95,625,236
Common stock, shares outstanding	132,919,498	95,625,236

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2012	May 02, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	BIOHEART, INC.
Entity Central Index Key	0001388319
Trading Symbol	bhrt
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		136,975,326
Document Type	10-Q
Document Period End Date	Mar. 31, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		152 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Income Statement [Abstract]
Revenue	$ 40,485		$ 1,249,016
Cost of sales	417		551,251
Gross profit	40,068		697,765
Operating expenses:
Research and development	96,729	170,111	64,387,840
Marketing, general and administrative	468,099	490,508	35,127,583
Impairment of investment			58,695
Depreciation and amortization	4,325	8,705	887,650
Total operating expenses	569,153	669,324	100,461,768
Net loss from operations	(529,085)	(669,324)	(99,764,003)
Other income (expenses):
Development revenues			117,500
Loss on change of fair value of derivative liability			(25,026)
Interest income			762,277
Other income	11,353	3,389	264,184
Interest expense	(429,160)	(409,720)	(13,323,081)
Total other income (expenses)	(417,807)	(406,331)	(12,204,146)
Net loss before income taxes	(946,892)	(1,075,655)	(111,968,149)
Income taxes (benefit)
NET LOSS	$ (946,892)	$ (1,075,655)	$ (111,968,149)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.01)	$ (0.03)
Weighted average number of common shares outstanding, basic and diluted (in shares)	114,974,051	40,517,481

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Common stock	Additional Paid in Capital	Deficit Accumulated During Development Stage	Total
Balance at Dec. 31, 2011	$ 95,625	$ 98,915,155	$ (111,021,257)	$ (12,010,477)
Balance (in shares) at Dec. 31, 2011	95,625,236
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock	9,321	158,179		167,500
Issuance of common stock (in shares)	9,321,430
Common stock issued for services	250	9,750		10,000
Common stock issued for services (in shares)	250,000
Common stock issued upon conversion of notes payable	27,724	359,309		387,033
Common stock issued upon conversion of notes payable (in shares)	27,722,832
Stock based compensation		19,051		19,051
Beneficial conversion feature connection with issuance of convertible note		170,525		170,525
Net loss			(946,892)	(946,892)
Balance at Mar. 31, 2012	$ 132,920	$ 99,631,969	$ (111,968,149)	$ (12,203,260)
Balance (in shares) at Mar. 31, 2012	132,919,498